var title_f26_48_27392="Branchial cleft cyst";
var content_f26_48_27392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Branchial cleft cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A cystic papule is located on the lower neck, anterior to the sternocleidomastoid muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27392=[""].join("\n");
var outline_f26_48_27392=null;
var title_f26_48_27393="MCL grade2 injury MRI";
var content_f26_48_27393=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of Grade 2 medial collateral ligament injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This MRI image reveals a partial tear, with high signal edema (arrow heads) seen both superficial and deep to the MCL fibers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27393=[""].join("\n");
var outline_f26_48_27393=null;
var title_f26_48_27394="Patient information: Chondrosarcoma (The Basics)";
var content_f26_48_27394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/63/33778\">",
"         Patient information: Bone cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chondrosarcoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chondrosarcoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5325415\">",
"      <span class=\"h1\">",
"       What is a chondrosarcoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A chondrosarcoma is a type of bone cancer. It happens when normal cells in the bone cartilage (the rubbery material where 2 bones meet) change into abnormal cells and grow out of control.",
"     </p>",
"     <p>",
"      People can also have growths in their cartilage that are not cancer. Sometimes, a chondrosarcoma happens in a non-cancer growth that a person has had for a long time.",
"     </p>",
"     <p>",
"      There are different types of chondrosarcomas. Most types grow slowly and do not spread to other parts of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325430\">",
"      <span class=\"h1\">",
"       What are the symptoms of a chondrosarcoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A chondrosarcoma usually causes pain and swelling in the area of the cancer. The pain can come and go, but it usually gets worse over weeks to months. The pain is sometimes worse at night and with exercise. Some people might also see or feel a lump on their bone or in the tissues around the bone.",
"     </p>",
"     <p>",
"      Some chondrosarcomas grow in a skull bone. These can cause headaches and seeing double.",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not a chondrosarcoma. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325445\">",
"      <span class=\"h1\">",
"       Is there a test for a chondrosarcoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will first order an X-ray of your bone.",
"     </p>",
"     <p>",
"      If the X-ray shows that you likely have a chondrosarcoma, you will have other tests. These will probably include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        An imaging test, such as an MRI or CT scan, of the area with the cancer &ndash; An imaging test creates pictures of the inside of the body.",
"       </li>",
"       <li>",
"        A biopsy &ndash; This is a procedure in which a doctor removes a sample of the cancer. Then another doctor looks at the sample under a microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325460\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began, and, if so, how far.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the type of chondrosarcoma you have, its stage, and your other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325475\">",
"      <span class=\"h1\">",
"       How is a chondrosarcoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A chondrosarcoma is treated with surgery. The type of surgery you have depends on where your cancer is and how big it is. Most people have surgery to cut out the cancer as well as some healthy tissue around the cancer. Depending on the type of surgery, the doctor might need to &ldquo;rebuild&rdquo; part of the bone after surgery.",
"     </p>",
"     <p>",
"      In some cases, instead of cutting out the cancer, the doctor can do surgery that involves using a tool to scrape away the cancer.",
"     </p>",
"     <p>",
"      Doctors don&rsquo;t usually use radiation therapy to treat a chondrosarcoma. But if your doctor can&rsquo;t safely remove all of the cancer with surgery, he or she will probably treat you with radiation therapy. This involves getting high doses of X-rays (radiation) aimed at your cancer to kill the cancer cells.",
"     </p>",
"     <p>",
"      Although rare, a few types of chondrosarcomas grow quickly and spread easily to other parts of the body. Doctors usually treat these chondrosarcomas with surgery plus radiation or chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325490\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if the cancer comes back. Follow-up tests can include exams, blood tests, chest X-rays, and imaging tests.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean your chondrosarcoma has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325505\">",
"      <span class=\"h1\">",
"       What happens if my chondrosarcoma comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your chondrosarcoma comes back or spreads, you might have more surgery, radiation, or chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325520\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for a chondrosarcoma involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325535\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=see_link\">",
"       Patient information: Bone cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/48/27394?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83152 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27394=[""].join("\n");
var outline_f26_48_27394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325415\">",
"      What is a chondrosarcoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325430\">",
"      What are the symptoms of a chondrosarcoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325445\">",
"      Is there a test for a chondrosarcoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325460\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325475\">",
"      How is a chondrosarcoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325490\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325505\">",
"      What happens if my chondrosarcoma comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325520\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325535\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/63/33778?source=related_link\">",
"      Patient information: Bone cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_48_27395="Veress needle for insufflation";
var content_f26_48_27395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Veress needle for insufflation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 167px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCACnAdQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxeLKCAtMpmjkJ8vuAV4b3HpT9O8me8SJJZC5fYem1gT054PQ1CgDgb2CsHQl5JCDtAwBj8OtX7eaDDg27JFHDGNwbBlbd159+fbFIZCkbmG32At5kZGxX4QCTnPHH41T1CydUvXA8y3j3MxDEEep56Z4xWpqd1IDLbRl4rfy33RjOcEghj/vfrUdt5lzptzay7bldytDub53G3BQjvgHIHsaAKc1pHG+HZmeVI2ABYkDHHsemPyxUpsooopGaWWQCRYrd3DfvEY4yo4IGexxyBRLFOxZbW3aWaJ4wjIC7IoHyjHbHf1otrS4WLzLb/SRLkAKzghQ+S2T0xz+dIY1limSQSSwkhHQhYnG18gYI7DvipSYLrS2jbEV4krqPLTmddvBB9RgHB6ZNNaOSOSW4kgK20cjNuAZg6lflDc5AxxnnpWhdWltarL9hjkkdTGXUIVVWZRnnIOCCOO5GTQAyZY5Vijh+VoTG6xJCyo5kHzFfYjIxn3o02S+tLeKRIFa2VWSVJIg5MbuQWXk4J55GOmKV7u3FsECJC0Ult87s56ZVl2ntzuwP5VYnTNrPukPlpHI2HgK5j3dcjnJP5CgCncyxzQxQiIKolnJYrkZz9e3YDpzWETNcXx8iIw+bl87QoBxzt5zgc81e1mOWEQrcxAum5iDAV2ttBAz0wBjn0xQIYpfOlnD+Z5csshS3G1G/uYzyOTz0FACW93JLYGF4WMG55JCkfz5C44z6gj6Va1nT/JsIbkxTpB5bNIpTHkuFAIOTndjnv2qrA9xHvj8yM7VaL54gMk4YhQPQrg+1aEsSQG+kkPnZleRY3GCq+XwxycA84wf6UASRWskd5PHcRsInuYkkfyiRGoXcG6+mOnNWlknSGC6tYz9oIihCGAbAA52qByDkBjnvk+lSnTjHa2v71hc+VDujMO4KMfKpAPc9Seo5pxhkksrS9s5iPNthuHljacvjC5xyu44Pb6UCKGoyQzPZrDPM0G9khFuiLv8AmwRk555IJ7AAVVFr5zzlT/o/lzXKNsQBEBABPpnJ9+mBUUlpNaxx2gQCSJsbiEChh0Cn0GCT+PvUEpaZWMbSP5KO6mRUG7nbgAdenb/69AzTsRGhEd6kmYtjRy4RlB2Hluzc+mT0PUVWtref7RZOZFktWSKSWQKsfGzdyOT/AA+2e/UURJHc3aPfXMEAXYz/ACrh/lCqqKO6/keSatSw3bwpDcGeG3g8sSEIi/dy21vU8KB+tAEMbN5BkmWMq9vm4aONCAGY4I55bB5HUYrYs1SOXy23LOfOuI8YMbKSEDOegIAJxVCDTGv7EvsWF1gZ1VyoU4PmBVGOvrjkkYNWo9MNv9stfPUyyzZtisaunmsm47h2zwABQIlZEMQS4DyRCRHxAFBkXYFJGOCc5HHA6mq2q6XbR26goQEFuXBkSMMQzKfXb/CPc5JqxNJJZ3MUV5dSIP3duz7o1BVEO8rxjb85wMck+oqJLiO2luPJuFV0S03Rlo288nPT2G8AkcKQc9KAMKLRJbi/j+0iN9zqSkMqqq7TlsnHOQfxqe409ZfDttcx3Mo89GjZnkCbTn5VIzkLg/jxVy5uWjktjZTyiLH7xpGASMAEALgYxtyAepzxWGLy7BtMtuWZowshX5n8vPOSO+SAvrQMkVIpLORJGMcxhLDLKNvzDrxwcADHqTVmSK7S9LwyRvJC/wDrWZTgj5ShIGD1P4enFZyrbT2MrrdSEmHiCV8MzbwWU8dvTpV+LzIbeFpdQZZ2SaWE7vkLKQMHjJ4559Bn0oAfayLaKwivHfeJk3Ky4YKu3P0OSRn0HrTZ7dZV+yk71Z/KFxCDlsqNrkL2znirZumfbeMvyKHMwibAuFZVBKNjIGQCcZ61Uu7o2832myQQRuYZB5LOCFZcNj1OVPT19KBF3SIYNPs4pJRavL8waNJ3LuzKQA3GByM+/aoXmM13CxuCrRBj5pJ3nAwV56kn16cU+3vFEsrBUMK+VsZ5TuGP4uB1J4BHcU2TUVF39pMMauYlQx5b92AxBbHuTyf9kdaAKOqQtZxndbje5k3R+cSqqemT7EZAPXr2qFHW1lZBGS5I3tljtBAJXnoTyPxJPSt3zLIjygJpIrgNMHLMxQoRtXHOWGAT7Hms+byW810l3OGzKMO4kATcxz2ySPp9KAM25DSAyK481yGA+YsgPb3PTmnTXJkd1t1l8slQV3EOwVSAjD0BPH1q44ixESAFXYzKVbG487cdfQ/hT5DI11YSRQoJ/JDMvl8hdzHJ5+YBQefrTAWzZ4rb9xEgeKSN5JTFknkkcen+TxT4rpDJ5klrA7L5nmRGPaMsdxBbsc8j06VVuGEsQaNBFBIWkDRDaJEyCOCenb8MUryRXE000scatuEhZUXBYfKq4J6HjJ/GgC7qE9uIL1IZWZpZZJRK0ZKqCudoyeB1A9uatWri2W2MqfJCVlWJlCl1ZQPMdc8kZBx6c1ljyRZbWMTITJI26PcQdoCknv1O30GKlgZWjWOIW5jWENuZVDbVbqxzwTnbn0pAXbB7aExSRAyRRh44iSobBGd/PU9SfTgU6aCOZy1pIpZp2mk+0uuZSV+/x91cfLj16VZhNvHaG0ht2hbJEG0hg0jMflxn0OKiVFS8Kugity7mUMFRz5YIKY644Ax0yaAM0QPqNqiQs0ciQlEjR16uM7QOuDn8h61XjntZFkEiNJKVjO5JkUCQcBeRjHXOKt3ckiTLd2YYNG6kShjujJTGxQBgr2B/D3qKSzuZLwRFvs/2RVR2mAKxhl6EAdTuJ/4FTAoWs3+lRKZ2eGQqzGOThflIb7vIJGR7ZxV6EvdyxOHCtMkcZbOPlBPBIHIxxx79aW0s7iKG3jW1VHkdIPszs2XON+CAMnGM496vkm3s3t4beCRViG5WVtqlnA257YGenYnvSAzxNNbGYRsoY7wmcuqKGwox0+90qOS61F7eWOQyJCWfuxUfKATtzxnIA+tVp0c3FwqkySbQwkiU4LF8EewH5miMTb55YlV7iWPJPUpk7QMjj73FMCy0D7A3zu5DhlyxKFVySxJ64z9BWvYzKItqRxum6NGLRNiM4ByAOCeTx1571lxKnlRpbwqrGVkeIZO9gnJP0x19DUllftHcQ7JIll81JIVYKsJGCAxwfXPbsDQBq3DRxWUMaK7yW7M7QKjAp8xH7wjnnI4zyaZcXN4lyVjhgM8IdBG1tlUQn5mUn+LGeSfaqLXBnuFvJYozCx2ukO3bK28gdTxzk89sGrdrFeRWEckANzeSSshjlRBEJmfaGIPVQBj070AY1ztijEEcsfnLHJJCs0agqGI+Z2zy2Oe/oKW7toZiWsTLI0ckcREihB8qbiQO+cVeW2gvL54orVxJcyyQmcbdsSooyyj04P4Uisty7tbs0c0gSIEOoxHtPB7E4HX6UgMOzkE0Co2Nyxqihyo2gyZwOO/SrmrG3nikCzbbXzJNiNgAAYyRxn73HvirdnFFEILiW1mWFIVCxO4VwdwZQwxk8c/Tmq87RyWEpE4ku43lUndtOMhgVOORnP1pjOfuIoy4jhnD5QlhJuAHPPbr0p1xBHHI4jlM4MmxCQR8uPfv7VYvY/szxySIrZLSeYzsCc4IX+tWHZbl1gURPJ5u5NiHJZhyPcYB/KkBVZ7by4Sy4JTJCncBye9FaJVI1SLULhVmjUIEEW4ooHAJA6/40UAa2nwWyX/lM4dxGs5kDZL4HzKM8Anp7daS7aH7J9qjeZWkQ/IX3IOuOfTGB9eaSyiCT24iMAMhCKrlyVByN2AOc1r6VZW9ha2j/u/tLK6qz7ise08uRjBPoOnvQhHOxxSRTNHqPlss64SRmcqBuHPqQBxWjpsi2N81025Layjdgr7ow8i8jB7NjjP505bWMR29u11LcrPE7yyqpbaqtz977u39arLYuY4pJ0ZFSQu+9ckIF6nByc5BxTAs+TLIt2LFMrdBGSPJBRnx+8z3yMj9azW0q4ktYJY4QixsQGErEZD9QCQOxGBV2TZGJJZi6SNbW8YAjdQjknaV59Dn8qqyAWkcMZCSyWqmJQ0eRuLYwTnnOew45pDMyYLJa29y6yNEXkXO04ZVbk8nGfbtgVuwqkqRQuiNBOzgSPGU8kICQMfxEgjrwDzWLfPEJTtiSO05SNGA5IYF9ozzj1rQae0t9mEjdomdysoG2SNxuDNz1A6D2xQBKksLWtpt8pEOGEQTkFQBsznk5x9ee1Wbe3EEFoW+zT2OwxTTZBfeDyhXPGSeOPftWHBBcC6UF0iuIpFKx5VlUMvUeuOOvSti6jb7NPIY0E/2cFnaJVDbGHLAcgc9uuKAM2BntB9huFniV3DTlcSMoU5RST6Y57Gm3Dlrh4Z3Zb1UaKAYXGC+47zn/abnvgVt3VxPcPJqSz+ZDcO6RG4ICkLhWJ9t2MYHArMu1jfy5pZHWZyVKrs2nywON3IGMDj3oAs23lTKk12sLsI3WGIAfMrMBuPqRjJx0GKuJ5KPLBbH5fMc5wr78J14/H6e9RJdxx6wQZ3cWwKxzjYypC67iD0wd3Gafb3ENtdKskoRDgzIwARj5WRtYDjnPegRBgqtussb+bbnyi4jX5meMszMM/7oBHAwfWtf7YbXT9Ettkdq32dHBRV27943Ehj06D3pkd8rm1Tzg0MMD2wWUKnmEIDuzjJTlQD1z9azoryWHSkgukdYmiCrCYwZC+/BBBGcDg8dhQMhhus20kHmGF1DOG2qUk3sMgnGTjjp60+a18mKF7pd7SrKTHCwDxt93JIBxyOvvVe1m+yR3ErSPLM0RQtBIHICyZzyPlHU/QVauGisIWt7Pc/klmR45flIYhsggZK9/wDOKAJdOg+xST3ESRwxJMI9ksiMQmzGwnHDe578YqxqU8Fx9omu2leWZkYqsyiQdB9MYwffFVdQvbX7JeLFAxtpr37VKI3YhtyggAEYPOPm9arNeSIrSeYpDCCTkZDbWGQpI5IPPb8aBGneXhmsYkktRuRXk8x2CjA9BjnoMY61f+0zDUB86xrEyzruC9dhyxOMsTjAHT05rP0nUZftEkM9v9ptdzRfK2fKAOQo45yecfhSQ3gn+yW++4W1EpiMok/1ZVcKpJ57nHXr7UAW7drS7DEyLcqEi8tnmVXkc5A/Aqx+nrWPdX8VvcNFbtHcQvD9njlDAIhDEg/d6DG7ueDSTNOjJE7bJsq5jeUGRcZIUjGBng+uOMVnTSXNzZ2oxKI9jMu5uUVhwvyjqVI49PrQMJ7qdnI+0NLb+ePJxIfLQKuVI45I46+uOOtV4PJnNqjRJE7BXZ90nPONx9Duy2OlTtbSzfZo1jE1yxWNl3sCcfKS4/3iD+VR38X2VgyksiMFch2ZVCfKyDHUFuf0oAvyoZYmnhlKlVLgzDB2+YD5mADjJUkD65zTIHlKGIWQk8xpAvmOSFhDb33cZG7oTx97mmQXOYNkUcv2qSKRfKSMgPgjah5znBz6dqqCYi41A+bKsLqysybnCKwBIxnIxjJoA0576GRE+13LvckMIIQWQeUR8oUAcKpyOeSVFaV7aK0tq0TlvPjjlgg3PtHQD5h7K2R6kY71izQSSXpnWNd/lyESxq2w7gGVuTwpGT7Ut0119itPLluXiWBRblZCrF2PzHbnjjp9aBFiO3njlZnESxl4UbKkIG6jIHJ4JOetXbq1sltFSfTrqXUoSTNKzERmAuOcE5JHBB564x0NRoZLZom+yxzWpSOZGLOQmw7cMN3UZ2njJPHaquoi5+zh70SvFKWhjYxsSNpXBBzxj09qANWSMx28jWUpuJIrmQR43FcsmdoXgjGCcdcdax9RtXiZVlt/LsVRyYyxQtuOABzk5J5/wrRZJUYq8ASRrqcpErsxkO04fI4G3I/WorS184S2+W+YKsK+Vgq/lD5Rk8ADr7GgCGewuCLhp4nDqzqdy5VzsXaFbPY4xn6VXutKlilsikc267jjeURxcgnoF9sA8fnWjeSMl1shg3kyhhug4xtK52g44PzYHrntVufUJdiW1laCK2REMvnEyOzezZ4UDoo7Nz1pgYFwJo2gEkWxmUwqUVQUYPkAHOOhyahWKcWT3AXcZdpLoF27mJCp/sng5NalwVgRHkEaQuswcMqgkqVc5GeeRj8hSvkebFvZk8piUAUnBAdQXzjGCOO5/OgCqY90l2kl40Y2qpJZSz/KoK9O4UAAen1NLJLbGNjMuBGyT5AQckYCkjJPQ8e/NW5rTzpLUQ3gUTMG+bACExZyw7KOBkdATTdhtzLbT5E0LwqyxgFeBhjkKTjB4/GgBq2MzaZ50K+bCitGrJKFPmbtw+UjPGR7Cpb8SubpC5FzDNJEVY7iUYAtggdN2Oe+e1OSaGGdUE/2m0CMVVQwJGT8xOOp4HbOKbehZC8UksjT4YFSxD5MfzHJGSAwGSfpQBQvA5FrEYm2hY5I5BI6ichSSqgDHLZGfb0p9u8iQuyrKkbqivsdjuBBwxHXdggc9M+lPuUWKKyGw3MfLTNtfbbrjCoBwccFs+vFURDcHzkjMskwRSGxtboQDgnpg5zSA0xeS/Z0WFA0reVIs6q5ZnLbcrnpjGeoz0rPu7qWK1jgaSVgwYNGxc/P5gIP44zxwKuabaySWcs9pFAIXjSNEdwCDu6rzkg8nis9LWSVree38qZpfkTdEFBAcgnB789e+OKACOB7tLq7ZY4YIomD243EIHfhiAfUk57AetU7m2Mcd5h/JaIbHIVNoPBxjd6An6mraymNVe3MxRmZVZowCyjAwe+TkHntWeS1vc3QjZTbxl3dgAW5AXGPXOKBm1eSGCKSBllW3mfBmCL5vKg7cfwqTyT9KlL/AG9IFiWOO6kh37GiVO45UZ4AwePxJrPN81yuLoRFURQcYSR8IAyggdTx161p272s7W5eXYSsZmaUorygEgA+hAAz9KAJnjjt4FjkRru1R1DMioHAG1zsI/h6ZJFVJbhpmu7W9ZtjRpIFTBTzB8xJI7DPSo7S5EF68UDq4XKLM0mYzG5+YYAy4Oc+nFOQyR2yeZuuLd/OPlklXn4wX46DjAyexoEXJLr7RBJD5jQy3TMJZ84yjAYbgcj5c8etTiezkjtmhimRoD5twrMGa6AHyJyMA8ZHtVCL7TMJ1twhgDecSoYrHGEGUz6YzxRbXbRzs9vIphO0sgZysjgEADjPQj+QoA1Gnhnvbo/aQBFarILhzgXGTwqjGeMgcc/KcDmsi5E1rbmG1iVfLeUlC53dsjPbjP0zQiGSKSCcSRzpEzvMS/JRuQMevAJ7Vlz3smVCBlZpJJGjBOC3Ax168HNAxsrfaFiWQ/uFLhnILMOmMA+nSrkNk1rCktw1uIA+ZGlQlwBx8ozycN2qg7C4d3XILg/IsYX9c8dDWiZrq7tY4CQc4QlUG7sAGb06enJqrCuZNwygoI3ZWC4fAxk5PPJ6kYoq6lqDu3+SXDMG6dc+veilZBc1NLvJd86pG8rAxMHO4CMBupHfI446VtFzJAEtVJthI6RSLu27j7Z5y3btWCXEYgaOS486IghYwdoTdzk+p/rWraQrNdSPHj7OUKhdsipEwfLHr94gnkenvSAkuLRmsmvSVjtVjJNxFEzBwFxtxnnng1UmuZ01cQxW8BuJQMobcgxkpggc844x65rWunnsLhraOFGEbStFCy4VQFHBGcAknJ61Uub23L2SRiQmRA+wQgEsynhjntj8uaAM82ss8pikhVpd8ZQvnJ+crs68fz4xTY1jtwJBaiS5kSRobcpyg3clueOO/WteW6VrO1WZFEcSBlG1QZHXnBbOTj1HXnNVdYtYWDeVBgSxOWlkIRgdgJxz9RjkUDKN4beSKSEQy+eiNIk0ew7SyjZuXqQST+lRjSEjt47iG8t2Mkg3wsobYxj4JyPb8MiqsLpa+fNbhC20wxOyAbTkHB28k9zj0qyhafyFknjSSPfAAWGApBY5GOhb8ccUAQ2MzrNp8LAymPyuTIF29dxxjsfWtK/vZLmCJpFuQq2xjcFuoD79uccg1T0GS4tbi2Sy23LL5ReEp8znBHPsMg49K0J7y5+0XB1J4b1poZzMVkKKSpAVRgY4A+6Pz7UAQzbv7PFm8qSBZHRgSGXa4DbU46HgZB7dqy7p5LVI8qwmZ5esuVwBjb05PTPqKurdu6T3FxM1xGWM3lSKyq52qpDYxtA6k+hqGT7QG2plpxJsaQqw2EjIUA8EEAKD6DmgC3psU1vZf2jDIRBkpNAm4hufvEt/CqntViZvs00u693EtEm6Ql45tyn5uFx04+hqpdSJ9qX7PGsu4sWD7yPmQfIR1yAp9OPrTtWtg1yVsbrNutwBCsQYRsrICr8nAxngDoPagC/fW8ey4muftVrGjGGQK7OFYIGTJAyMsFI9MDNZ0dzePfG8klM0sSKsbNJlmDcuy5GCD9Op70zTru4WKRkZke63RSeZu2yzYwdvqzLzz68VFp90sc06hrhtpijR1yuFQ5wQQeMgj2/GgCeSNJbOZ7F4/KidA1sHJWMFmBXOOh4OOvYVRIni3SKz/aF8yYBwyll4wMHouPWt+xht7syvcEi3xG3lxxNuQl2YFTnoDx0zWdfxi4uLhdQDLOILh2yWOGOPlbkc4xntz+FADJlF1ZTzhJksfO+ebJ+X5QFwp6g4HTp+lRz2MkcDOqPJHFIgBGVCE4J78cgDAz7V0Okra29wj3USTCQCQQeWzKqbMFirdRypyOcnisnW9OvbO3RPLihE/lxy+XIfmYHHAJ5J4zj3FAitbXoh3RXKsblWkcoS4ZAT95cEBgvXb34NSiWSUbozMLZpd4G5kCzlcBm4ySx5AqqbZobecOUSPeY1mEZLoVY7kyT0AyDt9cCrFyivZWb2Sq/2gSSZUENEy/dUDPOM57AZyc0DKtxcSXd3Pczme4u3j8pIyGUucBd2QMFm6Z46fSte4giCZiMrokUbGCaRwIeytn0yMEnk9uKrz2McdoyFojcRgsygMobG37pzgsdw4BwCM9a0blliMsepJMDKypHkgjftO1duchR6/UmgRlW7zLNfSyAx+ZG6FiGUzAOCRu+oBz+FMWW3n0u9RrVzIrZSMqysoC8ZOcbcDd61pyNbajBafbp5gkcTxyFU+bKAHZjJ6njd37U64i099HinERuBPM0owu3DKuGO49Qo6e+aAMK0tp2Hl2kU7XUsnlKQjR9dpUbj36/h0pqwP9uSOCKUSkjKbQMNggjGeRnPJ/8ArVroY4NKSaBQrohxGxySzN1A3YJHb/e7VDZgRPcF0aCWSVbTdHHyi+XlyrZ6nkfj7igCXSNNu2laS8MoiiCMzbMBwMsUYk9DjGR1z6YrNS6iHlStahYRsuP3fyqpb7i5z069evFayPDdQsHAQTrHJGfK3CTDAMvUgEL37ng1Sl01WmkitDGotYQ2xgvzMjfOCCeeuKALtzdYieKAbC6EylUwU2vvVmBPckZxis++lt91/MsfmqwDDEYi2MMFsjPK5yOOT2qSwmt4JzcF4IomiIzKu533ffXavbacr/umopLGO1gDYzKs8sccMWyXcrLnk+oXv09KANxLRZ1e8aOKJ0nkVo0O8bWHy7RnnB2/rTmuHt7LyRLE0q7wjuAfMVlBckk8EYUDHpWdHeIt5cCWOF0eUyrLsVnTMe1SoBG7APPoabEsUSlVECRRwxlXaNcnIODyexPbt70AWV1CWWKeSZmVoSFYhUBJZACDj1B49MHNVFuXSzt2UNHF5XlRMdvTcFYt79senJqCMrJGltuRod6yNvKAHgDecdcY4Bx1FXLbybqBGlZLl3USMrFFwzNgu2OCBkEjtimBPcrC6yRIqpv3qGikTCoVGVJx/Fgc+1ZDTbpUkiYpE4JiO8BYJguCSMYzt/h9q0xItrFL5Jj3tNOwRmXLImFAYAEZYnPpj8KmeKR7yETagkk4nOJAnzOwX5gMDHAGOfYUAVIdS8q9+2TTSOkp2HfJkorpgR4A5PygnGKjtLlpbeKGRQu0rtKyOCAVJDEAdCMAD3qWa1iuJ44Le48yFyrARlysQKnBAxyVOR65+lRoEtC0qtPHIWihEMauTiPIyCeOSOCelADZGlttPMhh8qaVNgKuzbQWJ4HQ46bugz0zVyW8e9uIFWGIs0knlKN5JwoHLEjOe44/GkiSUaXBtie6eUmOKIBlKjJJViTjj1HU1DNZtJaxsYJFed1PmeW37pgOFIJHBxyfegC4L+aeGW3eGGWW9JSNpAWCFVAePjjaOOSeua5WS+LrJGIYozDELceagZ2BJJz068DHoa1As9tp62FtI0C3zqzOp8st3znOe2e2e9VpttzdW988UIbEYdHXruJIPXowySf5YpAOs3tpI1aG2iEEcsUgR03B9wK5PPzHk4HAxim2LxJeWj3MBjEjheijEaOc8nO0dsd6rx7478x4hiVSyiNQAmDnucnhcjP071YSCOW0Qq1tCnkxxEEjOGbLA55yMAE+4oGPTU/tqyS70tHlmaVWZQEV92AQR8w+XgD16U+/tY2e+mUu8aq3+sdS8nyg5475yM96asReWxC3iC3JS5Vl25j3SEIjjB+Y857DIpLh44IZY7aQBvsyxqzHOAJcsjH65H0zQBWuoirhEnLRQhc/MDuAXdheOSOFq4ENtEkc4/0u28mTy3YMQxJJTbjk8kYprWdxdXEkiSukLPMSIGzhVxlR0JJJHA/GpoklEtqk0MiXxljliuC7eYdpKsuD9evX0oAqxNElmTcROJ5gGCq5zAGkO3jAAUZHerkcM1qguoZ5WxFJbs6sX8pyxH45AOB+NOsJWR3e6TdKFCRRyhnGI3OMHocYHJGOw6GtBraUWM7NdOzedmZXXKyyuBh8JyCBwB7ZoEZa2Bg08SBpEEkm6KEFgJztwwz0HqeOlFq0JlubeCF3dli8iaMsd/Ulh6HqB9KsF74SW6Jdf8syVkCtmHK5PB78Eke1V7Ff9Jt5RFPE+I1TOflABwVOR1GSc+vpQA/T5beK3tZbGN5JZYxHKjl8R7jgNk9WYk5rM1fTrtbyUy2Mbq7SsrKpG/aMEjnnk8/Stm1mVra0gUFZZHEEflKzMzM52ljnbz+XFVby8MOnmGSMj928MiAZeNUfh1Oep53etAGZJb3FhHbyXCI0o3Hy2ClPlAyWH8OO3rVg30k1w8zbQ80itKqoArdxtHTA44qnI0EtncxZk8x5dwGFGFAwAx6//qqS1SOCMXUjCTbI7NHhXcrjHTseRzTQMrvDHM5dvvHrzRWouq3dqAlv5SxkAheMr2wePaimBYe0SK0aRSXmil37WUcfMMq2D09BVyJHtLpftBI2wygxqQvkjOVLKTgnkfn3quESN4U+dHlid5GdUXK5yNuehI79aiKzNCLqRVEp3yyqioShxgDPXJHb8akZJJA2w+ZcTmaZiFBKEk7OWJz/AC/nVmaAJLc/YoRDE/kskibCxBG3jJ+v41FEplmUxhkTBChQgOAmYxj2I5PvU8avDMGklgVrTylWUhWG5QXbORgnjA/WgQ2G5trO48y4s/LyUSQgriQKGwRnpyBn6mmXVz9lsIykUTRFyJ4X2yuXZtwZf9kd8YqpcalJNbkWsr7rkKC0qKCCz7jjjgdvb8qIJ7r7EkovB5oDRkllBA3fMuMcHA4P40DGSCO5kuDI3kKVkVXJz94gnPHP17fSrP2eay1U3cjLIHYxyLG/+t3p2bH3+2MdKlu4o2Z40G1sTOx8533navGPTH54ParFpDFLfxXBum2xlriJdzEyShOgbsW7jGRigCrHAVS5t2WQeYIwFDMuwdMk9vlyMng/WgxeRAD5DyW9qMAJEfLQBgWYbjx8vBH5etF5MzNFeGGGVtkcjpKWkUfP0PqozjjjNaiRXFz9rEskUyzQyO2VYGRwR8wU8ZGce1AFKW2ub5i727g/aXWCGN1aI4A6/NgfLj07dTWbqzSWrNa3MJhkkVfkZDmEn5sqwbnj+ddCTYIdyQeTJCw2RCA9dh3M3P3c9h61X1axhvLuJ7eBPLu0LtO6jcj4yEQZ4GAetAjNv7eIqpMUsc8srg4QqXDL8rLz97aBnJqvLYhrWNbaGaR3VJYFMRIOz5dgOeDjn+XpUx0ye8itolVVhlZpUt5IyWVtuBzn2GPQk1Ncx3UwhWVjFHJIGJePavmBCoUHPAP65zQMq6VckeaTbxCQASFdpC8sdyjnlsHqSBwBiq32YXUXlRb7kD57WRwRLLlx1OeRnr3OPqatSW6RSuksDCaRIiUyA4x94HJ5wBke+O1WbS1OoBYIiFVFU+UY1JjHzMWBB4XGOvPagDPtoUa4k2HAVS5CAguQ5A5Jxx7fzrVFsLm7nhuFaAyeYHdkBMYEecjkg8/l3zWfFYJeWN1cQxzu0kRkt3kAVH/efvWXHI4wMCtW/sES6aG0iDwptj5AUpuXJHJyTjOc+me9AiOzgSC9/wBI+a3UefBbMvzyAwgls7uFOB1wD+VLKkQle5s4fLSOVY1aVRIxYgYYg8KctkL+JqhJE73KpdQ3HkwuoUbVDsu0bV/HlvaiFUFvcP5DkxtG5j2DdIjcBmGeH9cfj1oAffWVxFp8fmW8Nq4YwI6EcbDndySHZscn6YqePJs8SWg86MTQuxUIgyMg8H72Bgjpn1ot7ZZbSBbmIpAJml+1IEyzHG1jk8gEYBAGe3FXZ5Jb6CRWlW3hiRflZU2ltnDMBn5gec8jFAENpc28+GnsgksuXkeJVAWNlI3bc/Ljafp+NJrLo2tI9lHAzyJE6xEA+YAAQNpPAwOMfjVvT7T+0m2lSl3MANyFQPmQKeBweQAOw5NE2nXKw6eyrbvJFbNCflQBSu3cffnPPXpQBnW0C/ZnuNPkUTIj2wUxKC8e4DHX7wGTnoTV5LCT+z7qON1RQ5LnA2qxZVZQBycnIAHvUul6dHdancG8LSWayCJ8FFGRJ8iBgDtX5Tnjp9a0ZYEaSSa4EcgkhiSPyFyyukp4A6BR2zycc0AU5NIFq7yKkD2ytKrBQoMZZeh9T9PXjPJqg0ixSghCsxlSaYbUZQSuQxA4Ix26DjuK1ry5nmSe2uI4HuUEqOURVLMzBSWIPOF4H4+lSaxpgvHhFrJbo21em1WZRGysSOgAAP6HvTA5WWzmL+VOVhIaHkhUjLk7m6/dXuar3a20Woz3UvzWoSUeZG4GSSc447nHHoD1rWmRYUt0kuonitzEIo22gklSwJ4zt2kKD6mqaNNeiUYWKNVw7GUqo+c4UDGOhweKAK01vc2k1uA0UV0ExIVVW/eNj5RgYAxjv6ipfsbwXzxzXEUYgkSJIGcgOcH5ckcj19OlPtIr63ee2uLh4LEo4TJG12Dcgn2Xniory7lh+1C6neO/jldkaSXdtRkAGARyzZBxSYE0TwfahK0kce2UNIAM7E27QibhhiNu7PvgVALS3RrcW86STOYSBxkkEnJGOCOB78VXeIypbrDctuDJ8zuS3K8kcdM/ljFbBSeddlszpHG8EKlXyrMerKSAR0b2yDQAaZ9nuXsohciCJ5CxEq7ivzE5ZtvI7ZPTPerUunECOSVvs8yKY41J2kqXODwMHn8cn8Kzp1jis4xHJI8HCyokhQOA3AUY/wAnPeoH1SWWSOGe6mWIJKQolckEuNvbjGPx570AabrbOH8uWWeORm3R26su4EqMdPlIYL+INJJ9o+xmWGOMXiyTTE7ncQ9F8oY/iXGSeRyOtVWEUt7IbZRFG7yOLhXcr5QIJOTxuyD19eafbSzfbLp7eDZHC5YEowjhQKN52HnOT+ZoA3rO0eB4zDO1nDCqSeVDli7MASobuRxnp7d6mfMdmXt5jb/aLlTK+3fIsXLHDNwG34H4/Ws2xJuor3yiECIWCFCQD2iwTjGAc/zq3ZA2KQzSpam5WMXKlIy5Y5PGD2w2R+FADL6zjs7ljK8i2dsxMzzKXctxwSDhiQecVR1mym+z8x7bg7cMpDY5JCcnG4jBJ46fhV9Y4Y7WIxm4Yq4jVAgZywGFB9Wx39APes+58v7PdXVzCCzN5WHZVZGBO87e529Pr60AZUduZ5xJIQ8CIVBcLI7KDkYA78556Dr0qs6FmvVeFYryTfIoCoNikgcnp17U+6muBLDJDKwyqxx8LH5YLYCjAyCQTWbcMyRp5juqkiBozKOVDEknA4XHb3oGXo4tltGjxTpAInmPlsgJXOBzj5gWH5CoppBctBgoHDnY6zKUbIDE8gD7wyabumt2ZxI88YQxbY3wdgHy7eOgyT74OazL66LKGjkaRWbJRm43gDsB9aAOjXyk3yXDhLgufMljcBSUxgjHUkkke9aR8kW9xNC8bRYkk2LIQJYyAccjnLEjPcg1wzzywq4LjJJYMvGM8sdvqeKlttW1Abo4JXETAx+WOV2rlgOew54oA7W1WR4GtrdGR4pS6kO2U+Xc5GB04HT2qeztor2/DpGzPIUxIrNvLu3yRx9i+Mn0/Wub0fVLqwvlu4HOWkyqybtpUrgrg9OAea2vDd9Kdb0eGfzSsVxAVSPcCC0nyjPrgj6UCPRtO+GXiO/1Ce2OnRSPAGiZzOo+zhu3B+9yenrU9/8ABvxlutkFpZmPKozRTjcQOhPPGMAcds1714c/sSy1e9s7KOOzvGuN0sKu+ZGIzuIbufbiuvZQcZ9eKqwj5Yb4I+LrdVnK2EksREgdZgXLAd8jGM571wHiTwlqmlQWb3lmFhlRo49rq5eY9SSDnPQYOPbivuC/lit7OWa4YrCi5cjqBXy98W7RV0Cwu7MyvDcXcxinkj2YxjGMn9aTA8gnk2TvGyFd6sZgVG4gkdDnt1HcVIunSw6fIkLJJIYiJGO0q6buWzj5sdP1ptwXjkF1duhIEm4JtG0sR84Hf0x6VVildLdUCqceYxOAFd2wB+GP88UDI/EURsbySLc+xGXcdwZXJAPXv35rNtrto7xbrLJIJPMDcbS2Pp6YrSPl3c7QTyp5Z3FHDcBgMdupyelQaX5Cn/Slg8ncC7u5BIzg7cc4PTNAGW92wdhFPJsySCRnOTkkcepNFW5YoJZpWXfCu8gIAflGeP0opDOgtJYbdpnnhMsksH7pcKcfNjn2H51c0yRhPEtzAsyEzRHJUkHbkEdBn3/Kvaj8CvC5k3nx42cFSMwDg9R1qSX4I+HZECf8J+wAYsoH2fgkYPfnj1oEeKahDDeGaZ7iMyjZdRlXUMBsxsH4dqy5k2/YkkH7u3CiXEp5YEnAP4jB9jXva/Afwwm0R+OWTawcYMP3h3603/hRHhoY/wCK+faG3Y3Q4z/31TA+dZQt7cFbRWTzGUquXYFs4644J5xnitdYUgSOO28+GWCLLHyyN7FsEc8cj29a9vX4C+GYtxh8fGEsQd0ZhU8c/wB6nt8DfDhDg/ED5GGNpMWB/wCPf5zSA8Wu5zFcOLeNJLfzHAkQttbI5U54JHr789KPOnSKHyLZHjgdQVVWdpQy8ncD0wcf8Br29vgt4dNr5B8d2/l544iyB6ff6VFD8E/DsB/cfECFCH39Ij2wBy/SmB4zbo8cMkvn7y67ETy3JjBkBBHt1BHTrVaZprjasBkwHYSGJGwgZsDPX73OT1wK9uHwS0Lylj/4WFGyrgj/AFfbv9//ADmoz8EdAFrLbr8QreOCUguEEQLEEkHO/PegDxJ55YPPmiMTyIWSPjkkKAcjPtwe3ek07ZIgEYmaQzkskioEQ7B1JJHY9BgY969mn+A/huR2c/EO2QshT5Y4BwTn+9196c/wL0Fg/wDxcS0JYFctFASAcdPmoA8Vknki08yMgDPOEEUZQnPXdn1GR06Y9azr27laSbCqWOHkZEwoIXBABPJ4zn1/Kvdrn4EaBPCY3+IVkMnO4Rwg5xj+/wDpQnwH0VU8tPiLabSoXb5cPQcjHz8UAeLRW95qdnawSRIUiIlAAQOxY87j1xgZ+tLDc+VYQIdwjZ45RlRyFk45HJOCeOM8V7MnwG0OIAR/ESyVgysG8qHPy9B9/ke1I/wJ0TMp/wCFjWKtKCHPlQnvk4+fjmkB5zY3VjYQ3LxW5luoXQhJMEJFuzLIpHAI4AHfPtUE9vYy6xbFQE3SffZFG/5AQcevv9TXqC/A3R1lkkj+IungvyQIoQucAdN/pTovgjpMaBI/iLp2Fyq/u4sgEf7/AF96YHkBtovOj82aORiqusayKCqlsMWPocg+hwarS/uZXaQedCiI29ynDDrkdxtyMegr2R/gjpaDA+I+mxjfuYBIlye/R/aq7/BDSFUI3xI0jhVB3JF821iQSN/PJPWkB5herZGK1SGbcjkuHkYbAjqQBu9cg846Hir9ukd7HGkLiN2lSJVZRlgBgEAjnP8Ae6ACvRE+DelxxGIfEfRtrO8h4Qctnp+84HPQUP8AB3TZElB+JGkBJcqyhlwVIGV/1ntQBwVrI1vPHKqE7fKSNgFXcGYgvjtxkj6Zq1PqMFwEk1BInVHIfzpFTI3AfOOvIwMjqPSu3n+EVjJKkzfErRgVKdFjwdvT/lpx+FV5fg9pMkiO3xG0Nip4DCPpuzj7/TigDiba9s4ru1uzZI6MfMMQmUeUpfJAXHykle+T0qzeXsU7wXBC28hafacqEUliSNp9ckA9812EfwitQGVfiToshbcTkoOT34ftyPxptz8H7W7Mv2n4g6BMkuTscqyjkEDG/oMfXBNMDzzUdVF489uyiCaYNG1wk2fl4Zh04yAQCKc+sKktxJN5nkyYeFmYBzGY1ChiFOc7Q2Pau5vPhDDJMXb4jaDnHG+TOOAM/f8AT+dRP8Jo2lZpPiN4clZiMlpecgYH8XYUAcLfOmopvAjtrwTiUPOdzFdo2qCOcqfbHGKyWurmKOR4bgo+xH2K4+ck5x0+Zwck44ANemP8J4SqoPHnhNlA+UNKeOdxP3uufyzVS4+ETSYeT4h+GWkQjbIbg5Q57c8EjigDzia7meCZp7vy2id/MJZnOWOHx0HQg/zqtHKGN1LDCXxGDEQhI34BXkkEZUZJ54r0qb4ToIlQ+O/CvyymQ/6QcE4wMgnFV5fhRPMmG8eeF2YjlvtHzHPfrSA88jby1guIpJN0YQYXeykZwfrycZ/GrMj3M1vDd+aomVvNSNQzbeSQF+me9divwguLeILD408MBc4GLrr7H5vxqxL8MLtjF5Pi3w1GY0UNsusFiM5Oc9/SgZ5ybyVijvKzKIXDkoxTqMZweeQD6c1HlVt3uIWwXUKyjOSQeW/2e5x6Gu3n+FFwNobxT4dk2MBn7QB3zjG7jn0qCX4X38QiibxJ4fCR7iCJlIOTznnmgDlHuZCfJUyBQZCsIDAIhXJxzzn7wrXsbuGMF7tmZmKeYQvKADnvz29a1h8LLxgEg8TeHCFwuBcqMhRnnJrs/ht8H2k8W6Xdarqug6lpomWWa1SYM7gK2AFzzlsE/SgRk+C/B+ueKZI7rT9LPlbwElkQJGq98n0PfrmvVtP+D4+RNcvfN2Ekx24Cg5OeW6+levWMa2r3MaBAildqqMBR6Y7VceINJISeAc9KqwGJo3hHQtHtFSy0uzicKD5nlhmyOhyeava1oWm6tatBd2dq3m4G8wqWHuCR1q7cxkwOg27ipAJ/nVPXLxNO05Ly5cR28DJJLI3RVHU0xHgNx4OivNM0hxa20s2o6zJabZIl2xFGKrISOc4Xt61j+IvCmj2Hw21vVJ9Cs31o6rHp1qkeTsbzAPkAPJY5+oroLWya1sdAt7gpBcaPrUmt3iNcqPstq7KwlPPKnfnHPermlWMFpoOsWV1ZQXF9LrA1+zjkulBhh37vtYPYAA8DnnpUjPCb1dJtJtVjudMvLQ2Z8ryzI+UnyOG5wP4uKzINM0K/tLiRbprdI2X929zhncnGQCOcDqa+iNX0VNYtPFyWdvpbr4gu47/TR9oUm9jQkvLyODweDXF+ItG0Kf4TiW30uOOSPWTETEytKf3fGSoGF64H40gPOLXwLDeovlahKEZzgsQyDpzn6VB4l8CXGiaNJqIu/tkKy+VIIgSYwTkMcE8cEH8K9d0DwibvwrpNpZGWPG+bBkwF3dSxH0xXo3wh0qL+w9f3fubpR5QnD5AXYeR+I60wufKWhaHrXiO826Vo+pXaMxT9zbyOijbjOegB789K7XRfh54xi8Q6XBf+HNRRkkhLSld2cOD94HAAAH0Ga99+HEV7qmiMLzxG+wgBYlvAWQZ68V0+vXEuk2Et754uvJAk27+u3jHHrjP1JoAuXdnA3jWN7eGSW9Zd8krv8kKgYUhe/J9a6a7cJ5GXKlpQox3PpVRJiZbadYiDcohYEcpxnrU2qHCQYR2IlVsqM4piE1uF59HvYoohLI8TBU3bdxx0zXk3xZ8I3/ibwNoVt4eFtJDbyFpGnk2CJSuMk4J4Oc17MxwhbFYer2ka+HNRtkd40NrK27OMEgnOfrQB8X694W1fSLq5tZ1spgikCVLlcOGIJIOB+dc5eabeK+0XlqGCZb96cNz6Y7DpXpOp6dJMSz6jZOxXhiCSD781zkmlTu5jjvLFWPAwh5pDMzwn4at9V8R6TYXdzE2nNOfNSJ2Rih/hU46muz+Kngvwn4f8CQahoUd8t+l55H+lPu3KQcYHbHbFdF8GvDnn+ObJLrUYGhWOSUxRrhmIHC5PYdfwrV+PGg2Fr4F1O5F0ZbiW8D20Z/gUHaVA/rR0A+Zx50o3qrlexRTg/nRUnllMJlk28YH/ANeimO5oavoYsbm6Q3SyLAw4SfnDHpx6d6qvpdxAZPLaUrgsV3kgqehBrajtg0E8ouFc3TPG0RDEjB4Y56DPApVghiuWTc8vkuwLMrFcbep55HepAxmtJIbtUMlxIpIG1XfPIqx/Z0RQmO5uRtAWXG8gMe3HU1tR2kQjnZlCSEDJijYyKCnJwcCr9lawSTxPZxt56LGxHlECMjIDfj1+tMRyNvpryxxnN0Y5VDBkZ/lIOOB3GcZ9KtHStiXM7zviHePLSRztZQPvn3zxW9aRMJRHb77dopEkkYqd3mHLBGOehHzHgZ4qzFcTSTrdI8V210SzTyqNzsrBVGzoBkHt0oA52LTpmkIZ5CQ3AjeX5gVznBPA7U2XTbi4iRoLqVVYxoAHY8spyCSeCuOa3bm2WG1/fSmeBxKI9oO4c4YnnPBzjtwAKjtZHSdpoYU+z7pWlijRRhVQIHx1LE446dfrQBgSWhjtU8u/umEsqMrbyMADB79STgA4wOTVaG2u/LuJWvLkhI9+0XGSG3YAA7j+ddE1lDI3lXcDCQCN4mTaQSAA5bHXAwBj1JNVLBhaLeSQQpGZfKQy7iXjI/i3dACQRgUgMq2F2WfzpbkK0bkEz8Bx2z27/lxVZba5khMkV3cj5iMvPt3ccEZPPcHHSt8COeW9d1EauJWhBLtFuPqAM5AGfT6Cn30RZpLgMGhjd0hmErOVi2Y4BH3NxOW78igZzMi3QCsLiYk5AQTuccdc9+TUz2tx87PcXCsCibPPbduwcg+/Qn0rpL+SYzCNUaeR5mVCrOPuIBwcD736Ade9QRNeTQvO9yEIkDtPuYpBOVxuPHJYccetAGDbRzmSFWuZEbZuDSXJVJFz2PqMHrRIl23nMs88BDNsVp2y3zbcDsfrW5DYytfQZmZoleIECb95E3dThefXjkCnRvGtmk0tu5ldZMP5xVMB+igDkc47EHk0AYMK3zv5YupEIyu6S4ZV3ehPrwcDqalt4bu6ureNL6dW4SUmRzzgkDoPT8c1vyXkcEkkYtkgtUV1uY97MWnbBDb9pJzlQF/M1n23227kV5VlEYIiOQ2wkAgqeMb8YHc9AKYjNY3aTCKK7knJjRiI7k9TnK/73+FRSy6gsaSJeyldo5SZiHGcZHpgDB+orYt7TabVXMjSpER5UJYysHJUHIGAqg9O+DT5LaO6t4005S3lIymQBgr9twGAFXjAHQHnrQMyV/tAFXF/O0JDurecwyAOvsAeOcZqRLq5eFZFvJWyoQOJXG1uuGHr3/CtSLRroyr50caGWKWRevmbBgE88nBPA6d6ghsG/dQzv5TRtGoAibGWxkjtuxkkk5waQGZHdTmOItf3CupAbczNnLY6Dr/+qootQki3ZnuyrFI1cOTkg/MT79sZrRXSY0aRXWTy2jxE6xEgtkjIGc9Twfwq1a6O/wBnt5oxHNOtzHAtpJCAZTkkttBzgccnvxQIyZL+7kiXynuPOcsm1XYENuGCM8HgdvWra6lczXH2iVZ0tFkdQEZir/L0PrggenWp5tOlS5aW5hS2j2ylC8RwFjbkbeTkk7frU9xZnLSQQqsaY3ExgFcxhtgG7gZPPp9TQBjQ32pBAPtMi7mdGwTlQFHrxnnrS/bNTuZIiJJYmChMDoCoycrnJ7ZPqa1odIYCUoAEUxtxGCuWU4xzkZ29/rVK3tnS4sWZWWfKGT9ydofJXaCDyDwT6mgYxptRazjuTczxxqWDBCSxwu4lh2zn8KjNzqsUEaPNMHl/dpxkb/r61tR2dt5ha+tTHPFbiWz8qLCy7fveYcnCBefUk0lraR3GlLF5SPOriBsJgIZTuHzhsE429OmTTEYiyajcSEreypMDIdjdWC8nAH4/TFV2utVYt5NzcSx8bjgdcfnjFa8drL+88rYrsXUOmFIIf5ghz7gD1zgZ5qiiGI3TRFYoxI53CMKQIwMfLnvnBHc0hmdFqd85DG8nEYxtJIPt+JzTpL/Uo41V55FjAJU5XOM4z/8AWpJLaeJo1uDFE5CkIAuDwCM+/OKXyVSa2RlRYscSMQcuR7Z45FADItQvAU3XE7jsAVOeec/mKY93cgSJJcSNICchcbQQfpzVg2xCRRs5KCPG5ygGA3PIz06ioZYFWNlVyZMMOCOBn7vufypgEV1cu4xdBQPmy+0dFJwBjrxWz4M8V6p4Z8UaZrNm0NzNasHEcxBRwQcqSOhwSKylt3FyrkqFUkktIPnYAbjnHOeenNTLAd6iFiEXZ+8RiR3OOnUDJ9sUhn154C+N3hfWmI1Of+yLu4wTFdt8mM4yH6EfXFerW11aX2Li0uY54X5WSJwyn8R1r86Z4nVpFk8wRsAY5ACWcA/yP9K0fDOvaloV1DLoer3elshyzxyMY2BY8lcbeBgY5zTuxWP0MvIi9lc+WRvZDtz2NVfEcbnw1ebWjV0tWO6Rdyghc5I7jjpXzd4P/aE1yK3Np4i0lNScZxLbqYpHTucDK5xyelbGs/tFfb7O6ttL8NNuULGyzXXzfNxjCr1GemaLisdXreoy22seL0Nxp4MXhqG5TdZ5JOCMk/xrkHCj1FWNV1ttL8H3evGfSJ9MXRIoGQxESfaTGSq5H8J3KNvUV8/6r471e4ea/TR7J42tQhaWR5PMTGBxxjkYArM/4WZ4tj0a40uFdPj06bBbbaE42YYMMk8849xSCx3lr8XT/wAUkmn6ClxOLOS3Kx7kBuW3ARxknBGSM855q34G+KF14hivtI1GDRdJER+e4mvVikDAEYw6ndg8dq8W0vXtZ0qC1htZLVDDObm3DWaMVlK/eUkcH5fwqprfiLVfEDwS6tdR7VBKLDaxxBfUkKBk5x19TQM9VsfiJJaxNDd6ncPOjGIyW8KkFQf4eMfjXT6V8ZdN0HQNQNzDf3qzARpG/lq7M2Ru6cgD2r5tkWSRmLu7Ene4yOh7+mc9qQIQyM6sVXA6gHHJ/nTA+jvB/wAZ/B8Gn3EGp6ff6dM/PnJaQzJj6DkHr2rpr34veFptd0ux0HUJjZPLGJbj7DuXqAVwcfie3avlWyRpRFGxbAw33hgZPJ+vWtXSIwL6FURXgEwbDSYwQR17+n1pAfe19rQ0/wAV2Npdqq2uoqYreUtk+avO3HbIPX2rcvxmFBkDMiDn/eFcP4ttLu98Q+C7i0ge4toLzzJZYvmVcr1JHau11QAwR56edGf/AB8VRJYuZkt7eSaZtsUalmPoB1ri/HfibTfD/hGe51/f5F5viiWJSS24ZVfbiup1+N5tD1CKJS8rwOqKOpJU4FeP/tIxv/wrfSTNEVaK4iZiwP7shOvHof5UMDy258VeCXUlbK7CqcMMP16VT/4STwTFcRk2N1uONrbmOK4W7gWBmLhXWSXDbkbLnHXnqAfzrI+y5mgVUGZB8pKFtuG5I9elIZ7v8PfEfhQ+NtNs9MDw3NxL5UbyFgAWB4ye/FXv2jIdOPgoXNrdwXMjagsBKzhmUrnKgA8YxXzXLHIyBnXDZBUqMbue/PHamJ5kkYCshIPfAI5570ASwsjJlyoOT1AJ/WimvB5LFXbnOeCD/WimB3MtlFZT3jRp5sXkpCsrEqzsG+dl9Tz06VQS5aK7vEhij2O7tuZWcrtBGD6g/pWld2c05l2QOLsRGacxsxRA4BUE5x05xVOC1iZlFqJN0wkQmNCA46MvJ6g/5NSBah8yEyxXiPDM5jaAuCycjHb88dRii3iuWksjMiTBgu5RuVd24r8zA/Nzz+lTW1i5vJJXtvMtwzNt3kmLahznkngfnU6YjSzdLSJy8O9hMpVXhB4kxnO8kcDApgQLHfuZjJaw/uJVeWORPkOz5WLnO49QcetaFtcweZPHHYoIP3jSK45AUBsDnoCQBj1Pesi6DnTre9tRLE9yJZHYn7w3AAlT3HHT0qK1R21G4jMaXJQu5YhGGdgGM5zn/PrQBFGs0S+e8B2M7iMqqAruUcAk9ssRxkcVajure5S2WfC7oGWJhKoby9nzB2xwcfj+dGsQeRPbPMUxJx5ShcIdp5PHpkfiKoSmV2nmUxpKZRHHsXey4AAyQMYOc59uKQGtAl3cSSSpOYodjKvzYKRlQdqgDqWH0Gaq2ylIIxczRRPHAjGQMWVpFbgLxg4Bx6Z7mtOZLmFreNn8xo7mO127wB9w7mU4+UHnryagS5S2u5RPLGrRruOXYBXR/ujjvjjtxnrQBXfT5Uup5XupltVhk2uXYNKM4KrjucZx6DtVXU7i4t4444pwzOrQM0hZwy/eB6YyOeOnUnpV7VGeyS63XxZfKMr4dvLQN0iQY5OTk+uOaqRzs18gn821Yxt5pyzM5YKpwSOMDIx7nvQBWeZnnXyWuWeZJImkZmKg7fmycfNuGen04qqsczSJOWkUxJtWNS7bBsAX5cYPfoM961YQ/wC7njsZoYrgkLGzsXi4Awemd/OB2AzmnSxTBbR2jCOiq6OhkIB5BPuMEAj8qAM6E+UoELSrHLJFKXBbd5nKkdOSQcE5xUqQbPKe6geVGcGWDdI0ceZCCM46Zx8oPP1zVXdbm7ih8hDwEUjeVVTuCkDnOGyfftiri28srw+WZ3V3VnQlgGwcNuyeARggdevvQMaEhlumkuHMDt50pUMyuNrfIxHTryGPTGD61IpdbWexhJSSXzHRYi7NJhA3yf3Wy2S+T1+lSadCR/xMLeMshnntomKOWdCMbG55CncQPbmpHVpkure4RjeYCRSLG+4b1Chjz95goYDsO/agRFqVzNP5BMe10SCGP92y7XZBuXtnjLEfgDUMFsLq1iiEzqU2CLCOpcmQkjPRRwMHvn2q3cac8sV3PeNbGALGQJAQo2ENKTlst6Y759KrQ6Sh09Gt5CC4E/nQhkxbI/LdcHAIOT3wPWgCzpQnGreanmZLzxwWxZhIdpGeerDdj2GKZGLWa0VLtHVNyqkKRnYPmyWyT95juzntRcloLGIuuZEkkljbrug+6TwRhg2D6E1ekht9QuWgjxExQRqvl8MnlgluCQfcZHOMmgCpfTQ3EVvNDCRC48lyG3MfnGH69x0PYce9VXs4/NiPkp5k0hMY27SJXbaFHOSvHUdAD6mtI6RLDKjXMMUzyRouBGqCYfMTjJ4HAJ9hzVd41msYlt4sySRLysXzs5faTnoM5GBnNADLqP7WPswgM1z5UhRXVlVIxIpB5bu4IwefzzULB7vT/OmGGWaVmLW25QoPyqvPzHLH5egrT1y6a8aWWNYowdwRUteFMeOnOT06Djng80urO8kcUF79nJmaYmZ0VcYVQSRnhjkfkeDyaAM2xsjDsS2EqKsiRvKY1IBXLZAJx+PTJq+Vj3WdvHujhJ8rc4XcCruwZCTyDySzd6bZWc1veQJMqLI0qOrEIVZxGThwpwFIyB6/hSS2ciojWzIsoRFjCCPjf8zKc8A5/DGM0Ac48cvnWscYiWWMlF8rYV3ZZmye/BAJ6D8KlSW3KRo1u6F7VYhHGFZQQx5Bz/EMk9xx0rWvpk+x2zL+9jWWLaY/LB4Py7Rnk5J68Hk+1UWtIJJmtzdWMQiBSQyMrB337gAcAckj2OKAJLuysobcS/aIlZ1khFpEqhgQwUO/PdWyD7dhVWWWzKQTNFILVJgA48sDBTn8SRwecdqdco091PALhHX50jRthDOHTk4HQ9AB14HSpYoHcPPdgRTJBKLViwGCH+8MDbs6DHA6k9KBmY8UdzBNKZniGFldNq5bAxwP9rJ5PArBtHkiuICkzfK2QUJP4jIwTxjFdTJbzC7+xxSLbXi3RMrvMN020fKFOOAMEL69cVR060H9oR3MUDGCNknYNuKsMn5Scdc56de1AFOSO3ZUaMyopiBjUEOx+ck7gBweg/Gk8uaV953St0I3H5Dv6nIA4Jxj1Jq/JHE7smnRuPMCyLGxZmi+cgqWGOeck9OKlTy/sIluvmtpfN8qc5ZcjGOOwBGOe/NMCvJFdQXSwLG4gtmkdYj821CNxYjHAz7/AKUyOCWURMg8yVBFGzrIwQbs4wQP4hwfyq1fi6d5G8uP7KPLt5HG9h8wHGTz2xjvkUnmXV7OwsraOBJF2lI1wIjs2jlj0ULkHtk0gKN0g81gQFcMFKpvYJhtu0Hr34HHpUZhdLUyLbR7mD7yyHYADg4PT/PrWrZ24YRsLfzJVi8yKNY+GjDNudxnt2696otHN9oSIpBHh3jMhIxjOPmOcBff3oAn0+CYykWoWQIc7CCEfI2qBk5x1ya6GxtLH7RHIYlaGKJbeZ/KZSCwyW25zkcnPfNZulD/AEa0uZNPia1aWQQuhLM4UBTx3GcDsK2tPCQ2+5rSMXjHy/spGAiGTgZzktnjnsT0oEVLnTmn0tAkCCWJHjA2HcUVuGJzy2QeT24rGulYyzGCKNXEEogKRERMN43Ec9cEj24raVVa0lEiMse6Yt5i5yvBYFi3XIHQdM0zYJLyPT5I1ijCvhMKyiTIc59BwOOc7femBzF3HGHnmiRWjSVosMoXcMYPOfx+pquEVbY7wrSK5xgrtJz/AAgD5v8AE1oQr5MFxGUTY5WUHCklmGVGedv8XHrite70W0sSjQanblGBIi8zc0fmD0xyOPvD8OlAHJQRBThmTjI+8MjPfmvoH4FfDzwn4s+HWo6hrlhJPqVvcTx+cs7L8ojV0ICnHGT/AFzXgawusgOS4QDau48jHY4r274DfEPR/CnhvxHY69LKj3DrLbKilvMzEUKAgYBGAceh70wPV9b+DngiDw3e3Nno7RyxWIliIuJPlcAnd15PAri/hb8OdA1zWZ01SzkKxBztSdl5PHb2rRvvjnpc+iz6eyRLO9isTAl/lbO0j7vJwRxnHvVP4afEnRdH1p3vRO6zgpujTJU+pBxxSA+g/Duiaf4a0WLTdGg+z2UO4pHvLYJOTyST1NVvF5P9hLI2dyzwtwcc+Yv+NWJtf0iO3aSXUrJYxGZCfPUjbjqMHn8K4bxP8TPCsmgNHHqDTTBo2MUcLk4Vxk8jGOCKYj1CuL+LlrBeeDpIb22W5tGniEqNnGN2M8e+KXT/AImeEr+/gs4NXjFzLwEkRkwcZAJIwOKZ8RfFmmaN4bN209vdBbiL90kgYthgxGBnsKAPC/B/hnSbzx7ZaXfaTbXVlLcuWWYMc4UnnJ56DivVF+G3g+OWyj/4R6yVWupoyAG+7hvl69K8gPj62tfGi65ZRny1uQ4jZSQAwPB/DNdVpfxu086jC2rBBZi5eYNCpygcEDOe2SaSGeXftD6Vo+geOGs9Gso7OzS1jPkwqNgck569M8fjXl8DSRSR7490ETAkAAEgE55/E16J8XfFFl4v8ZXepaUjm1mhRbcyIoclOrc8Yz2rz2BGi3NHGszLEA4JViFJ6D3oTHYhLIXfaDjcfQd/8KKTaInkUwsp3E4JFFAHpkN0trNcNh3Dq0LW4VstsfG8knHPAP5VI0YMbwfYVid3kI2D5t2MkIScL9egp9ppVtdXjW+EIBa5iRVyJFDEjdzkc8mo2Tba3dndYRjJKEuCoO0AbsZz07cDHSkIltIJZ5bqG2SMTTTqysp67U+dcZxgDqfalt7MWN4j7VeaGKPcxj+8rkk4544579appevp87zrBDGjtGzPJhiU2kAAZ6e3rzzTRrF3J9luo8JPfNFKx8tQQNrLt56LgfnQBQSFYLSFJoc+XHJ95lbduPHOetX/ALPJLA0jKZCCfNHylcnACqAOvC/N6U5fJNtA0exYgzI6ZA2oufu8cEk9T2Bq2k15f75DPD5wJUtGVUR5xtJHp0zn0oAW1uI5IkgumlRy5lJaQkEKgXdnHAz+YH41I2mW0cxjiVws00byB5mBiKpnIIHGQAR9cc067tbp3uI7mQ3CqZI5mjOfNO0YUkDpj07CqtzPeNBKs8zIZEiJCMwaWQ4VduB2XjHpQATSxNatcqR5kE32tVSVpTHK7YJORySowCBgZ4qSRPsLytLHvZ4lCbmYhhydg46kd+vBzVd9NMEkUkqyIYIhGwQsCzK+Bj12DJxjAq3dokxDr/pETyTFJ0MhAYEbgB65LcDv1NAFlbG3ku4befei75VKu7/xKrAk4+Ubc/U1lXenQXMplSeJmaOR1nEjiQuDk9fY8n06etdFqH2iWd3Ad/NXd9oXI+Qr94sT3+U469KgmksJrDy5jc2tzbWU8zRiMgSBiEDRk9WYAL83QZ4oA5uR21OeSVYRJNKVgR3V1KNs4PXkkEkfh2qldefZafPOJMsVWZg4L7UMZGcn/aXIB6nNdH4h0uJbq4S3Ek81tPGqJErYYNHtAHIOTz79+lcnf6Pc2Nq947xxW8crvG8zI5YCPGHA64LAcdfc0AMUobezQtbCNlhkjeSIlizZJBGdxHXHrjsKnjSa4lnne2WRpLaWJmjiwCyNlmJJwCOp9MYHWq0uitFa6hFPAEvSsFw6K6DyY8EMPY852+4o01lexvpWU7ljWFZCU2x5OCAAcj5eMdM5JOKAOwhsDNqCvCQJQhZEjUoATGBwmfl4B98nnOayktzaottfFCjGMCVUbfJuU7W64IU4GBxyT3rLhd1lljuo4VRZTI5jZcgKp24b+7gn1JJAFTXc0ciWi2JicbyPLEYd0/dkx9D34zjjIoAWOJ28i6nhhUC5NyVmi6oxIPfPy4G0d+/FaNjoc7xwKGSNfKdI5LkbI/MaQkF8nlNuDx1I6CqaLCyrtt0Ihjt9iGNPMJAySwJI25wT+tSu0lxp9qzsQghZ1VgrEFW5DMe7D7o469hQBFHHbwCdJJbaRLaRzaupVllWTJ3HcR8oIYgdhVmz06KxMCySQRrE6ykthUdmyCCc8/NjA7dTmq01m86kWRMzs06xSsEOWchmGOh6YJ6DgDrTBLBIjSym3F490ziMBDiHymJ56ZJPX8BQBdTR0t7uGMwyMIZI4/McDhxlk5LdCfvdOOe4FWpd9xor24mjaTyZZGcQj7ysNwGDwCThepxWZ56ZtnsbhjeXEcJlaSeMmRdo/dr2Xbg546DAq/a3s32iTZJBDJPZGEsSjDerHLL37A4/M80wCSE20trHcXyPIgZ45CqAIu5XGBz0xnaeuPaqF5b2cCKvC2G+SQFZF3Fd6swYn7zZ+n04qazhEVgscs6zWsi7VRnRHRup3HHK7R7nJqTSUt7pp4TqMbtePJdk7cqfLG1BjAwcfpz1NIAtLmaDbHK26d7i4uIg+1RvwAoPqNpGF65zTftyxbbaExNZxbVTzdjeajEbgcjswJBzxxx2qYWwtpY4ZLktKLmZo90qlnBDAvhhxuPVvbAxWbG4lggtp2QxJBbj725o8FgxZ1XhfY85PrQBPdT2Y1RwNi229ZliEvyRupbDbguFDFlwB0I96jsrOKx3+aEuriSMq0hk4YqAfuEfKxGRj0GabPY3NvDelZnDI3mPFAzSRxnzPkZWxzzg/X0Iq1A5nvGkmuX3P9omMmXRnTCgMOO/Lc+hHWgCOSxjSa1ZJUmt7fbtW2IZix+YEMQON2Dz6U27gTefNu1dmEts6O5EnksodYsY+YLnPHJOSalMazy2dxHMLd8SSKfNJMT7c5Py/eb+724+lV4bqC9l3yx29sVRi6u8hw5TqD2ZiBkdwSelAF2a7Q3TXmVurm3dGFwH+UlVwHAC9xkY/KssQgwSNe3JB8kBA5fCFW5G3AGWyOueK0Yoxb2MnnLJNZTTRi7lVXVraNUDkZxgjJwOM4zzVPV3e/u5FdRAZI4LVgkT7YBzsQZOfMwAxJzkmgDmprdkMkaxCR2VwTGGAOcYznjAOev0rTh0uZrWe3aKRVmDu0qEDKgKQcE8Dtx61F9oWadYXs9ryMBJd3DBfLbIDBUJ+YADAye+a1rOytYkiuUmhltWkkktplj3PjbjawzwMnBB6c46CgDMAhiuNyukYkZZBLKC2z5DxszyQ2OT7HtTYXSxms5ZbaJUm2yFlAfYQdm3O7BPJJJ5qO40U21krRR72lg3mVgI4yucEYOT2PT2q3b3JFxbyx2ixrKis4dUPmcFBlTzjHQeoBNAyKBlawmaGVI18t45otw+RQcKVwe/fvU1toimO6kYpLPEjboolUFDjK5HcEHJx6+tBjiacQXcWxIlK52Ij7WfB2kfebHAPb8qtKsCXU9+dTghWJHURzMjfKduEUKOcnHI54NAi7p8CQak7SPb28kW99siqoUbNp3EHAweAo5z61UQE6WqTRxeZsjWOSUAOUMgc455kOOR6AdOateW9lHaC3nE0gjjmZWAyHbIxtI+Ydcdhn1rMhuQy6ULmK5CLhonDKpVN2ANuMH7y5J6D8KANDWZVuN5hiQtcSTRvECoRWChT83ZmwSO/YVRub2SN5ljaJNpYowZFCNtAXoME5xk/SrcEcNlCZGvXuLxkninjSQMwlPyo4GMbSOc8cH8Kzp1itJUgvFS4t7chTE75UZCsXbAzgHJ55oAfOWtr2IiLfNEVZ5VdQitjGRgEAHjr6+9ZkzsxEzSGTYyqmZSWyOwGBnHX2rX1a9nub+d5Y44o3uTHcP57BLhcKVYgDA2qq9uBisy0udsKmV53jR1nSNS22Q/NkcjgHnnPSmBHFM0aW0gj8wMu7EbnBIJDjp1xgZoQStbiT+BQkgj3N8oxgp0+pz78VYjkZpHWVCoVQ/lkHMW5SAoUe5B6nqKmtYJb75AJY2dYBIULZ+RWBXnqPlyT3oAz5IXR97t5kZ+bI3DIGOv9BUbtOT5iPMlz5jCM4JIB698AYPStLVDBLbRXsVqxFxAz+XGrsF+cDfuPX0z9atzWX2ZrWCRoCZZZkUQLlSoUHHJ4PbnsKQEdsyOYI7hNkYnWGEyKQoAG4s2CcDGCfYVIzTyxNNAJJ7ZGd1k3Ntn2scMMnoTkjP5VFa4laMJCVtsSrcyC3A8pWQYABOM/LnP4VBeG6axEkAzZPDDgS4zIxO0N1+XA5oAS+vQY7iR5VX5m38ASOePlXB7Z47Yqsss87wiaNfkkMIIUAom3g9Rk4HWmSSy2l2jWkwiYM8XmhEAOCOnvzVia5jGmtPdMJnEbQwgMrPFlznOR37+g6UDGWV0y39st2wVC6IgWNdpjAIJx+B6+tVZZGNmxRQ8SKWwQqhAXAzn61ZEhdoTcRwmOSXbstwAFUIFJYnnBHToM1RaXZaRI5RPmVFxtGVU45GOM9fwoAbf/aLSWRJHdZCjEKNuFRj0Pp61TjMvmSLGOVzIwD4OenUDv1NW7+5nuGnaecyyTgRM4ICEBsjHHAB/nVS4UiRwZlcCQqvlt97jpjv9aANC0iYxksCzliWwSQD6Z78YoqoXXaqLMkAQbceYQW/2j7mii6Cx6PDZap9ht7MRhxO2wBIgCzEb+XB+7jANRXNxaxaLcTxWrrdRTyDMiDyyxXGByD1zjrn261esdURFt5UlUSWkTJbxYVRhj+8Y88kcAZ5qGcC+UyXgSYvIY2wqooTZgMfQ+p7k0xGGZJppY7SXyy8qsIAAgUELgbzjgj261XkufJvpJ5QTcLLCh2dAEHHGOcHvXQtpYhvLW6kmSLyXPltJtYbXXghegwe/astShs4bq6nH79RHsRwCWVsKG9ByTx6e9ICaxvh+8WUxiR4COXGWJf5mwR93HYdK6a3t7e3s7m8t5TPKyFNsbH53ZwSW7cKAR9K4e6MP9mu9jcXC3QiRHMp3MdrkFcdlzjBHYc1v2GvXsl1cQvALeLLuSSRGgQDJPHPHGfegDUvnaSO/FrPJFIsoW3IlLctgtIccE7cj6VYniN/He/ZHlKAxKGmZn+fBw2OoQ+vXNcxb6lczELJ5kTLhEjTc4k3LxtHHPoc1c0rUplN15oeSFHjS42FgFGcFSPQYHTv0oA2oEb93FFctNJbq2+RFYmX5grMW6e5I9KtC0dJreMnaZrmQIU3AoW+d1A6AMBuz74rM0W5ExNr/AKpXikVEVHCsiNk5z0ySc/StxorbUJrqaLzpEnchk5BzjdlSTnBwoPtQBkTRGztRDukRZnKqDAfv7d7LyfTHJ6DpSa/azPHcJJDLBbNBNFgfLKmAGVWOec/ePXHA61p389tc3cgnSOZmhywClNiuQR1PGeQT6YFVNizWM8CWzR/NI6ylg0z7j+7UsW4GBzjsAO9AGXqsbTXMV0FRWlWN4yIi29dmCcs3BAHBNS6PAbi622ypHaxsqLG0CBHd02k4Ppg9MevPFMkVtUWe2EUUxYrFGkZTzDkc85wv3OnoGPes+6R5rgsGhSKEFpmIQI0hiyMLySQeg9eOtAE4s4WihtUlykAiJ8oKAGDnBJP3gMdD688Vl21xPeMzRIEuDHKH2mMKiCTczD2xjaO59qXUGhNo8bJmSa2i2rG6jJDfIv4MOV6nPNPsLAS3DpPcoQjTGZTMke6TaMEkjO3gg4+goAgi06RNqWFqQY3ldTdlXGGwQcjqccZ9elOtJ43keO7S4gW4kRZVjdPmjEfCY6jnO7mr/iOW6jlivQ0ci3dqju2UCRhVOxWUdG3Z+X0PPNNtwIblUlhdHbyZdqSoPmdNpQHr0zzxjHqaAK+g+XLrUcrReVbuYm8jzAWaLoFJPfcM8+wrTkUwxTr8somjeF0Z08x3MpKoM5BXvzzg8dMVLeC0tLbZcQNa/Z4o45wI1LxOJGCHHXCqcgn3JzimzxRyRPMtzb2shUwl5WTHmHbsI68Yxn8aAKikWFtcIqpNshl3PGyEx4OflBHKnv644p6gNFdmEwPPI6MyQ7AiIFXCuCPmYdePepLhniWW3s/NnLzzJHnYrs+3ap/3Qcn3B9BURvHeWCaGOT95cRiJdytiB42B3ce2N3btgUAUrq6VmZWRJmjEEjzKyIu4ZIBAHKgHBx0PqaoWrzzwW0ccyIVB2M0oOQZQWwu3AGcHbk4AP0qayWaC7gi3h3DxebbK4GxAcbSwHTBU56VbiuI7awhCqI3j3WgLvl2QSfvADjAVgRk9QBwc0ACq0wjN1dpbnznRUeQPIysyqX2bcY3ZbPoO1MjRrWxNxYTlEuIn824kkJVWjlBQE4wDkfdHc81tRXEH9oR3kbQTW7TNE8FszFzl+dp77mGB7nrU8axHThawW/2i2Anlijy4580YUADkq3APPXPJ5oAwNOuvtE9xAYvP+2liiyyYMigF3jLYBYhjnqOu32rSkkKQfaZGWI3SpI0COVWFcKVRQF+YfyJ/GrMqNb6mxthscQzs8SuWYrIuSzHBwy8LxyaqxLcagLJ71nn1JTbooO8mQhe644BwDx60AQQXFxO6MjXMdmy4ByzKm+TA4AyxYFmAxis8eV9kWW4trhZolZo7ecuQFWTj26A/jn0qzYvNdy2dyiwi6miaYo0spVSsgAXI/iC5+gOBTn0+4SG5u7idDb2JaKMykgLKz7QpBPTJPPQZ/GgChHLcROlrIBNGssri12MBM8mCqk9VPTp2HI5rUtLAPJdLfQtaq/71SPNKncuOBz/tDuSB2zUlzCku+0X7Ump2++OK52lj5+CqhCxyV28k9QW9qZftcljFBcbCzrZCaCFizIRncOS29j8ufQUAUmgRmvEaO4lDrHBIj7sLujJVip4OOCO5xU9irXTwxOojezlRpYfmKMWG1WcknPGSTnOcVG0UnnoPIJZpI7dR5TDJAYsz4PL44H4H2qOGEtcQG5V45njdTHHEWCYJ+YnPzNjPrk46AUAZs8CyXCWqWm5IWaKVjb+YZNrbtx5z2Az05xVrUELyK7HEFy7o4SPKrPg5Uc4GM9Pp1rVSHy9pjUyXA85QDGOAQdoOCMkAYOOBn1qrBpNzdNcRwKzrHIpjSJFXZIVO5sHrwQSMdByc4oAwlhmuZ1a2tGjQOkUfmgFVIX5mwT8oxz9akFvFa3Fk8lxiVjvSbKblO7ksp/DrV2OwjtLqGQLJAcCOVo3QD5gRhRknGRzn8afpWjwyQGFWh8ojb+9cD/locE+v4/UjtQAyzjjstEa6Ev8AorF4Sv7ttoVtwznn733iOTx2FEsk1wsSyNFgbk2oFI3FSxAGMt1xxwPlHvW7Pp0JQXcSZe4knKJC6kFVVOpIyMkA4xnB44qjqD3FtqUM00MqSM+6RxMFYkqSVUqMD7ozxzQBRjulbT51murQNLcRSr5jDeoaLLHj+HjHs1Os7jWYNP0ybDjTUiHlvKQiyqXwVj46e/J471hf6RtnZJZTZqRJNM7E+WSCuSSOhyRgeuatQ2NxKtkt1A1y0J3KrBnSNBzsBHIGOoHHPagDWS9leG6hjg+xSTxyvmPcWCAKdo6d/nz9BVbUNOsoLWCa1v7kZWSRmnhfa7/KgUqDxwSxNVN0st3bxbpIGKSossjuqqGXeqsR0XA4A68Zq1FcG7tFghUveyGRkW4ZtyOMAoF4+8CHLE8UAUZbW7tYZxNNPJBbz7Y5HVvKlLIG+ZR0OBnn1Hoaow3U8bwfNvYhAzPEzOxCk9M8jr+Faup6dNHLLbGMTTR3BV1Ri/lqsYB5zk/Mep61Xt0tfsEEckLi52o0UypzLGTgZ7ggk/p6UASOLZks7gyiSFlCNJ5cmWKnO4juCx2jHp2qzCDLLeTWkbKypEj7wzIm1vnHPGCTjB67jUESQWcVsrJHeRwSNtkSMnB4wpOeTkjNTzQJaWBMyhpTIUkfLBSwbkkE4ZgeB2PtimBFHH59vALhBIwURGJFcDBYudpzjjjOOCOlTSxolhNLPEWY3H7wTo3yKBlWODzweg/Wq0lhEY41WZooSWYjPl+WSc7VJPpg8fhW1Z2KN5015HAVWdFAORK5MZMO0FuuSdzc0gK3mR28EEU0Rkk2KGjRPkSVATDu5+cMTyOvy1VvbO6isVkurSBGuIzGPKRVDZXfhfpzwetaTbLSONofKje1iX5/LVnDow6jPIGTjue9WoJHEJgliV4XmaYusgLI2Ony+gIyB1yaAOclsy0qQwh/IupY9qsUb5yoyyN6A5zj1xSS2EVvAwktnndJHMLsQHBYYIIx03c1p2kzvJbyg/ZrhVIPlyLgBztIXjCghAfUYHerWnO13LY293fxpFCzS3CO/wA1wCcHccZHIHze/FAHL6fMhhIvUkyoQY3hT+7bjtzjrn0HellL3XmG4lM8zISZYmTbgHLkgDAJH5VszX9ndRGJIEdpYhGpEgOP3nCE478rxVK5hlW2me3bbMWuDJGCcsuRgFcDg4I7ZxQM5+S4dbMwGXKIXwAQM7mGD06ACpvsZSSGS4EkCKylWLBisYwC59jnirGp+VDcSW5MyJhThwx6rjbjHUZ7VSS9MjCJAEDpskly5zxkAg56YoA1Xe1tZHiiu7VrcMfJe4xvdM8EjHGeeKKkh8OvdwRTTBJdyjbvnEbKo4AIJz2z9CKKANp4Vn/fG5t43W3k80l0Vjhsljjp+HNLpuo28ljqEd2fMhmkCAOwAMZAwGOOTnFZVvBhXCzJHiJ/NU4Bxnp06Hjvk1as/Mu76BJLgyK0+NyyYQAjLZGPTjI74xTEWNQ1K1ld3jRozmMfNKuGweh9vp0pNNiDPbTSOkywtHtIchGOWy+fTtn8O9XvsMM8oVBuhJRgHbCqqqQAeMtjO4itSFoIYZPMnieK0t1Ty+nJbPHrjgYHqe9AFCxMVpHbGYwrCdp3SSlmJV/mXj1znHsPWui0uKEJtt382XyJXYOj5GXI4z0yeM+1cZdH95N+8WSMSPIojMjjzFI+XpwcEn8K2fDty0vmj7XcQOY9olV3OIy245z0bngdRmkBrTaHHbCSIRsYbZoZJAWfcM5GAO4PBI5PSsDVrZpBOscckBBEbABhFnzMFeep5HJ9a6u6nGowtBd3sh2pGkQmjJwckgMy4JPuck+tZXnJYG2d13/uclWJO/D7WZ8/xDjjv0oA5mXSNWt7i6AWNJYd1sYYvuMAC7ZO7pjjI61at90SNHdR3Rne4SWMxsD5ZK9DzzjGOeMetdLq14IbK4e2mUvZyDymIRQG3DOR3+8QB61QuYbec36naIZZTEuAFdYwhyM577jz78UAEEIv7i2tord0t5lwIpIQpeTZkc5JCcnJPHTvWlfIosZTLM4SCVJGkjVQBGy9S3Q8DPt3rL1C+jvLdYYESJ7iKHzSqL91cjdnPHT9M1kPrcNp5oeaJpZ4omcRop8rqWTngZAX8M0ATW80t7eSSldpZYpmlj8sB2G7DHjjKqMY47nk1SnvklFrYx/uZPLWWacsiOyyIRj2ZRkZ696nsNVedVjtwPtT/ZpQXKhYucKoOOfU5FR6p9m1BYpIFxKvPmecEZiGwRjHy9vU4U0AZ2lzi9ksoRFCJfMiZUL7NxVyoy2PlO085/wqTUj56va2z2puYZJI5JhKTvcN8q9BwvHPfHpWfDBLEkSvYiUugyr7hG4BO5j75wfT2rW0bT4ne6863W4uYYkl8jzSN5bO5gCMABemT1FAG1p9xGZntLS2yiySw+ZIygqFVAz4xkqwztycnPpV95LKYKlrtWSWSOOJJJQCEbcwkcdgADz6msa4thEpjnvruNXkeMBMouWTKE4HA7d8mrVpDbRQp9ucOkHlz74pC+5iOecfN/CvPTbgUAQJf2ouYZLy5wJz5zu7kyCNT8hdiOoGcA+tW9Rj0wwajHZ39vJasJJYsbMP+8DAgHByWBGO5PoKiaWFLWL7RKkty7/Yw0RKlo2cmQsD2BPUZPOPq4wW7NcWt00dwkE8kwKZESL1Djj+EkAfXNADb+R2urwsYYIy8ckZE2CjYKuxwDyTjJHJ46CnrcyaZkYj23DKsLtNuVk27dg4yMEMWPvgdaqXd8ksUsdkxBJQPG7nh+WPQZDZHTNSLaq8lzEG8totjRfM+JGxncOMhs8YPb60AR3F/b3UmPtDvG0P76BmOVYMMBmHQgnGOAOetaH2a1M7pbXRkfeyh3mMI5AO8A9NpAG0dep7VWKLDCkFjFFNGluHl27juKnJPbJxnrjPals1mee4WSN1t5EmgRokcPHtwwccnk5IP+6KAK8NxHZRM9wqtb27SQrDlxIDkMufQkksMgDODVSHxjdWbvDY2zyNEjuondihXAwQDwAOuT3/AArS1uC3b7Z56fI84Mk8wbbkoBvCjPJJXr7VkS6Z5M8y3UKvOHWEBYtoZipwuWPPbntQAt1r1vcXVqsUUhPzDaVYBwynoP4hgd6taXrrw6fJGquI7UwqkTStmHqQOmck4Pv9Ota+txd3MSwGRchYnYW4XyjjAVWJz2I54796qohmsIpViiCS4Lbl67HAIyTknJwfUnjgUAWhr88l3cTuHtbl4z5aLEVzuYgE84UHDfiak/tWVZVhura2g8wyiJF3YJZtpA54K4yScDnPWlisnnmuWhUsH8xwZIwQV3qd27rhc429zx0purWEpEMetBp7kvIp+ziJUAboSR7549vbNADn1qznkS6uLRXjE7FREvzn5duRkknLDqPUk1PptxHYQyzJHFGIUjjOAGKbfmDKCeBkFdw7mqVyu6ET3ZjE1ofMBtnRhFCgAxt6Etjp6c96j0q1We1k/wBIggS2MTpFIqSDK9M8e/b8aANiaOxubeVtMmTY6iXzHUJvLEb0HOckZGfU+1U7jXLSBQiuy+egKt5Kjy9s3zjr128VqT6fb2kU15b28MkpjFxNNPcxsuV46YzjdzgdKxJPscyT3MqqHJzGqyoNzF8KVHTkKSc/QUASTaxYG9ilgdIrcSOweSEBtrMQMgHoCRnocEVKt5Zl7e7sGnz5zCLaqqd4xuVgAeoPQn7prJuNPgtwgN3AjGcR28iy/Ko3ZLHHTbx/vE0ksSz2NuLWL9558kZ2SN5mRnaSo5AznPJzmgC9cajEzCaQxtKoiM8aMgZk3tlRx1Oc8dO/UUlheI8gljkNnZSA7T5iqpw4KrjGcgEA5/xrLhtUEZlnlcABXdOSSyuA6rgYx+fTAzTop5dzyzSf6KIPOURqxCs5xzx1HfHHXFAHXkg2rqCs13MZXM7ThEZNu1gT3bOeOhA7AVRvNVku5o48PvZEwLqUvtAXa+4gD723jj26VkySulrOouBKEEpkBVyY/wC6uO2SePqM96kvL2XTri3uXuHnkVVMGI23b+Sw2+mcZz05xQBHaTwsjQXttauqMJBK8h+ZQT8pGOTkr9NuKui5dNLtbOBFbMTzKIw7E7TgugHBJ3dOlY094bwH7KjTXU0MBWFNyhmLkkfQfqavXOpWzafmN2eWFSkMnkyYRi43bW7EL0HqB9aAJ9b8n+zbhLABoopkUyqzssDAAOhz2LEAcdSe1ZUk86rqCwuinYd6hXLxhlAypzncSABn3Nb82oQFrhVnYpdeZITLAchERSgAzzyc+uRWTd3KzTz29ss/loXhhTygJceXmQsc8klRz2zmgB8EY/tjyvkUCeO0MKQnbuKMTHg8t079+apX9oIJ7QRlFuYo1VgoBWNt2CucjPXr6+mKvaRLJJeW0fmO5SWKOYCBQCTEQy+uDwM/U9TWhbpZtZ29tdRSGYws8sYRR5UobaGTP8B4Ge+OaAOV0tR5nlpCkhKrsEgG3LOBk9/Xnr17V1M0r3UzyxwlBHFIsdrLEqx+XtyX2g5ycD5j6DFSXOhXLIsGn5mYloFRY0wSQWBb1JIzx26VWcAWlzdyYR7iKWRpQ6BR/BjJ6HcPu0AQ6daW027LxyWwcztIkQ4UoBxk4HLcD2qW7trW1stNcjzoBhldypbyEYkAj1yTyfpUs1jBBcboL4IqT7cllXCiMbypx8wI4z+XeqW1bZYlWRxEtwkKuuDtjAJy2Pu5JAB5yfoKALepTvDKi7xJZkyAQ5TOC5Y4PJBIboemMe1Uobg2i20QH7oXG8oSGzLs3ELgcjoPWodWVIHmubJ920YkXeH8lt5+UjoeOv51HIZbiSedkE17I5EZhyCCygF1HQdO3NAFeO/m+R2naXywkqYKj5wxzjC/NjnrV6bUJZreWeO5cyMISscTg7ucMAMZ+92B4zUMflW0UhXHlZVBIoZhIRwR9ScnFVrZEjWZLRZTPI0flhLcjMQQ7mHPBDduvQigZdjgl0uKGSVJDCzP9nmjwwLLn+HHCg8+tQXN/dO1pIpbcgkzK7MpkdgWDEfjkisp7iP94hlZlSQv5u07RkD5cdifWpr3zJbWGC5/eFJHKts+dUYZA+v1oAxpLq5Vi7u7Ng43kkqSOTyeCKglkaYBCAMDOBwOR1/HFaMvlM6RwqTAXEYJTBIA7+/Sqs8bHcHDNht3zAfM3T/IoAqyEluoIwMZXdx7Z7UVYW0d1DRKcEc5GOaKeoXOs3rNCIVz5z28ssg3YTk8cY64FMjvFtpoTvACOXCgtwQuMAdPfPrRRQI67+14IGLl90VzGJQXZisY2YKkbecgdaxINRt5rRIZD5UzwQwxvjeWy5LfiM9TRRSGV7i8EaM8ZHn5kEqKCfMc8fMTweOePStLw5HbXVi9rKu7zCFdYk8s7OMgNnjjJ/DHeiigDatHtWa3kjXZZy3B2MY/nMaqcseepwOOvGTzRau+pQOq2qQR2wAiZlVjLGeSzDJwcZIGfrzRRQIrqiSWVuyrJNYziaWIMEBYYCpkdhxz3pCpN8bi5Vw8kqtMxVAMbM8gew/pRRQBn3F7LDC1wUeKe0ISCSJ1BVmQqDjbg43n2xnvVVnTUmdkt/JkMfkoFlIRZDHjzGAHNFFAEr3kslpdROzpLE1srZbhyGHOQMk+hPTFZ2kRvNe7YpWjQu2WEjExqAXcAdywG36nNFFAyNLgXQt9u5zKVRI5GJaA78Dn7uBgkdce5rbtlMsiujxLqEztZCVy57fK3T68HueaKKBF+4s7u4laGd2CsUhZWmLozqo9s45/oO9MgBkliW7vCgSWO1jnR5C0S5Py4x6c5A74oooAS0t0nWUsS0UkXyYkYeWQ4BUemBk59TVXT4JIvLWNooiVliyXdi646e2SR/P2oooAbZs8ty07iJ0iuEikUyOSzlNodyR8xDkmrFhqJh+wgyNLd3rRwsHdgI9uQXyOpJA49D7UUUDEtDAIPtVjPGbfarme4V3JlLkEsOCQMEY6Ee9TWmpxyqJjOhtUMixjySNzcEH1DEk9yOBRRQIRQk99LdWskf2aJvNdZYyfn2HJ689Rntn2qnGGvLme5EizWNuD5TPEAzEpuEzDP3gcqMdKKKAHStC00VtceWhtGWKcLCHAlK/MeT8xPHPrzSFLayS08xQT87Mvlgogjfjvk5z16568UUUAQ38yRveXczzCMwSxxy+WpCy7hgkZzk7hntxjpWhdQLJP5QiPkATWyoqpvJbBGXPbbnoOM4oooApaVdzXd1LaciGa68pUREQqCoZSTz1AXOOgyKox3EtnAtzCHCNiOFTtISMgh+MffJBGff2oooYGlpsrabZRz39nNNNeeUImNwGRt24KGB/2sMfp3qG0vRcagRHE4iMSRpH5gDKvmkEk7cHPTHbJI60UUAZ0jSpZv9iMisSpEKkeXbx7wPkz3P6HmtNZ2WG7kuWlMMEjReXFJhpUbAKA8Yyx5J659qKKAKmvWEtnp9mihSwtxKW3soQAjaQB/EMkccDtUP2d5Hu0e2jV1EgZY53UjBXauMY6NkHnHPeiigYwRlJGjiaJ3G6VHy+FKEKOOMk8nJ74Jp1pdRzwXLXEEaTtAxMkhZzgxkFx7lQT9aKKBFWMWqTW7WR/eEwQlZUOIeCex56qePWp4YLWG2K2rbpYYfJKtlUUlyGk75IwCO/5UUUAZflnyZX8lWuirtDtQKiABct94n14ro9OsF1VPssOE08zfZZi6DzA5UBiCD2xj6HvRRQA28M0mqWUGyP7O6mAmNFVY8Ah8Dr90cHtk1X0om2+zXmnRyKVby03hcBDu2BTkkHpnIPSiimBPZX1xbLZ+SzRBejYUDazhQeO/VefXNazC2lSWw1Efa4nmaaGBEC/xBGO4jqHGccAiiikBjRzXdvqrJLCbmRvOSMvID91SNygjCjk/L05pZL8xXNw0szRiWUO4VBgJwqRDjsVznpxRRQBBeqsEjuob7O9s7GUSHcxLZ3Yx1PGR7VBPKjLLG08QlUllB3n5iBtUHsBk4PrzRRQM1oknWSHEMDxrdiVBvZcRrGcH8Np6c881gPYstjFeSMEjuonKSLnP3uCBng845oooEinJaWtjeWxaRpY5UZy6rjdng8E9hmmxCGS0mdVcSkYSQ/dRUH3sZyflzx60UUDIJLf7L+68zdGh83lc4XsTz1xjj3rQgaA2cCxjzZJGXyBKgwuc9fY4NFFAGdd3djFcOstkwYH+GTOfeiiiqsFz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27395=[""].join("\n");
var outline_f26_48_27395=null;
var title_f26_48_27396="Phases of perinatally acquired hepatitis B virus infection";
var content_f26_48_27396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64996%7EGAST%2F76907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64996%7EGAST%2F76907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Phases of perinatally acquired hepatitis B virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 662px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HBV: hepatitis B virus; IU: international units; ALT: alanine aminotrasferase; AFP: alpha fetoprotein.",
"     <br>",
"      * All patients with hepatitis B virus (HBV) infection should have baseline assessment for risk of hepatocellular carcinoma (HCC), and follow up monitoring. We generally monitor AFP and liver ultrasound every 12 months beginning in late childhood. For patients with elevated AFP, cirrhosis, or a family history of hepatocellular carcinoma, we begin monitoring earlier and monitor more closely.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Course of perinatally acquired chronic HBV infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 219px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the natural history of perinatally acquired chronic hepatitis B virus (HBV) infection. This form of infection consists of three phases: an immune tolerance phase, an immune clearance phase, and a late nonreplicative phase. The immune tolerance phase, which lasts 10 to 30 years, is characterized by high levels of HBV replication, as manifested by the presence of HBeAg and high levels of HBV DNA in serum, but no evidence of active liver disease as manifested by normal serum ALT concentrations. During the immune clearance phase, HBeAg seroconversion is frequently, but not always, accompanied by biochemical exacerbations (abrupt increases in serum ALT). The nonreplicative phase is usually characterized by the absence of HBV DNA and normalization of serum ALT.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27396=[""].join("\n");
var outline_f26_48_27396=null;
var title_f26_48_27397="Inguinal anatomy preperitoneal view";
var content_f26_48_27397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inguinal anatomy preperitoneal view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 493px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the anatomic structures of the right posterior inguinal wall as seen from the preperitoneal approach. Note the relationship of a potential direct hernia and indirect hernia and a femoral hernia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27397=[""].join("\n");
var outline_f26_48_27397=null;
var title_f26_48_27398="Inguinal hernia reduction 2";
var content_f26_48_27398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alternate method for bimanual reduction of an inguinal hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 588px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Anatomy of an indirect inguinal hernia. Note the position in the groin of the hernia \"neck\" extending through the internal and external inguinal rings. B) The fingers of one hand are first used to sweep along the inguinal canal from the anterior iliac crest to the distal scrotum. The same hand is then used to grasp the testicle, hernia mass, or scrotal skin and apply gentle pressure. C) The index finger and thumb of the opposite hand are used to apply \"upward\" and lateral traction over the hernia neck to help in keeping the internal and external inguinal rings open. D) The fingers of the hand on the scrotum are then used to \"walk\" the bottom of the hernia sac progressively up toward the inguinal rings until the hernia is reduced.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King C, Henretig FM. Inguinal hernia reduction. In: Textbook of pediatric emergency medicine procedures, 2nd ed, Lippincott Williams &amp; Wilkins 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27398=[""].join("\n");
var outline_f26_48_27398=null;
var title_f26_48_27399="Upright tilt table testing in the evaluation of syncope";
var content_f26_48_27399=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Upright tilt table testing in the evaluation of syncope",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27399/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27399/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27399/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27399/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27399/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27399/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/48/27399/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upright tilt table test is commonly performed for the evaluation of syncope although the test has limited specificity, sensitivity, and reproducibility. It may be helpful particularly in young, otherwise healthy patients in whom the diagnosis of vasovagal (neurocardiogenic) syncope is suspected but not certain&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It is also useful in older persons in whom the cause of syncope remains unclear, but vasovagal syncope is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of and protocol for tilt table testing will be reviewed here. The general evaluation of the patient with syncope and vasovagal syncope and other types of reflex (neurally-mediated) syncope is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2009 ESC indications for upright tilt table testing in the following clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent episodes of syncope in the absence of organic heart disease, or in the presence of organic heart disease after cardiac causes of syncope have been excluded.",
"     </li>",
"     <li>",
"      Unexplained single syncopal episode in high risk settings (eg, occurrence or potential risk for physical injury or occupational hazard).",
"     </li>",
"     <li>",
"      When deemed of clinical value to demonstrate susceptibility to reflex syncope to the patient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link&amp;anchor=H11#H11\">",
"       \"Reflex syncope\", section on 'Upright tilt table test'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tilt testing is reasonable to discriminate between reflex and orthostatic hypotension syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tilt testing may be considered in the following clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For differentiating syncope with jerking movements from epilepsy.",
"     </li>",
"     <li>",
"      For evaluating patients with recurrent unexplained falls.",
"     </li>",
"     <li>",
"      For assessing patients with frequent syncope and psychiatric disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tilt testing is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for assessment of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ]. Studies indicate that tilt testing should not be used to guide therapy since the mechanism of tilt induced syncope is likely to differ from the mechanism of spontaneous syncope episodes. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Comparison to implantable loop recorder'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TEST PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The upright tilt table test is typically performed in an electrophysiology laboratory using a special tilt table;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    is often infused or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is given if the initial tilt test is negative (",
"    <a class=\"graphic graphic_table graphicRef60161 \" href=\"UTD.htm?25/11/25789\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/5\">",
"     5",
"    </a>",
"    ]. Tilt table testing should not be performed in patients who are orthostatic at baseline.",
"   </p>",
"   <p>",
"    The basic facilities and equipment necessary for performing a tilt table test are straightforward (",
"    <a class=\"graphic graphic_table graphicRef60161 \" href=\"UTD.htm?25/11/25789\">",
"     table 1",
"    </a>",
"    ). The test should be performed in a quiet room with minimal distractions for the patient. The patient is placed on a hydraulic lift or swinging bed capable of smoothly and rapidly moving the patient passively from a supine position to a head-up position between 60&ordm; to 90&ordm; and quickly ( in &lt;10 seconds) returning the patient to a supine position to avoid the consequences of prolonged unconsciousness. The table should have a foot board and safety restraints. Patients should be encouraged to report symptoms that may develop. An infusion pump and intravenous catheter are necessary for administration of fluids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    if indicated. Patients should fast at least four hours before the test and should not have orthostatic blood pressure changes at baseline.",
"   </p>",
"   <p>",
"    Continuous ECG and noninvasive blood pressure monitoring are employed throughout the test. Careful monitoring is required because occasional patients have a pronounced cardioinhibitory response characterized by symptomatic hypotension, bradycardia, or both.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tilt protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of protocols have been described for the test that vary in the angle of tilt (60 to 90&ordm;), duration of tilt (10 to 60 minutes), and the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef60161 \" href=\"UTD.htm?25/11/25789\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, the patient is monitored in the supine position for five minutes to obtain baseline heart rate and blood pressure measurements. A longer supine time period of at least 20 minutes is recommended if venous cannulation is performed just prior to the test [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ]. The patient is then positioned in a head-up tilt position. The 2009 ESC guidelines recommend a tilt angle between 60 and 70 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A passive phase (upright with no",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    infusion) of 20 to 45 minutes is generally recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ]. Heart rate, and symptoms are recorded every three to five minutes and the ECG is recorded continuously. The blood pressure should be monitored noninvasively by beat-to-beat finger arterial monitoring. Alternatively, the blood pressure may be noninvasively monitored by arm cuff every three to five minutes. If the patient experiences loss of consciousness or is unable to maintain posture in association with a significant fall in blood pressure or heart rate, he or she is returned to a supine position, and the test is considered positive. If, after a period of 20 to 45 minutes, no symptoms have developed, the patient is returned to the supine position.",
"   </p>",
"   <p>",
"    One study suggested that it may be possible to reduce the time necessary for the tilt test and avoid the need for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion. In a study of 109 patients, a heart rate change &le;18 beats per minute during the first six minutes of the test prospectively predicted a negative tilt table study with a 96 percent specificity, 98 percent positive predictive accuracy and 87 percent sensitivity, even with the subsequent use of isoproterenol [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Isoproterenol infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient has remained asymptomatic during upright tilting, a second tilt while infusing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    is commonly administered (",
"    <a class=\"graphic graphic_table graphicRef60161 \" href=\"UTD.htm?25/11/25789\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/5\">",
"     5",
"    </a>",
"    ]. The infusion is usually titrated from 1 to 3",
"    <span class=\"nowrap\">",
"     mcg/min",
"    </span>",
"    to increase the heart rate by 20 to 25 percent above baseline. The patient is then placed in the head-up tilt position for an additional 15 to 20 minutes. In the ESC protocol, the infusion is initiated with the patient already in the head-up tilt position. Although a controlled infusion of isoproterenol is safe in patients without heart disease, it should not be performed in those with coronary artery disease since angina and serious arrhythmia can be provoked [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion was illustrated in a study in which a single-stage isoproterenol tilt table test more frequently induced syncope than a standard passive tilt study (56 versus 32 percent) and reduced the time necessary for the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/9\">",
"     9",
"    </a>",
"    ]. There was, however, a lower specificity (83 versus 91 percent for standard tilt testing). (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Test performance'",
"    </a>",
"    below)",
"   </p>",
"   <p>",
"    Many investigators require either loss of consciousness or postural tone to consider the test positive while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    is infused. A modest decrease in blood pressure with symptoms is common with isoproterenol and is nonspecific. The 2009 ESC guidelines include no separate diagnostic criteria for tilt test with isoproterenol infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another pharmacologic agent that may have a complementary role to the tilt table study is sublingual, spray or intravenous nitrates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Nitrates cause venodilation with consequent reduction in venous return and stroke volume, without impeding the sympathetic responses of increased heart rate and arterial vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/13\">",
"     13",
"    </a>",
"    ]. The 2009 ESC guidelines recommend a fixed dose of 300 to 400 mcg of sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    administered in the upright position for nitroglycerin tilt testing (",
"    <a class=\"graphic graphic_table graphicRef60161 \" href=\"UTD.htm?25/11/25789\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    to tilt testing increases the frequency of hemodynamic changes and reproduction of symptoms and may shorten test duration but also increases the rate of false positive tests. This was illustrated by a study of 149 patients with unexplained syncope and 83 asymptomatic controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/14\">",
"     14",
"    </a>",
"    ]. Subjects were randomly assigned to a 20 minute nitroglycerin (800 mcg metered spray) tilt test or a standard 40 passive (no administered drugs) tilt test. Nitroglycerin increased the frequency of a positive tilt study in the patients from 11 to 36 percent, although the number of normals with a positive tilt study also increased from 11 to 28 percent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    has been compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    as an adjunct to tilt table testing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      administration during tilt in 71 patients with unexplained syncope and 30 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/15\">",
"       15",
"      </a>",
"      ]. Rates of test positivity in patients (49 and 41 percent, respectively) were similar; however, sublingual nitroglycerin was simpler to use, better tolerated, and safer than low-dose isoproterenol.",
"     </li>",
"     <li>",
"      In a study of 96 patients with unexplained syncope, sublingual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      with tilt led to a higher number of positive responses than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      with tilt (55 versus 42 percent), especially among patients with positive tilt without pharmacologic agents (94 versus 67 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16409466\">",
"    <span class=\"h2\">",
"     Use with other modalities",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Carotid sinus massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus massage is performed to demonstrate carotid sinus hypersensitivity, which is the mechanism for the carotid sinus syndrome. Although carotid sinus massage is usually performed in the supine position, the diagnostic yield may be increased by performing massage during head-up tilt testing. The carotid vessels should be palpitated and auscultated first to exclude bruits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=see_link&amp;anchor=H6#H6\">",
"     \"Carotid sinus hypersensitivity\", section on 'Combination with tilt table testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Clomipramine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/20/43336?source=see_link\">",
"     clomipramine",
"    </a>",
"    administration blocks the reuptake of serotonin in the synapse space and increases stimulation of serotonin receptors and responsiveness of the central serotoninergic nervous system in subjects with vasovagal syncope; this leads to sympathetic withdrawal. One study of 55 patients with a history of vasovagal syncope found that an intravenous infusion of clomipramine (5 mg in five minutes) increased the number of patients with a positive tilt table test (80 versus 53 percent without clomipramine); only 1 of 22 controls had a positive test with the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RESPONSE TO TILT TABLE TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive test for vasovagal syncope is characterized by the development of syncope in association with a cardioinhibitory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a vasodepressor response (",
"    <a class=\"graphic graphic_figure graphicRef55504 \" href=\"UTD.htm?17/10/17582\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60161 \" href=\"UTD.htm?25/11/25789\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The clinical significance of abnormal responses other than induction of syncope is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ]. Less common vasovagal responses have been described such as postural orthostatic tachycardia syndrome, which is associated with relative hypotension and tachycardia. A rare cause of syncope is cerebral syncope, which is associated with cerebral vasoconstriction and can occur in the absence of systemic hypotension (",
"    <a class=\"graphic graphic_figure graphicRef55504 \" href=\"UTD.htm?17/10/17582\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=see_link\">",
"     \"Postural tachycardia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The vasovagal reflex seen on a tilt table test may reflect a given patient's predisposition to vasovagal syncope; however, the actual physiologic response on the tilt table test may differ from episodes experienced clinically. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    increase the sensitivity of the test, these two interventions also decrease the specificity (ie, more false positives). A positive test does not necessarily indicate that syncope is due to a vasovagal cause. Interpretation of the results and its relation to a cause for syncope must be made in light of all clinical data.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Test interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of response to tilt table test varies depending upon the clinical setting (",
"    <a class=\"graphic graphic_table graphicRef60161 \" href=\"UTD.htm?25/11/25789\">",
"     table 1",
"    </a>",
"    )[",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without structural heart disease, tilt testing can be considered diagnostic with the following results:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When reflex",
"      <span class=\"nowrap\">",
"       hypotension/bradycardia",
"      </span>",
"      is induced with reproduction of spontaneous syncope, the test is diagnostic for reflex (neurally mediated) syncope. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link&amp;anchor=H11#H11\">",
"       \"Reflex syncope\", section on 'Upright tilt table test'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When reflex",
"      <span class=\"nowrap\">",
"       hypotension/bradycardia",
"      </span>",
"      is induced without reproduction of syncope, the test is suggestive of reflex syncope.",
"     </li>",
"     <li>",
"      When progressive orthostatic hypotension (slow progressive decrease in systolic blood pressure) with or without symptoms is induced, the test is diagnostic for orthostatic hypotension syncope. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"       \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with structural heart disease, arrhythmias and other cardiac causes of syncope should be excluded before considering a positive tilt test as diagnostic of reflex syncope.",
"     </li>",
"     <li>",
"      Induction of loss of consciousness in absence of hypotension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bradycardia is suggestive of psychogenic pseudosyncope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Test performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the tilt table test is frequently positive in patients with vasovagal syncope, it is not the gold standard for diagnosis of vasovagal syncope as it has limited sensitivity, specificity, and reproducibility.",
"   </p>",
"   <p>",
"    The sensitivity of tilt table testing is as high as 80 percent depending upon the protocol and patient selection, but this high sensitivity is at the expense of a lowered specificity (ie, more false positive tests). Among individuals who undergo a tilt table test with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    , a positive response is seen in as many as 45 percent or more of those who do not have a history of syncope (ie, induction of syncope in normal volunteers) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The performance of the tilt table test depends in part upon the study population. One report evaluated the role of this test in 145 patients with a history of presyncope or syncope. The following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with recurrent syncope were significantly more likely to have a positive test compared to those with a single episode or with recurrent presyncope (41 versus 17 percent).",
"     </li>",
"     <li>",
"      Patients with structural heart disease or with a noncardiovascular cause for syncope were significantly less likely to have a positive test (16 versus 42 percent).",
"     </li>",
"     <li>",
"      When multiple factors were combined, the yield ranged from 0 percent in patients under 50 without recurrent syncope who had structural heart disease or a noncardiovascular cause to 73 percent in those over 50 with recurrent syncope who did not have structural heart disease or a noncardiovascular cause (",
"      <a class=\"graphic graphic_figure graphicRef67278 \" href=\"UTD.htm?10/44/10944\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The additional yield of positive tests with the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      (isoprenaline) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35156?source=see_link\">",
"       edrophonium",
"      </a>",
"      was 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited data suggest that tilt table testing is not helpful in patients with bifascicular block with unexplained syncope. In a study comparing such patients with control subjects with bifascicular block and no syncope, no difference in the incidence of a positive tilt test (28 versus 32 percent) was observed, suggesting that test specificity in this population is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism for syncope during tilt table testing appears to be different in normals (false positive results) and patients with a history of vasovagal syncope. This was illustrated in a study that compared eight normals with a positive tilt test, eight normals with a negative tilt table test, and 15 patients with vasovagal syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with vasovagal syncope had a shorter time to syncope (9.5 versus 17 minutes); an immediate and persistent drop in mean blood pressure, suggesting an impaired vascular resistance response; more rapid peripheral pooling of blood, as determined by left ventricular end-diastolic dimension on echocardiography; and higher peak serum epinephrine levels, which probably induced increased cardiac contractility and may have contributed to impaired vasoconstriction.",
"   </p>",
"   <p>",
"    The response to tilt table testing appears to vary with the patient age. Younger subjects are more likely to have a bradycardic response, whereas older subjects tend are more likely to have a hypotensive response [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to tilt testing can be highly variable such that a patient displays a cardioinhibitory response on one day and a vasodepressor response on another day.",
"   </p>",
"   <p>",
"    Tilt testing is generally not helpful to identify patients with situational vagal syncope, ie, syncope due to situations associated with enhanced vagal tone such as micturition, defecation, cough, or vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link&amp;anchor=H23#H23\">",
"     \"Reflex syncope\", section on 'Situational syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no evidence that therapy can be guided by repeat tilt table testing. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     False negative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported false negative rate is as high as 14 to 30 percent, but can be higher depending upon the protocol and patient age. However, the true false negative rate is difficult to determine since there is no gold standard for comparison. Thus, vasovagal syncope cannot be excluded by a negative tilt table test. Ambulatory monitoring of patients with recurrent syncope but a negative tilt table test often demonstrates bradycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asystole in association with recurrent syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/24,28\">",
"     24,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Comparison to implantable loop recorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implantable loop recorders can aid diagnosis of the cause of syncope by providing a means of capturing spontaneous episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/29\">",
"     29",
"    </a>",
"    ]. Among patients with recurrent vasovagal syncope, an implantable loop recorder can more accurately establish a causative relationship between bradyarrhythmias and syncope than upright tilt table testing or other provocative tests (eg, ATP infusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Use of an implantable loop recorder can also help exclude an arrhythmic cause [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on comparison to implantable loop recordings during episodes of vasovagal syncope, tilt table testing is more likely associated with relative bradycardia and hypotension whereas spontaneous episodes are more often associated with asystole [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/24\">",
"     24",
"    </a>",
"    ]. Tilt table and ATP test results correlate poorly with the mechanism of spontaneous reflex syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore an implantable loop recorder may be indicated in lieu of conventional provocative tests such as tilt table testing and ATP infusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link&amp;anchor=H13#H13\">",
"     \"Reflex syncope\", section on 'Electrocardiographic monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications are rare but prolonged asystole or hypotension occasionally occurs. If either occurs and is associated with syncope, the patient should be placed in a supine position immediately until recovery. In one series, 77 of 179 patients (43 percent) with unexplained syncope had a positive tilt test; 10 patients developed asystole, often associated with convulsions, requiring a brief period of cardiopulmonary resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27399/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upright tilt table testing to diagnose vasovagal syncope is indicated in the following clinical settings (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Recurrent episodes of syncope in the absence of organic heart disease, or in the presence of organic heart disease after cardiac causes of syncope have been excluded.",
"     </li>",
"     <li>",
"      Unexplained single syncopal episode in high-risk settings (eg, occurrence or potential risk for physical injury or occupational hazard).",
"     </li>",
"     <li>",
"      When deemed of clinical value to demonstrate susceptibility to reflex syncope to the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive test for vasovagal syncope is characterized by the development of syncope in association with a cardioinhibitory",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a vasodepressor response. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Response to tilt table test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interpretation of response to tilt table test varies depending upon the clinical setting (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Test interpretation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients without structural heart disease, tilt testing is diagnostic of reflex syncope when reflex",
"      <span class=\"nowrap\">",
"       hypotension/bradycardia",
"      </span>",
"      is induced and spontaneous syncope is reproduced.",
"     </li>",
"     <li>",
"      In patients without structural heart disease, tilt testing is suggestive of reflex syncope when reflex",
"      <span class=\"nowrap\">",
"       hypotension/bradycardia",
"      </span>",
"      is induced without reproduction of syncope.",
"     </li>",
"     <li>",
"      In patients with structural heart disease, arrhythmias and other cardiac causes of syncope should be excluded before considering the response to positive tilt test as evidence of vasovagal syncope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The upright tilt table test has limited specificity, sensitivity, and reproducibility. In addition, the hemodynamic response to upright tilt testing may differ from the hemodynamic mechanism of spontaneous syncopal episodes. Therefore, an implantable loop recorder may be considered as an alternative means of establishing the diagnosing the cause of syncope. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Comparison to implantable loop recorder'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/1\">",
"      Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/2\">",
"      Grubb BP, Temesy-Armos P, Hahn H, Elliott L. Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin. Am J Med 1991; 90:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/3\">",
"      Oribe E, Caro S, Perera R, et al. Syncope: the diagnostic value of head-up tilt testing. Pacing Clin Electrophysiol 1997; 20:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/4\">",
"      Grubb BP, Wolfe D, Samoil D, et al. Recurrent unexplained syncope in the elderly: the use of head-upright tilt table testing in evaluation and management. J Am Geriatr Soc 1992; 40:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/5\">",
"      Almquist A, Goldenberg IF, Milstein S, et al. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope. N Engl J Med 1989; 320:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/6\">",
"      Mallat Z, Vicaut E, Sangar&eacute; A, et al. Prediction of head-up tilt test result by analysis of early heart rate variations. Circulation 1997; 96:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/7\">",
"      Sheldon R, Rose S, Koshman ML. Isoproterenol tilt-table testing in patients with syncope and structural heart disease. Am J Cardiol 1996; 78:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/8\">",
"      Leman RB, Clarke E, Gillette P. Significant complications can occur with ischemic heart disease and tilt table testing. Pacing Clin Electrophysiol 1999; 22:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/9\">",
"      Shen WK, Jahangir A, Beinborn D, et al. Utility of a single-stage isoproterenol tilt table test in adults: a randomized comparison with passive head-up tilt. J Am Coll Cardiol 1999; 33:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/10\">",
"      Aerts A, Dendale P, Strobel G, Block P. Sublingual nitrates during head-up tilt testing for the diagnosis of vasovagal syncope. Am Heart J 1997; 133:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/11\">",
"      Zeng C, Zhu Z, Hu W, et al. Value of sublingual isosorbide dinitrate before isoproterenol tilt test for diagnosis of neurally mediated syncope. Am J Cardiol 1999; 83:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/12\">",
"      Aerts AJ, Dendale P, Daniels C, et al. Intravenous nitrates for pharmacological stimulation during head-up tilt testing in patients with suspected vasovagal syncope and healthy controls. Pacing Clin Electrophysiol 1999; 22:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/13\">",
"      Gisolf J, Westerhof BE, van Dijk N, et al. Sublingual nitroglycerin used in routine tilt testing provokes a cardiac output-mediated vasovagal response. J Am Coll Cardiol 2004; 44:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/14\">",
"      Parry SW, Gray JC, Newton JL, et al. 'Front-loaded' head-up tilt table testing: validation of a rapid first line nitrate-provoked tilt protocol for the diagnosis of vasovagal syncope. Age Ageing 2008; 37:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/15\">",
"      Raviele A, Giada F, Brignole M, et al. Comparison of diagnostic accuracy of sublingual nitroglycerin test and low-dose isoproterenol test in patients with unexplained syncope. Am J Cardiol 2000; 85:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/16\">",
"      Del&eacute;pine S, Prunier F, Lefth&eacute;riotis G, et al. Comparison between isoproterenol and nitroglycerin sensitized head-upright tilt in patients with unexplained syncope and negative or positive passive head-up tilt response. Am J Cardiol 2002; 90:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/17\">",
"      Theodorakis GN, Markianos M, Zarvalis E, et al. Provocation of neurocardiogenic syncope by clomipramine administration during the head-up tilt test in vasovagal syndrome. J Am Coll Cardiol 2000; 36:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/18\">",
"      Grubb BP, Samoil D, Kosinski D, et al. Cerebral syncope: loss of consciousness associated with cerebral vasoconstriction in the absence of systemic hypotension. Pacing Clin Electrophysiol 1998; 21:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/19\">",
"      Carey BJ, Manktelow BN, Panerai RB, Potter JF. Cerebral autoregulatory responses to head-up tilt in normal subjects and patients with recurrent vasovagal syncope. Circulation 2001; 104:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/20\">",
"      Kapoor WN, Brant N. Evaluation of syncope by upright tilt testing with isoproterenol. A nonspecific test. Ann Intern Med 1992; 116:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/21\">",
"      Fitzpatrick AP, Lee RJ, Epstein LM, et al. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart 1996; 76:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/22\">",
"      Englund A, Fredrikson M, Rosenqvist M. Head-up tilt test. A nonspecific method of evaluating patients with bifascicular block. Circulation 1997; 95:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/23\">",
"      Leonelli FM, Wang K, Evans JM, et al. False positive head-up tilt: hemodynamic and neurohumoral profile. J Am Coll Cardiol 2000; 35:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/24\">",
"      Moya A, Brignole M, Menozzi C, et al. Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope. Circulation 2001; 104:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/25\">",
"      Brignole M, Menozzi C, Del Rosso A, et al. New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification. Analysis of the pre-syncopal phase of the tilt test without and with nitroglycerin challenge. Vasovagal Syncope International Study. Europace 2000; 2:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/26\">",
"      Kurbaan AS, Bowker TJ, Wijesekera N, et al. Age and hemodynamic responses to tilt testing in those with syncope of unknown origin. J Am Coll Cardiol 2003; 41:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/27\">",
"      Kochiadakis GE, Papadimitriou EA, Marketou ME, et al. Autonomic nervous system changes in vasovagal syncope: is there any difference between young and older patients? Pacing Clin Electrophysiol 2004; 27:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/28\">",
"      Sumiyoshi M, Nakata Y, Mineda Y, et al. Response to head-up tilt testing in patients with situational syncope. Am J Cardiol 1998; 82:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/29\">",
"      Sheldon R, Rose S, Koshman ML. Comparison of patients with syncope of unknown cause having negative or positive tilt-table tests. Am J Cardiol 1997; 80:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/30\">",
"      Krahn AD, Klein GJ, Yee R, Skanes AC. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation 2001; 104:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/31\">",
"      Brignole M, Sutton R, Menozzi C, et al. Lack of correlation between the responses to tilt testing and adenosine triphosphate test and the mechanism of spontaneous neurally mediated syncope. Eur Heart J 2006; 27:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/32\">",
"      Kabra R, Gopinathannair R, Sandesara C, et al. The dual role of implantable loop recorder in patients with potentially arrhythmic symptoms: a retrospective single-center study. Pacing Clin Electrophysiol 2009; 32:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27399/abstract/33\">",
"      Lacroix D, Kouakam C, Klug D, et al. Asystolic cardiac arrest during head-up tilt test: incidence and therapeutic implications. Pacing Clin Electrophysiol 1997; 20:2746.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1016 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27399=[""].join("\n");
var outline_f26_48_27399=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TEST PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tilt protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Isoproterenol infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nitrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16409466\">",
"      Use with other modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Carotid sinus massage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Clomipramine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RESPONSE TO TILT TABLE TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Test interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Test performance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - False negative studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Comparison to implantable loop recorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1016\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1016|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/10/17582\" title=\"figure 1\">",
"      HR BP response tilt table test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/44/10944\" title=\"figure 2\">",
"      Tilt test in syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1016|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/11/25789\" title=\"table 1\">",
"      Recommendations for tilt testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=related_link\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=related_link\">",
"      Postural tachycardia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_48_27400="Types of renal disease in multiple myeloma";
var content_f26_48_27400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Types of renal disease in multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27400/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27400/contributors\">",
"     Nelson Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27400/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27400/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27400/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27400/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/48/27400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease is a common problem in multiple myeloma. The pathology is very heterogeneous and may involve a variety of different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. The frequency with which this occurs varies with the definition used for renal insufficiency. In two large series, 43 percent of 998 patients had a plasma creatinine concentration above 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/3\">",
"     3",
"    </a>",
"    ] and 22 percent of 423 patients had a plasma creatinine concentration &ge;2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also a general correlation between the presence and severity of renal disease and patient survival. In the first report noted above, one-year patient survival was 80 percent in those with a plasma creatinine concentration below 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (130",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    versus 50 percent in those with a plasma creatinine concentration above 2.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    at disease presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/3\">",
"     3",
"    </a>",
"    ]. The response of the renal disease to therapy also appears to have prognostic value. In the second report, renal functional recovery was seen in 26 percent of those with renal insufficiency at presentation. These patients had a median survival of 28 months compared to four months in those with irreversible renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the types and causes of renal disease is the topic of this review. The pathogenesis and diagnosis of specific associated renal diseases, and the treatment of renal disease in multiple myeloma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=see_link\">",
"     \"Treatment of kidney disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement in multiple myeloma is usually the result of monoclonal immunoglobulin light chains. However, in rare occasions, monoclonal heavy chains or the entire immunoglobulins may be involved. Non-monoclonal protein-related renal injury may also occur. The types of kidney disease can be classified by the primary site of injury:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glomerular",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary (AL or rarely AH) amyloidosis",
"     </li>",
"     <li>",
"      Monoclonal immunoglobulin deposition (light chain deposition disease, heavy chain deposition disease, and light and heavy chain deposition disease)",
"     </li>",
"     <li>",
"      Miscellaneous (monoclonal cryoglobulinemia, proliferative glomerulonephritis due to monoclonal IgG deposition)",
"     </li>",
"     <li>",
"      Collapsing FSGS due to drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       Pamidronate",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Tubular",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Light chain cast nephropathy (myeloma kidney)",
"     </li>",
"     <li>",
"      Distal tubular dysfunction",
"     </li>",
"     <li>",
"      Proximal tubule dysfunction or acquired Fanconi's syndrome",
"     </li>",
"     <li>",
"      Acute ischemic or toxic nephropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interstitial",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasma cell infiltration",
"     </li>",
"     <li>",
"      Interstitial nephritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In autopsy or biopsy studies, myeloma cast nephropathy is the single most common finding among patients with multiple myeloma and clinical renal involvement, accounting for 33 to &gt;60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. This was illustrated in an autopsy study of 81 patients with multiple myeloma; 41 patients had clinical renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/9\">",
"     9",
"    </a>",
"    ]. Among these, 27 (65 percent) had cast nephropathy, and only 2 (5 percent) and 3 (7 percent) had light chain deposition disease and amyloidosis, respectively.",
"   </p>",
"   <p>",
"    In the largest reported biopsy series, among 190 patients with multiple myeloma who underwent a kidney biopsy, cast nephropathy, monoclonal immunoglobulin deposition disease, and amyloidosis were present in 33, 22 and 21 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/11\">",
"     11",
"    </a>",
"    ]. Forty-eight patients had a non-paraprotein-associated disease including acute tubular necrosis (9 percent), hypertensive arterionephrosclerosis (6 percent) and diabetic glomerulosclerosis (5 percent). The low prevalence of amyloidosis in this study compared with the autopsy series cited above may be explained by selection bias; patients with amyloidosis diagnosed by a means other than kidney biopsy (such as fat pad biopsy) usually do not undergo a kidney biopsy thus would not have been included in the study.",
"   </p>",
"   <p>",
"    Myeloma cast nephropathy is also the most common diagnosis in patients with significant renal dysfunction. Renal disease is frequently the presenting manifestation in multiple myeloma, with detection of monoclonal light chains in the urine leading to the diagnosis of a plasma cell dyscrasia.",
"   </p>",
"   <p>",
"    Amyloidosis or light chain deposition disease should be suspected if nephrotic syndrome is present (eg, heavy albuminuria, hypoalbuminemia, and edema) and the patient has a monoclonal gammopathy. The urine dipstick for protein should be positive in this setting, given that albuminuria is present due to the glomerular leak. In contrast, the dipstick may be negative in myeloma cast nephropathy since immunoglobulin light chains are often not detected by the dipstick. Electrophoresis of an aliquot from a 24-hour urine collection will demonstrate the presence of albumin, while immunofixation will identify the presence of monoclonal light chains.",
"   </p>",
"   <p>",
"    Other causes of renal failure or renal disease in multiple myeloma include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volume depletion (as a contributor to cast nephropathy, or due to acute tubular necrosis)",
"     </li>",
"     <li>",
"      Hypercalcemia, with or without nephrocalcinosis",
"     </li>",
"     <li>",
"      Tubulointerstitial nephritis (often drug induced)",
"     </li>",
"     <li>",
"      Plasma cell infiltration of the kidneys",
"     </li>",
"     <li>",
"      Hyperviscosity syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Acute renal failure (ARF) may also be precipitated by nephrotoxic drugs (eg, nonsteroidal antiinflammatory agents, or angiotensin converting enzyme inhibitors or receptor blockers), infection, intravenous contrast media,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , and hyperuricemia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. There are a variety of other less frequently described findings. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Miscellaneous'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ROLE OF LIGHT CHAINS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Light chains may not be detected by the urinary dipstick, which primarily senses albumin. Thus, the urine should be tested with sulfosalicylic acid (SSA, which detects all proteins) in any patient with acute or chronic renal failure, a bland urine sediment, and a negative or trace-positive dipstick. A markedly positive SSA test (as detected by the degree of turbidity when SSA is added to the urine) with a relatively negative dipstick is indicative of the presence of non-albumin proteins, such as light chains. Their presence can be confirmed and quantitated in plasma and urine through the use of the free light chain assay and immunofixation (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Light chain characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical characteristics of the individual light chain appear to be a major determinant of which disease (if any) will be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, infusion of monoclonal light chains from individual patients into mice produces the same form of renal disease (cast nephropathy, amyloid deposition, or lack of disease) in the mouse as was seen in the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/12\">",
"     12",
"    </a>",
"    ]. In vitro studies suggest that almost all toxic light chains, but few of those that are nontoxic, are able to undergo self-association leading to the formation of high molecular weight aggregates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/13\">",
"     13",
"    </a>",
"    ]. These aggregates in vivo would then lead to cast formation in myeloma kidney and tissue deposits with or without fibril formation in primary amyloidosis and light chain deposition disease, respectively.",
"   </p>",
"   <p>",
"    Additional light chain characteristics may be important in the determination of nephrotoxicity. Lambda light chains are found in roughly two-thirds of all primary (AL) amyloidosis while nearly two-thirds of the light chain deposition disease are caused by a monoclonal kappa light chain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Further contribution may come from the subtype of the light chain as lambda VI accounts for greater than 40 percent of the AL amyloidosis while kappa I and IV are overrepresented in light chain deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Finally, differential organ involvement in primary amyloidosis (AL) may be determined by the clonal sequence and germline donor patterns for the light chain variable region (Ig V-lambda) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The formation of reactive oxygen species, particularly H202, catalyzed by monoclonal light chains may stimulate the production of monocyte chemoattractant protein-1 (MCP-1) suggesting a potential mechanism of light chain-induced injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     One light chain renal disease per patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above observations regarding the importance of light chain characteristics and clinical experience have led to the notion that only one type of renal disease is clinically manifest in the majority of patients. Thus, patients with cast nephropathy rarely develop the nephrotic syndrome due to amyloidosis or light chain deposition disease, while patients with the latter disorders rarely develop acute renal failure from cast nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/23\">",
"     23",
"    </a>",
"    ]. It is possible, for example, that the light chain fragments in primary amyloidosis or light chain deposition disease are not toxic to the tubules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    less likely to form intratubular casts.",
"   </p>",
"   <p>",
"    In practice, however, pathologic findings of more than one type of disease are not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/9,23-25\">",
"     9,23-25",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one single center series of 34 patients with renal monoclonal immunoglobulin deposition disease, pathologic evidence of both light chain cast nephropathy and light chain deposition disease was observed in 11 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/24\">",
"       24",
"      </a>",
"      ]. However, all of these patients presented with acute renal failure (mean plasma creatinine concentration 7.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [690",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and none had the nephrotic syndrome, suggesting that the light chain deposition in the tubules and other structures produced limited injury. Further support for this hypothesis comes from the observation that 4 of the 11 had positive light chain staining with immunofluorescence but no electron dense deposits, while the remainder had less extensive deposition on electron microscopy than that observed with clinical light chain deposition disease.",
"     </li>",
"     <li>",
"      In a series of 190 patients with multiple myeloma who underwent kidney biopsy, 12 patients had 2 distinct paraprotein-associated lesions, including cast nephropathy and monoclonal immunoglobulin deposition disease in 5 patients, cast nephropathy and amyloidosis in 4 patients, monoclonal immunoglobulin deposition disease and amyloidosis in 2 patients and cast nephropathy and fibrillary glomerulonephritis in 1 patient [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One patient has been described to have developed cast nephropathy, AL amyloidosis and light chain deposition disease in the same kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MYELOMA CAST NEPHROPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloma cast nephropathy refers to acute or chronic renal failure that results from the over-production, filtration and overabundance of toxic light chains in the ascending loop of Henle, leading to both tubular injury and intratubular cast formation and obstruction (",
"    <a class=\"graphic graphic_picture graphicRef57572 graphicRef70405 graphicRef82327 \" href=\"UTD.htm?16/0/16394\">",
"     picture 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. One important characteristic of light chains that induce cast nephropathy is specific binding to Tamm-Horsfall mucoprotein, a protein normally synthesized by the tubular cells in the thick ascending limb of the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/2,26\">",
"     2,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Volume depletion is a significant risk factor in that it both slows flow within the tubules and increases the light chain concentration, thereby promoting the formation of large aggregates [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. A review of the factors that promote cast formation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"     \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who produce excess monoclonal light chains (or rarely excess heavy chains) can develop two other disorders in which immunoglobulin fragments deposit in the kidney and other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/1,14,15,17,27\">",
"     1,14,15,17,27",
"    </a>",
"    ]. These are primary amyloidosis (AL amyloidosis) and monoclonal immunoglobulin deposition disease (MIDD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"     \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In AL amyloidosis, the circulating light chains are taken up by and partially metabolized in macrophages. Light chain fragments are then secreted from the macrophages, and these fragments can precipitate to form the characteristic Congo red positive, &szlig;-pleated fibrils [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/14,28\">",
"     14,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monoclonal immunoglobulin deposition disease is pathogenetically similar, except that the light (or heavy) chain fragments do not form fibrils and the deposits are Congo red negative [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients with these disorders typically present with the nephrotic syndrome and renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/17,30\">",
"     17,30",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 63 Italian patients with light chain deposition disease, practically all had proteinuria (84 percent) and some degree of renal insufficiency (96 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/17\">",
"       17",
"      </a>",
"      ]; 36 progressed to end-stage renal disease, with a worse renal prognosis in older individuals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"       \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among 64 patients with monoclonal immunoglobulin deposition disease (51 with light chain deposition disease, 7 with heavy chain deposition disease and 6 with light and heavy chain deposition disease), 97 percent had abnormal proteinuria with a mean 24 urine protein excretion of 4.1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/30\">",
"       30",
"      </a>",
"      ]. Ninety seven percent of patients had renal insufficiency (defined as a serum creatinine &gt;1.2",
"      <span class=\"nowrap\">",
"       mg/dl)",
"      </span>",
"      and 62 percent had microscopic hematuria. An abnormal free light chain ratio was detected by serum free light chain assay in all patients [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence suggests that this process takes place in the mesangial cell where pathologic light chains are converted into fibrils or granular deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/31\">",
"     31",
"    </a>",
"    ]. This is accompanied by a phenotypic change in the mesangial cell according to the pathologic nature of the light chain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RENAL TUBULAR DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, the toxic effect of filtered light chains is limited to tubular dysfunction, with the glomerular filtration rate being relatively well maintained. The proximal tubules are most prominently affected, due to the reabsorption of filtered light chains and their subsequent accumulation in the proximal tubular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/32\">",
"     32",
"    </a>",
"    ]. The light chains that produce this lesion appear to have a unique biochemical characteristic in that part of the variable domain is resistant to degradation by proteases in lysosomes in the tubular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/26\">",
"     26",
"    </a>",
"    ]. Accumulation of the variable domain fragments, with subsequent intracellular crystal formation, is presumably responsible for the impairment in tubular function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of tubular dysfunction include signs of the Fanconi syndrome such as proximal renal tubular acidosis and phosphate wasting; the latter can lead to hypophosphatemia and osteomalacia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Proximal dysfunction can also exacerbate myeloma kidney by decreasing light chain reabsorption, thereby increasing light chain delivery to and promoting precipitation in the distal nephron. An important laboratory finding is the presence of hypouricemia (in the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    therapy) as well as aminoaciduria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER CAUSES OF ARF",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia is a common finding in multiple myeloma, with 15 percent of patients having a calcium concentration &gt;11.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    at the time of diagnosis. The rise in the plasma calcium concentration results from increased bone resorption, an effect that may be mediated in part by increased secretion of the bone resorbing cytokines lymphotoxin and interleukin-6. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link\">",
"     \"Hypercalcemia of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypercalcemia can contribute to the development of renal failure by causing renal vasoconstriction, by leading to intratubular calcium deposition, and perhaps by increasing the toxicity of filtered light chains [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The decline in renal function may be associated with patient complaints of polyuria and polydipsia due to nephrogenic diabetes insipidus. Both the renal failure and ADH resistance induced by hypercalcemia are generally reversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of hypercalcemia\", section on 'Renal insufficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=see_link\">",
"     \"Clinical manifestations and causes of nephrogenic diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Intravenous radiocontrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute renal failure is a potential, although infrequent (less than 1.5 percent), complication of radiocontrast administration in patients with multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/38\">",
"     38",
"    </a>",
"    ]. Prior volume depletion and urinary light chain excretion are present in almost all cases; the former may predispose to contrast nephropathy by enhancing light chain precipitation within the tubules. Intratubular obstruction also may rarely develop via an interaction between the contrast agent and urinary light chains [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/39\">",
"     39",
"    </a>",
"    ]. Hydration prior to the study is likely to be protective if contrast must be given. It is not known if nonionic agents might be safer by minimizing any charge interaction between the contrast agent and the light chains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nonsteroidal antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hypercalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    volume depletion of any cause are at risk of worsening renal function following the administration of a nonsteroidal antiinflammatory drug. As a result, NSAID therapy should be avoided if possible in patients with multiple myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195122488\">",
"    <span class=\"h2\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates are commonly used among patients with multiple myeloma and lytic bone lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bisphosphonates have been associated with acute tubular necrosis (ATN) (zoledronate) and the collapsing form of focal and segmental glomerulosclerosis (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ). In the study cited above, among 190 patients, 3 patients had ATN presumed to be associated with zoledronate and 2 patients had FSGS presumed to be related to pamidronate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricemia may be seen in up to 50 percent of patients with multiple myeloma at presentation, and may contribute to acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, sufficiently rapid tumor turnover is unusual even after chemotherapy, thus overt tumor lysis syndrome is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link&amp;anchor=H2#H2\">",
"     \"Uric acid renal diseases\", section on 'Acute uric acid nephropathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I cryoglobulinemia is a rare cause of glomerular disease in patients with multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/43\">",
"     43",
"    </a>",
"    ]. In this setting, the monoclonal immunoglobulin forms cryoprecipitates that can lead to a membranoproliferative pattern with intraluminal \"thrombi\" on renal biopsy. In addition, patients have been reported with type 1 cryoglobulinemia and membranoproliferative glomerulonephritis and monoclonal IgG deposits, but without evidence of myeloma or lymphoma initially or within 12 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/44\">",
"     44",
"    </a>",
"    ]. Type II cryoglobulinemia is very rare (and probably unrelated) in myeloma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma cell invasion of the kidney can occur in multiple myeloma, but by itself, is rarely severe enough to impair renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition to the direct myeloma infiltration, extramedullary hematopoiesis has been reported in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute renal failure resulting from acute tubular interstitial nephritis has been described in patients with plasma cell disorders including myeloma. This tubulointerstitial nephritis is associated with light chain deposition in the tubular basement membrane. However, the pattern of deposition is distinct from that of light chain deposition disease, as distinct granular electron dense deposits are not seen. Immunogold labeling shows that the light chains are deposited in the outer aspect of the tubular basement membranes and lysosomes of tubular epithelial cells. Glomerular deposits are absent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Renal vein thrombosis, a well-known complication of nephrotic syndrome, has been described in patients with multiple myeloma, but its contribution to renal failure is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperviscosity has been described in multiple myeloma in which abnormal polymers of IgA or IgG or kappa light chains are produced. This can lead to impairment in the microcirculation of the central nervous system, as well as other possible findings including renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12484?source=see_link\">",
"     \"Plasma exchange in the hyperviscosity syndrome due to immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both membranoproliferative and rapidly progressive (crescentic) glomerulonephritis have been described in some patients, although the relation to the myeloma is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27400/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932583\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal disease is a common problem in multiple myeloma. Severity correlates with patient survival. The most common cause of renal dysfunction is myeloma cast nephropathy, due to monoclonal light chains aggregation and precipitation in the tubule lumen. Non-monoclonal protein-related renal injury may also occur. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The types of kidney disease can be classified by the primary site of injury. Glomerular disease may be caused by amyloidosis and light",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heavy chain deposition diseases. Tubular disorders include cast nephropathy (which causes renal failure) and isolated distal or proximal tubular dysfunction. Interstitial lesions include plasma cell infiltration or interstitial nephritis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biochemical characteristics of the light chains are important determinants of disease. Whereas lambda light chains are found in roughly two-thirds of all primary (AL) amyloidosis, monoclonal kappa light chains usually cause light chain deposition disease. Characteristics including the clonal sequence and germline donor patterns for the variable region may determine differential organ involvement. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Role of light chains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myeloma cast nephropathy refers to acute or chronic renal failure that results from the over-production, filtration, and overabundance of toxic light chains in the ascending loop of Henle. Volume depletion is a significant risk factor. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Myeloma cast nephropathy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=see_link\">",
"       \"Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary amyloidosis (AL amyloidosis) and monoclonal immunoglobulin deposition disease (ie, light chain deposition disease) results from the deposition of immunoglobulin fragments in the kidney and other tissues. Patients often present with the nephrotic syndrome and renal insufficiency. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Amyloidosis and monoclonal immunoglobulin deposition disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"       \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Isolated tubular dysfunction may result from the toxic effect of filtered light chains. The proximal tubules are most prominently affected. The clinical manifestations of tubular dysfunction include renal tubular acidosis and phosphate wasting (Acquired Fanconi Syndrome). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Renal tubular dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal failure may also be caused by hypercalcemia, radiocontrast administration in patients with volume depletion and urinary light chain excretion, hyperuricemia and drugs including nonsteroidal antiinflammatory drugs and bisphosphonates. (See",
"      <a class=\"local\" href=\"#H195122488\">",
"       'Bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Other causes of ARF'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/1\">",
"      Sanders PW, Herrera GA, Kirk KA, et al. Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 1991; 64:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/2\">",
"      Sanders PW. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 1994; 124:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/3\">",
"      Winearls CG. Acute myeloma kidney. Kidney Int 1995; 48:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/4\">",
"      Cohen DJ, Sherman WH, Osserman EF, Appel GB. Acute renal failure in patients with multiple myeloma. Am J Med 1984; 76:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/5\">",
"      Haynes RJ, Read S, Collins GP, et al. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrol Dial Transplant 2010; 25:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/6\">",
"      Blad&eacute; J, Fern&aacute;ndez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/7\">",
"      Sakhuja V, Jha V, Varma S, et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000; 22:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/8\">",
"      Pasquali S, Zucchelli P, Casanova S, et al. Renal histological lesions and clinical syndromes in multiple myeloma. Renal Immunopathology Group. Clin Nephrol 1987; 27:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/9\">",
"      Iv&aacute;nyi B. Renal complications in multiple myeloma. Acta Morphol Hung 1989; 37:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/10\">",
"      Montseny JJ, Kleinknecht D, Meyrier A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998; 13:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/11\">",
"      Nasr SH, Valeri AM, Sethi S, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis 2012; 59:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/12\">",
"      Solomon A, Weiss DT, Kattine AA. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/13\">",
"      Myatt EA, Westholm FA, Weiss DT, et al. Pathogenic potential of human monoclonal immunoglobulin light chains: relationship of in vitro aggregation to in vivo organ deposition. Proc Natl Acad Sci U S A 1994; 91:3034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/14\">",
"      Buxbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990; 112:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/15\">",
"      Ganeval D, No&euml;l LH, Preud'homme JL, et al. Light-chain deposition disease: its relation with AL-type amyloidosis. Kidney Int 1984; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/16\">",
"      Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/17\">",
"      Pozzi C, D'Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003; 42:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/18\">",
"      Ozaki S, Abe M, Wolfenbarger D, et al. Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstr&ouml;m's macroglobulinemia. Clin Immunol Immunopathol 1994; 71:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/19\">",
"      Cogn&eacute; M, Preud'homme JL, Bauwens M, et al. Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease. J Clin Invest 1991; 87:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/20\">",
"      Vidal R, Go&ntilde;i F, Stevens F, et al. Somatic mutations of the L12a gene in V-kappa(1) light chain deposition disease: potential effects on aberrant protein conformation and deposition. Am J Pathol 1999; 155:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/21\">",
"      Comenzo RL, Wally J, Kica G, et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol 1999; 106:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/22\">",
"      Wang PX, Sanders PW. Immunoglobulin light chains generate hydrogen peroxide. J Am Soc Nephrol 2007; 18:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/23\">",
"      Hill GS, Morel-Maroger L, M&eacute;ry JP, et al. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis 1983; 2:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/24\">",
"      Lin J, Markowitz GS, Valeri AM, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/25\">",
"      Lorenz EC, Sethi S, Poshusta TL, et al. Renal failure due to combined cast nephropathy, amyloidosis and light-chain deposition disease. Nephrol Dial Transplant 2010; 25:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/26\">",
"      Leboulleux M, Lelongt B, Mougenot B, et al. Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 1995; 48:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/27\">",
"      Paueksakon P, Revelo MP, Horn RG, et al. Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 2003; 42:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/28\">",
"      Durie BG, Persky B, Soehnlen BJ, et al. Amyloid production in human myeloma stem-cell culture, with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med 1982; 307:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/29\">",
"      Dimopoulos MA, Kastritis E, Rosinol L, et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008; 22:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/30\">",
"      Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 2012; 7:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/31\">",
"      Keeling J, Teng J, Herrera GA. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004; 84:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/32\">",
"      Sanders PW, Herrera GA, Lott RL, Galla JH. Morphologic alterations of the proximal tubules in light chain-related renal disease. Kidney Int 1988; 33:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/33\">",
"      Decourt C, Rocca A, Bridoux F, et al. Mutational analysis in murine models for myeloma-associated Fanconi's syndrome or cast myeloma nephropathy. Blood 1999; 94:3559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/34\">",
"      Maldonado JE, Velosa JA, Kyle RA, et al. Fanconi syndrome in adults. A manifestation of a latent form of myeloma. Am J Med 1975; 58:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/35\">",
"      Rao DS, Parfitt AM, Villanueva AR, et al. Hypophosphatemic osteomalacia and adult Fanconi syndrome due to light-chain nephropathy. Another form of oncogenous osteomalacia. Am J Med 1987; 82:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/36\">",
"      Benabe JE, Martinez-Maldonado M. Hypercalcemic nephropathy. Arch Intern Med 1978; 138:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/37\">",
"      Smolens P, Barnes JL, Kreisberg R. Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins. J Lab Clin Med 1987; 110:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/38\">",
"      McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/39\">",
"      Holland MD, Galla JH, Sanders PW, Luke RG. Effect of urinary pH and diatrizoate on Bence Jones protein nephrotoxicity in the rat. Kidney Int 1985; 27:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/40\">",
"      Kapadia SB. Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore) 1980; 59:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/41\">",
"      Uchida M, Kamata K, Okubo M. Renal dysfunction in multiple myeloma. Intern Med 1995; 34:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/42\">",
"      Fassas AB, Desikan KR, Siegel D, et al. Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma. Br J Haematol 1999; 105:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/43\">",
"      Nasr SH, Markowitz GS, Reddy BS, et al. Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int 2006; 69:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/44\">",
"      Nasr SH, Markowitz GS, Stokes MB, et al. Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004; 65:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/45\">",
"      Nasr SH, Alobeid BB, Otrakji JA, Markowitz GS. Myeloma cast nephropathy, direct renal infiltration by myeloma, and renal extramedullary hematopoiesis. Kidney Int 2008; 73:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/46\">",
"      Gu X, Herrera GA. Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006; 130:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/47\">",
"      Alpers CE, Cotran RS. Neoplasia and glomerular injury. Kidney Int 1986; 30:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27400/abstract/48\">",
"      Bourke E, Campbell WG Jr, Piper M, Check IJ. Hypocomplementemic proliferative glomerulonephritis with C3 nephritic-factor-like activity in multiple myeloma. Nephron 1989; 52:231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7210 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27400=[""].join("\n");
var outline_f26_48_27400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H932583\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glomerular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Tubular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interstitial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ROLE OF LIGHT CHAINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Light chain characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      One light chain renal disease per patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MYELOMA CAST NEPHROPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RENAL TUBULAR DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER CAUSES OF ARF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Intravenous radiocontrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H195122488\">",
"      Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H932583\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7210\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7210|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/40/41603\" title=\"picture 1A\">",
"      Myeloma cast I-light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/30/33253\" title=\"picture 1B\">",
"      Myeloma cast II- light microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/60/13248\" title=\"picture 1C\">",
"      Myeloma kidney-immunofluorescence microscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21545?source=related_link\">",
"      Clinical manifestations and causes of nephrogenic diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34040?source=related_link\">",
"      Clinical manifestations and diagnosis of the mixed cryoglobulinemia syndrome (essential mixed cryoglobulinemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22551?source=related_link\">",
"      Pathogenesis and diagnosis of myeloma cast nephropathy (myeloma kidney)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12484?source=related_link\">",
"      Plasma exchange in the hyperviscosity syndrome due to immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30409?source=related_link\">",
"      Treatment of kidney disease in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_48_27401="Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease";
var content_f26_48_27401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27401/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27401/contributors\">",
"     Scott B Snapper, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27401/contributors\">",
"     Daniel K Podolsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27401/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27401/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27401/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27401/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27401/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/48/27401/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 29, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune response has long been implicated in the pathogenesis of inflammatory bowel disease (IBD), including both ulcerative colitis and Crohn's disease. From a vast body of literature investigating the roles of both host and microbial factors, two basic themes in the pathogenesis of IBD emerge [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysregulation of the innate and adaptive immune system directed against luminal bacteria or their products found in the intestinal lumen",
"     </li>",
"     <li>",
"      Inappropriate immune responses to organisms in the intestine that normally do not elicit a response, possibly due to intrinsic alterations in mucosal barrier function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will focus on our expanding understanding of the immune and microbial factors associated with both the initiation and maintenance of IBD. New insights gleaned from murine genetic models of inflammatory bowel disease will also be discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE MUCOSAL IMMUNE SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the process of carrying out the absorption of essential nutrients, the human intestine must discriminate innocuous food antigens from infectious or toxic agents. To protect the host from the latter, the intestine relies upon an effective barrier, and a natural (innate) and an acquired immune system (",
"    <a class=\"graphic graphic_figure graphicRef74195 \" href=\"UTD.htm?7/53/8024\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effective barrier depends upon an intact intestinal epithelium, with its overlying surface mucus, normal peristalsis, and the secretion of numerous protective factors (eg, trefoil peptides).",
"     </li>",
"     <li>",
"      The innate immune system is comprised of so-called pattern recognition receptors, which bind stereotypic microbial products on epithelial cells or phagocytes (neutrophils and macrophages), and natural killer cells and their products, which provide the initial response to potential pathologic foreign antigen exposure.",
"     </li>",
"     <li>",
"      The adaptive immune system is comprised primarily of B- and T-lymphocytes as well as dendritic cells which confer specific immunity. The acquired immune system is designed to respond to foreign antigens displayed by \"professional\" antigen presenting cells (APCs) in association with molecules of the major histocompatibility complex (MHC).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both humoral and cell-mediated mechanisms are involved in the acquired immune system. Humoral immunity is mediated by antibody secreting B-cells within the gut, which are largely of the IgA class. Dimeric secretory IgA antibodies are specifically transported across the intestinal epithelium into the lumen where they can interact with foreign antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link\">",
"     \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cellular immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular immunity is mediated by T-lymphocytes, which can be functionally divided into CD4+ helper T-cells CD8+ (cytotoxic) and regulatory T-cells. CD4+ T-cells respond to processed antigen on professional APCs in association with MHC class II molecules. CD8+ T-cells respond to processed antigen on all cell types in association with MHC class I molecules.",
"   </p>",
"   <p>",
"    CD4+ helper T-cells can be further subdivided functionally into Th1 cells, Th17 cells, and Th2 cells.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Th1 cells secrete predominantly interferon gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-2, and IL-12 which induce cell-mediated immunity. IL-12 (consisting of the heterodimer",
"      <span class=\"nowrap\">",
"       p35/p40)",
"      </span>",
"      is secreted by APCs and is critical for the generation of Th1 cells.",
"     </li>",
"     <li>",
"      Th17 cells are a lineage of helper T cells that have a critical role in regulating the inflammatory process and may have a central role in autoimmunity. Th17 cells secrete predominantly IL-17, IL-6, and G-CSF [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/3\">",
"       3",
"      </a>",
"      ]. The IL-12-related molecule, IL-23 (consisting of the heterodimer",
"      <span class=\"nowrap\">",
"       p19/p49)",
"      </span>",
"      is important for generation of Th17 cells [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/4\">",
"       4",
"      </a>",
"      ]. Receptor mutations in the IL-23 receptor have been associated with susceptibility to IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/5-8\">",
"       5-8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Th2 cells regulate B-cell differentiation by secreting predominantly IL-4, IL-5, and IL-13.",
"     </li>",
"     <li>",
"      Regulatory T-cells include three populations, designated TH3, Tr1, and CD4+ CD25+ (mediated at least in part by the expression of the forkhead box p3 transcription factor). They block or downregulate TH1, TH17, and TH2 cells either by production of specific cytokines (IL-10 and TGF-beta) or via cell-cell contact [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These cells are collectively known as the gut-associated lymphoid tissue (GALT), and are distributed throughout the lamina propria, between epithelial cells, and in discrete lymphoid follicles. Epithelial cells, \"professional\" APCs, and other leukocytes within the GALT also secrete a variety of soluble protein mediators (cytokines), which serve to regulate responses to foreign antigens. In addition, alterations in the intestinal microcirculation and neuronal afferents can modify the composition and effector function of both immune and nonimmune cells within the GALT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     IMMUNE DYSREGULATION AND IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies suggest that IBD results from an abnormal mucosal immune system. An aberrant innate immune system has been a particular focus of research. Nevertheless, this is still a greatly contested issue. Several suggested specific abnormalities have not been consistently observed between studies. Furthermore, the relationship between immune defects and the development of IBD is not always certain.",
"   </p>",
"   <p>",
"    The following five examples illustrate these issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lymphoid cells isolated from lesions of patients with IBD display numerous activation markers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/10\">",
"       10",
"      </a>",
"      ]. T-cells isolated from IBD mucosa may show increased proliferation to antigens in vitro, suggesting that they may respond abnormally to resident antigens [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/11\">",
"       11",
"      </a>",
"      ]. To determine whether IBD results from an altered response to single or few antigens, several investigators have studied whether there is a limited repertoire of T-cell receptors found among T-cells in the gut or peripheral blood of patients with IBD. This remains an unanswered question since some, but not all, studies have found a restricted repertoire [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/12-18\">",
"       12-18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The findings of increase numbers of circulating B cells and autoantibodies in patients with IBD suggest that abnormal B cell regulation may be involved in the pathogenesis of this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Putative colonic autoantigens [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/21,22\">",
"       21,22",
"      </a>",
"      ], and atypical (ie, not directed against myeloperoxidase) perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/23\">",
"       23",
"      </a>",
"      ] and other autoantibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/24\">",
"       24",
"      </a>",
"      ] have been identified in patients with IBD and their relatives. However, no study has yet shown that antibody production is directly involved in the pathogenesis of IBD, and titers of ANCA do not appear to correlate with disease activity [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Measurement of serum antibodies may be useful for distinguishing Crohn's disease from ulcerative colitis. In one study, for example, children with IBD who tested positively for P-ANCA, and negatively for anti-Saccharomyces cerevisiae antibodies (ASCA) were more likely to have ulcerative colitis than Crohn's disease (sensitivity 57 percent, specificity 97 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/26\">",
"       26",
"      </a>",
"      ]. Conversely, children who were P-ANCA negative but ASCA positive were more likely to have Crohn's disease (49 percent sensitivity, 97 percent specificity).",
"     </li>",
"     <li>",
"      Some inflammatory cells, such as neutrophils, found within diseased mucosa in IBD are not usually present in the lamina propria, and therefore must be recruited from the vascular space. This process is called \"homing.\" Homing requires several coordinated steps. Leukocytes \"roll\" along the endothelium, and are induced by chemokines, resulting in firm adhesion. Once adherent, leukocytes traverse the endothelium (a process called \"diapedesis\") [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/27\">",
"       27",
"      </a>",
"      ]. Enhanced expression of adhesion molecules on mononuclear cells, and increased leukocyte binding to endothelial cells in cells derived from patients with IBD have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]. Furthermore, there is some evidence that these abnormalities may contribute to thrombotic complications and secondary abnormalities in the vasculature that may be associated with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/31\">",
"       31",
"      </a>",
"      ]. Therapeutic strategies to block mucosal homing or prevent thrombosis are currently under investigation.",
"      <br/>",
"      <br/>",
"      Two antibody mediated therapies that target the alpha-4; beta-7 integrin heterodimer that are important for mediating lymphocyte trafficking to the lamina propria have received much attention [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/32-35\">",
"       32-35",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      , an antibody directed against the alpha-4 integrin, has been approved for use in Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/32,33\">",
"       32,33",
"      </a>",
"      ]. MLN002, an antibody against alpha4beta7, was effective on both Crohn's disease and ulcerative colitis (UC) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/34,35\">",
"       34,35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epithelial cells (and the overlying mucus) are the first barrier along the gastrointestinal tract preventing infectious pathogens from entering the body. Alterations in this barrier may be important factors in the pathogenesis of IBD. Although still inconclusive, alterations in intestinal mucus, high numbers of bacteria within mucus, and increased intestinal permeability have been associated with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/36-39\">",
"       36-39",
"      </a>",
"      ]. Epithelial cells express receptors once felt to be limited to immune cells, and to present antigens, similar to classical antigen presenting cells [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/40-42\">",
"       40-42",
"      </a>",
"      ]. Investigators have begun to study whether abnormal antigen presentation by epithelial cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      interaction with intraepithelial lymphocytes is associated with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. One study suggested that epithelial cells in IBD cannot induce CD8+ suppressor cells, whose absence may be associated with the initiation of an inflammatory response [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/45\">",
"       45",
"      </a>",
"      ]. Moreover, abnormalities in the manner in which epithelial cells (and in particular highly secretory cells such as Paneth cells) handle unfolded intracellular proteins, a process that is associated with \"stress\" on the endoplasmic reticulum, has been associated with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The first confirmed IBD gene (IBD1, also called NOD2 or CARD15) confers increased risk of Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. IBD1 encodes a protein that appears to regulate at least one aspect of innate immunity: macrophage activation in response to intracellular LPS. Curiously, the variants of",
"      <span class=\"nowrap\">",
"       NOD2/CARD15",
"      </span>",
"      associated with Crohn's disease activity result in reduced response to LPS, at least in the in vitro assays utilized. This counterintuitive occurrence implies that failure of this response in some way leads to sustained activation of other inflammatory pathways.",
"      <span class=\"nowrap\">",
"       NOD2/CARD15",
"      </span>",
"      is expressed in intestinal epithelial cells (including, notably, Paneth cells) and mononuclear cells, and likely serves as a key component of the innate mucosal response to luminal bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/49,50\">",
"       49,50",
"      </a>",
"      ]. NOD2 deficient mice are susceptible to bacterial infection from oral but not from intravenous or intraperitoneal pathogens [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/51\">",
"       51",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Mutations in IBD1 appear to confer susceptibility to ileal and fibrostenosing Crohn's disease in Western populations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/52-57\">",
"       52-57",
"      </a>",
"      ]. In a report from Germany and Britain, an individual inheriting one mutant IBD1 allele has a 2.6 fold increase in risk of developing CD, while an individual inheriting two mutant IBD1 alleles has a 40 fold increase in risk [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/54\">",
"       54",
"      </a>",
"      ]. In contrast, a study from Japan found no association between the common",
"      <span class=\"nowrap\">",
"       NOD2/CARD",
"      </span>",
"      15 mutations and Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/58\">",
"       58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Mutations in",
"      <span class=\"nowrap\">",
"       NOD2/CARD15",
"      </span>",
"      are also associated with complicated (stricturing of fistulizing) disease. A meta-analysis that included 49 studies with 8893 patients found that patients with",
"      <span class=\"nowrap\">",
"       NOD2/CARD15",
"      </span>",
"      mutations were at increased risk for complicated disease (RR 1.17; 95% CI 1.10-1.24) and surgery (RR 1.58; 95% CI 1.38-1.80) compared with those without mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dysregulation of secreted products",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, leukocyte and epithelial responses in the intestine are carefully regulated by protein mediators secreted by all cells found within the lamina propria. Abnormal levels of several of these immunoregulatory and inflammatory cytokines correlate with active IBD in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The potential clinical relevance of this type of regulation may result from control of T-helper cell differentiation.",
"   </p>",
"   <p>",
"    The generation of inflammatory Th1 lymphocytes is induced by",
"    <span class=\"nowrap\">",
"     IL-12/IL-18,",
"    </span>",
"    and inhibited by IL-4; in contrast, the generation of helper Th2 lymphocytes is induced by IL-4 and inhibited by IL-12 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The secretion of IFN-gamma and TNF-alpha by Th1 cells has a marked proinflammatory effect, whereas the secretion of IL-10 by Th2 cells suppresses the Th1-mediated responses. Th17 cells are induced by",
"    <span class=\"nowrap\">",
"     IL-1/IL-18,",
"    </span>",
"    TGF-beta, IL-6, and IL-23 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/3\">",
"     3",
"    </a>",
"    ]. Ongoing studies are targeting the",
"    <span class=\"nowrap\">",
"     IL-12/IL-23",
"    </span>",
"    axis given its critical role in the generation of",
"    <span class=\"nowrap\">",
"     Th1/Th17",
"    </span>",
"    cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. CD8+ T-cells also secrete IL-10 and transforming growth factor (TGF) beta-1, which suppress Th1 responses. As noted above, mice and men also exhibit a third broad subset of regulatory CD4+ cells (Th3 or TR1) and CD4+ CD25+, which can also act as \"suppressor\" cells. While some regulatory cells are generated in the thymus, other \"induced\" or \"adaptive\" regulatory cells can be generated in situ in the GALT. Although aberrant regulatory cell function has not yet been implicated in IBD, therapeutic strategies targeting regulatory T-cells are under active investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some investigators have found that CD4+ T lymphocytes isolated from patients with Crohn's disease secrete large amounts of IFN-gamma and TNF-alpha, implicating Th1 cells in the pathogenesis of IBD. These findings are consistent with observations in several mouse models of chronic colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. Furthermore, these studies have led to therapeutic strategies using anti-TNF-alpha antibodies for Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/71\">",
"     71",
"    </a>",
"    ]. IL-23-dependent signaling and secretion of cytokines by Th17 cells may account, at least in part, for some of the aberrant cytokine secretion previously attributed to Th1 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/3,72-78\">",
"     3,72-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TL1A",
"    <span class=\"nowrap\">",
"     (TNFSF15)/DR3",
"    </span>",
"    axis has also been implicated in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/79\">",
"     79",
"    </a>",
"    ]. TL1A is a TNF-like cytokine that is increased in CD and interacts with the death domain receptor (DR3) and enhances IFN-gamma production by T and NK cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Several studies have implicated the",
"    <span class=\"nowrap\">",
"     TL1A/DR3",
"    </span>",
"    axis in animal models of colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/81,82\">",
"     81,82",
"    </a>",
"    ], and more recent studies suggest that DR3 is upregulated in Th17 cells and that TL1A can expand Th17 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/81,83\">",
"     81,83",
"    </a>",
"    ]. As noted below, TNFSF15 is a well established susceptibility locus in CD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some intestinal growth factors, while not necessarily having a direct role on the immune system, may be involved in IBD pathogenesis. These factors regulate the growth and differentiation of intestinal epithelial cells and thereby affect barrier function. In addition to protein mediators, several other biological products have been implicated in IBD pathogenesis when found in excess. Examples include arachidonic acid and its byproducts, and reactive oxygen and nitrogen products (",
"    <a class=\"graphic graphic_table graphicRef71237 \" href=\"UTD.htm?27/51/28476\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Role of stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited epidemiologic evidence in humans and clinical experience suggest that stress can worsen symptoms of IBD. However, the immunologic basis for this observation is unclear, although a role for sensitized CD4 cells has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ROLE OF MICROBES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distal ileum and colon contain high concentrations of bacteria (&gt;10(12)",
"    <span class=\"nowrap\">",
"     organisms/g).",
"    </span>",
"    These may include pathogens that could be directly responsible for initiating IBD, and factors that may promote IBD in the context of an underlying genetic mucosal or immune defect. Consistent with this hypothesis is the observation of an immune response directed against a particular bacterial DNA segment (I2) in affected mucosa from 54 percent of patients with Crohn's disease compared to 4 to 10 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/88\">",
"     88",
"    </a>",
"    ]. However, no single agent has been shown to have a consistent relationship to IBD.",
"   </p>",
"   <p>",
"    Because of the enormous number of anaerobic bacteria within the intestinal flora, any perturbations of the intestinal epithelium could lead to an inflammatory response. This may result from microbial products that alter the underlying epithelium, or from inherent defects in the epithelium which allow bacterial and food antigens to stimulate the mucosal immune system. Genetically engineered mice have provided experimental evidence for the importance of an intact epithelium. Thus, mice with an altered epithelium develop spontaneous colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the microbial microflora in the induction of",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    maintenance of disease has been demonstrated repeatedly in murine models of inflammatory bowel disease. As an example, genetically engineered mice deficient in the cytokines IL-2 and IL-10 or rats containing the HLA-B27 transgene develop inflammatory bowel disease in the presence of a normal microflora but not in germ-free conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. One study found that immunoreactivity to microbial antigens correlates with complications of small bowel Crohn's disease in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic studies (described further below) have identified susceptibility loci that regulate innate responses to the microbial flora. They provide further evidence for the role of microbes in the pathogenesis of IBD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linkage studies of members of multiply-affected kindreds have identified a number of genomic areas of linkage with IBD, suggesting that several genes may contribute to disease susceptibility. Nearly 100 distinct susceptibility loci for IBD have been identified, some contributing unique and or combined risk for CD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    UC [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/5,84,85,93-96\">",
"     5,84,85,93-96",
"    </a>",
"    ]. The following are illustrative of the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As noted above, the first susceptibility gene identified (\"IBD1\") encodes for the protein NOD2 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. The wild-type NOD2 protein activates nuclear factor kappa B in macrophages in response to bacterial lipopolysaccharides; this process was deficient in macrophages transfected with the mutant form of NOD2. Studies in model cell lines suggest that NOD2 has an important role in the ability of intestinal epithelial cells to contain invasive bacteria by the secretion of anti-bacterial peptides (defensins) and this function is defective in the presence of the mutant NOD2.",
"     </li>",
"     <li>",
"      Defects in ATG16L1 and IRGM proteins have been associated with Crohn's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/84,94,97-101\">",
"       84,94,97-101",
"      </a>",
"      ]. These proteins are involved in autophagy, a process that is known to mediate resistance to intracellular pathogens such as bacterial and viral proteins.",
"     </li>",
"     <li>",
"      Certain noncoding variants of the IL-23 receptor have been associated with both Crohn's disease and ulcerative colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/5-8,84,94,99\">",
"       5-8,84,94,99",
"      </a>",
"      ]. By contrast, an uncommon variant appears to protect against the risk of IBD. As noted above, IL-23 is a proinflammatory cytokine that is important for the generation of Th17 cells. Interestingly, loci containing STAT3 and JAK2 (signaling molecules downstream of IL-23-dependent signaling) and IL-12B (the p40 subunit that is contained within both IL-12 and IL-23) are associated with IBD risk [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/84,85,95\">",
"       84,85,95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several susceptibility loci have been confirmed for CD (5q31 (IBD5) TNFSF15, PTGER4, PTPN2, ZNF365, STAT3), UC (PTPN2, HERC2, STAT3) or both (3p21.31, CCNY, IL12B, HLA, NKX2-3, MST1) by more than one genome wide association study [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/84-86,94,99-102\">",
"       84-86,94,99-102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Susceptibility loci associated with CD or UC in at least one study include: ICOSLG, ITLN1, CDKAL1, C11orf30, LRRK2, MUC19, ORMDL3 PTPN22, JAK2, OCTN, PHOX2B, NCF4, FAM92B, TNFAIP3 for CD, and DLG5, ECM1, IL10, and ARPC2 for UC, as well as XBP1, NELL1 for both CD and UC [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/84,85,93-95,99,103-105\">",
"       84,85,93-95,99,103-105",
"      </a>",
"      ]. XBP1 and ORMDL3 are proteins that regulate the unfolded protein response (UPR), which is a critical cellular process by which highly secretory cells like epithelial cells handle endoplasmic reticulum stress. This process is also known to regulate the process of autophagy described above [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Defects in the function of Smads, a family of proteins that serve as substrates for the TGF-beta receptor, have also been linked to IBD. Overexpression of Smad 7, an inhibitor of TGF-beta signaling, has been demonstrated in mucosa and purified mucosal T cells from patients with IBD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LESSONS FROM ANIMAL MODELS OF IBD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of several animal models of IBD has facilitated investigation into both the underlying defects in the GALT that can induce inflammation, and essential factors that are required for the maintenance of disease. Numerous murine strains develop IBD as a result of genetic manipulation or \"knock out\" of genes that affect the mucosal immune system (eg,",
"    <span class=\"nowrap\">",
"     IL-2-/-,",
"    </span>",
"    IL-2 receptor",
"    <span class=\"nowrap\">",
"     -/-,",
"    </span>",
"    <span class=\"nowrap\">",
"     IL-10-/-,",
"    </span>",
"    T cell receptor",
"    <span class=\"nowrap\">",
"     alpha-/-,",
"    </span>",
"    MHC class II, WASP, A20, COX-1 and COX-2) or epithelial function (eg, G alpha",
"    <span class=\"nowrap\">",
"     i2-/-;",
"    </span>",
"    XBP1) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/1,67,93,102,107-113\">",
"     1,67,93,102,107-113",
"    </a>",
"    ]. Others develop an IBD-like disease because of the overexpression of genes (eg, HLA-B27, N-cadherin, CD3e) or deficiency of regulatory cell types (eg, CD4+ CD45RBlo, CD25+ T-cells) that are involved in either lymphoid or epithelial cell homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/1,70,89,114-117\">",
"     1,70,89,114-117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several themes have emerged from these animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27401/abstract/1,118\">",
"     1,118",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The absence of diverse proteins (or cell types) involved in regulating epithelial cell function and the innate or adaptive mucosal immune system can result in mucosal inflammation",
"     </li>",
"     <li>",
"      Many of these proteins, directly or indirectly, alter innate immune cell",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      T-cell function",
"     </li>",
"     <li>",
"      The presence of luminal bacteria is generally required for development of colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These experimental models of colitis have served to confirm, and to extend, previous hypotheses regarding IBD pathogenesis, ie, an important role for epithelial and immune cells and the intestinal microflora with a specific genetic background. Most importantly, these animal models have provided a foundation for future investigation into the mechanisms responsible for IBD, which will hopefully result in the development and testing of novel therapeutic regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two basic themes in the pathogenesis of IBD emerge from a vast body of evidence: (1) dysregulation of the innate and adaptive immune system directed against luminal bacteria or their products found in the intestinal lumen; (2) inappropriate immune responses to organisms in the intestine that normally do not elicit a response, possibly due to intrinsic alterations in mucosal barrier function.",
"     </li>",
"     <li>",
"      Abnormalities of the mucosal immune system have been suggested in several studies but there remain many inconsistencies, making the role of mucosal immune dysregulation in the pathogenesis of IBD unclear. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Immune dysregulation and IBD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple lines of evidence suggest the immune response to intestinal microbial flora is important in the pathogenesis of IBD. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Role of microbes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple genetic variations have been implicated in the pathogenesis of IBD. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetic susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/1\">",
"      Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/2\">",
"      Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/3\">",
"      Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/4\">",
"      Diveu C, McGeachy MJ, Cua DJ. Cytokines that regulate autoimmunity. Curr Opin Immunol 2008; 20:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/5\">",
"      Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/6\">",
"      Tremelling M, Cummings F, Fisher SA, et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 2007; 132:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/7\">",
"      Baldassano RN, Bradfield JP, Monos DS, et al. Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease. Clin Gastroenterol Hepatol 2007; 5:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/8\">",
"      Oliver J, Rueda B, L&oacute;pez-Nevot MA, et al. Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/9\">",
"      Boden EK, Snapper SB. Regulatory T cells in inflammatory bowel disease. Curr Opin Gastroenterol 2008; 24:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/10\">",
"      Matsuura T, West GA, Youngman KR, et al. Immune activation genes in inflammatory bowel disease. Gastroenterology 1993; 104:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/11\">",
"      Fiocchi C, Battisto JR, Farmer RG. Studies on isolated gut mucosal lymphocytes in inflammatory bowel disease. Detection of activated T cells and enhanced proliferation to Staphylococcus aureus and lipopolysaccharides. Dig Dis Sci 1981; 26:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/12\">",
"      Chott A, Probert CS, Gross GG, et al. A common TCR beta-chain expressed by CD8+ intestinal mucosa T cells in ulcerative colitis. J Immunol 1996; 156:3024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/13\">",
"      L&uuml;gering N, Kucharzik T, Fisahn M, et al. Crohn's disease (CD) patients suffering from peripheral arthritis or ankylosing spondylitis reveal restricted T cell receptor V beta regions in different temporal phases of disease. Clin Exp Immunol 1996; 105:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/14\">",
"      Kaulfersch W, Fiocchi C, Waldmann TA. Polyclonal nature of the intestinal mucosal lymphocyte populations in inflammatory bowel disease. A molecular genetic evaluation of the immunoglobulin and T-cell antigen receptors. Gastroenterology 1988; 95:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/15\">",
"      Posnett DN, Schmelkin I, Burton DA, et al. T cell antigen receptor V gene usage. Increases in V beta 8+ T cells in Crohn's disease. J Clin Invest 1990; 85:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/16\">",
"      Spencer J, Choy MY, MacDonald TT. T cell receptor V beta expression by mucosal T cells. J Clin Pathol 1991; 44:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/17\">",
"      Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 102:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/18\">",
"      Gulwani-Akolkar B, Akolkar PN, Minassian A, et al. Selective expansion of specific T cell receptors in the inflamed colon of Crohn's disease. J Clin Invest 1996; 98:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/19\">",
"      BROBERGER O, PERLMANN P. Autoantibodies in human ulcerative colitis. J Exp Med 1959; 110:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/20\">",
"      Greenwald BD, James SP. Immunology of inflammatory bowel disease. Curr Opin Gastroenterol 1997; 13:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/21\">",
"      Takahashi F, Das KM. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest 1985; 76:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/22\">",
"      Das KM, Dasgupta A, Mandal A, Geng X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J Immunol 1993; 150:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/23\">",
"      Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/24\">",
"      Chapman RW, Cottone M, Selby WS, et al. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 1986; 27:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/25\">",
"      Roozendaal C, Pog&aacute;ny K, Hummel EJ, et al. Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. QJM 1999; 92:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/26\">",
"      Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998; 115:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/27\">",
"      Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/28\">",
"      Malizia G, Calabrese A, Cottone M, et al. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991; 100:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/29\">",
"      Koizumi M, King N, Lobb R, et al. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology 1992; 103:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/30\">",
"      Salmi M, Granfors K, MacDermott R, Jalkanen S. Aberrant binding of lamina propria lymphocytes to vascular endothelium in inflammatory bowel diseases. Gastroenterology 1994; 106:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/31\">",
"      Souto JC, Mart&iacute;nez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci 1995; 40:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/32\">",
"      Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/33\">",
"      Honey K. The comeback kid: TYSABRI now FDA approved for Crohn disease. J Clin Invest 2008; 118:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/34\">",
"      Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/35\">",
"      Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/36\">",
"      Podolsky DK, Isselbacher KJ. Composition of human colonic mucin. Selective alteration in inflammatory bowel disease. J Clin Invest 1983; 72:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/37\">",
"      Schultsz C, Van Den Berg FM, Ten Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999; 117:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/38\">",
"      Hollander D. Crohn's disease--a permeability disorder of the tight junction? Gut 1988; 29:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/39\">",
"      Wyatt J, Vogelsang H, H&uuml;bl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/40\">",
"      Mayer L, Shlien R. Evidence for function of Ia molecules on gut epithelial cells in man. J Exp Med 1987; 166:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/41\">",
"      Reinecker HC, Podolsky DK. Human intestinal epithelial cells express functional cytokine receptors sharing the common gamma c chain of the interleukin 2 receptor. Proc Natl Acad Sci U S A 1995; 92:8353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/42\">",
"      Reinecker HC, MacDermott RP, Mirau S, et al. Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology 1996; 111:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/43\">",
"      Selby WS, Janossy G, Mason DY, Jewell DP. Expression of HLA-DR antigens by colonic epithelium in inflammatory bowel disease. Clin Exp Immunol 1983; 53:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/44\">",
"      Mayer L, Eisenhardt D, Salomon P, et al. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel disease. Gastroenterology 1991; 100:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/45\">",
"      Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest 1990; 86:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/46\">",
"      Kaser A, Mart&iacute;nez-Naves E, Blumberg RS. Endoplasmic reticulum stress: implications for inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2010; 26:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/47\">",
"      Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/48\">",
"      Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/49\">",
"      Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/50\">",
"      Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003; 125:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/51\">",
"      Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/52\">",
"      Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002; 122:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/53\">",
"      Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002; 122:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/54\">",
"      Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001; 357:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/55\">",
"      Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 2002; 359:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/56\">",
"      Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002; 123:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/57\">",
"      Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004; 99:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/58\">",
"      Inoue N, Tamura K, Kinouchi Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002; 123:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/59\">",
"      Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol 2011; 106:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/60\">",
"      Stadnyk AW, Waterhouse CC. Epithelial cytokines in intestinal inflammation and mucosal immunity. Curr Opin Gastroenterol 1997; 13:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/61\">",
"      Wallace JL, Beck PL. Inflammatory mediators in inflammatory bowel disease. Curr Opin Gastroenterol 1996; 12:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/62\">",
"      Monteleone G, MacDonald TT, Wathen NC, et al. Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury. Gastroenterology 1999; 117:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/63\">",
"      Fuss IJ, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999; 117:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/64\">",
"      Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/65\">",
"      Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006; 12:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/66\">",
"      Ding C, Xu J, Li J. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs 2008; 9:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/67\">",
"      K&uuml;hn R, L&ouml;hler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/68\">",
"      Berg DJ, Davidson N, K&uuml;hn R, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 98:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/69\">",
"      Powrie F, Leach MW, Mauze S, et al. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/70\">",
"      Powrie F, Leach MW, Mauze S, et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993; 5:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/71\">",
"      Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/72\">",
"      Izcue A, Hue S, Buonocore S, et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity 2008; 28:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/73\">",
"      Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/74\">",
"      Hue S, Ahern P, Buonocore S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med 2006; 203:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/75\">",
"      Uhlig HH, McKenzie BS, Hue S, et al. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006; 25:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/76\">",
"      Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/77\">",
"      Fuss IJ, Becker C, Yang Z, et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006; 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/78\">",
"      Damen GM, van Lierop P, de Ruiter L, et al. Production of IL12p70 and IL23 by monocyte-derived dendritic cells in children with inflammatory bowel disease. Gut 2008; 57:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/79\">",
"      Papadakis KA, Prehn JL, Landers C, et al. TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells. J Immunol 2004; 172:7002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/80\">",
"      Papadakis KA, Zhu D, Prehn JL, et al. Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes. J Immunol 2005; 174:4985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/81\">",
"      Takedatsu H, Michelsen KS, Wei B, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 2008; 135:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/82\">",
"      Bamias G, Mishina M, Nyce M, et al. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc Natl Acad Sci U S A 2006; 103:8441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/83\">",
"      Pappu BP, Borodovsky A, Zheng TS, et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 2008; 205:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/84\">",
"      Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/85\">",
"      Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/86\">",
"      Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005; 14:3499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/87\">",
"      Qiu BS, Vallance BA, Blennerhassett PA, Collins SM. The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis. Nat Med 1999; 5:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/88\">",
"      Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology 2000; 119:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/89\">",
"      Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/90\">",
"      Taurog JD, Richardson JA, Croft JT, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/91\">",
"      Contractor NV, Bassiri H, Reya T, et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 1998; 160:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/92\">",
"      Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004; 126:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/93\">",
"      Kaser A, Lee AH, Franke A, et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008; 134:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/94\">",
"      Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008; 40:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/95\">",
"      Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet 2008; 40:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/96\">",
"      Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008; 40:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/97\">",
"      Prescott NJ, Fisher SA, Franke A, et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology 2007; 132:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/98\">",
"      Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007; 39:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/99\">",
"      Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001; 29:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/100\">",
"      Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/101\">",
"      Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/102\">",
"      Goyette P, Lefebvre C, Ng A, et al. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol 2008; 1:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/103\">",
"      Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004; 36:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/104\">",
"      Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004; 36:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/105\">",
"      Franke A, Hampe J, Rosenstiel P, et al. Systematic association mapping identifies NELL1 as a novel IBD disease gene. PLoS One 2007; 2:e691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/106\">",
"      Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/107\">",
"      Sadlack B, Merz H, Schorle H, et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993; 75:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/108\">",
"      Willerford DM, Chen J, Ferry JA, et al. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995; 3:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/109\">",
"      Mombaerts P, Mizoguchi E, Grusby MJ, et al. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993; 75:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/110\">",
"      Rudolph U, Finegold MJ, Rich SS, et al. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet 1995; 10:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/111\">",
"      Morteau O, Morham SG, Sellon R, et al. Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 2000; 105:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/112\">",
"      Nguyen DD, Maillard MH, Cotta-de-Almeida V, et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology 2007; 133:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/113\">",
"      Turer EE, Tavares RM, Mortier E, et al. Homeostatic MyD88-dependent signals cause lethal inflamMation in the absence of A20. J Exp Med 2008; 205:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/114\">",
"      Holl&auml;nder GA, Simpson SJ, Mizoguchi E, et al. Severe colitis in mice with aberrant thymic selection. Immunity 1995; 3:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/115\">",
"      Morrissey PJ, Charrier K, Braddy S, et al. CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells. J Exp Med 1993; 178:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/116\">",
"      Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990; 63:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/117\">",
"      Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001; 107:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27401/abstract/118\">",
"      Kaser A, Blumberg RS. Adaptive immunity in inflammatory bowel disease: state of the art. Curr Opin Gastroenterol 2008; 24:455.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4077 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-219.243.220.100-85C35604D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27401=[""].join("\n");
var outline_f26_48_27401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE MUCOSAL IMMUNE SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cellular immunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      IMMUNE DYSREGULATION AND IBD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dysregulation of secreted products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Role of stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ROLE OF MICROBES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LESSONS FROM ANIMAL MODELS OF IBD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4077\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4077|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/53/8024\" title=\"figure 1\">",
"      Influence of cytokines on gut immune homeostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4077|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/51/28476\" title=\"table 1\">",
"      Biologic agents in IBD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_48_27402="Treatment of behavioral symptoms related to dementia";
var content_f26_48_27402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of behavioral symptoms related to dementia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27402/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27402/contributors\">",
"     Daniel Press, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27402/contributors\">",
"     Michael Alexander, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27402/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/48/27402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/48/27402/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/48/27402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral symptoms in Alzheimer disease (AD) and other types of dementia are extremely common and often much more troubling than amnestic symptoms. This topic will review the causes and treatment of behavioral disturbance and symptoms related to dementia.",
"   </p>",
"   <p>",
"    The approach to safety and societal issues related to dementia is discussed separately, as are the treatment of cognitive features of dementia and other aspects of dementia. Other clinical aspects of dementia syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=see_link\">",
"     \"Treatment of dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4552?source=see_link\">",
"     \"Safety and societal issues related to dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Alzheimer disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=see_link\">",
"     \"Frontotemporal dementia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychiatric symptoms are common in dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These symptoms include agitation, aggression, delusions, hallucinations, and wandering. Depression and sleep disturbances can also occur with dementia. One or more of these symptoms are observed in 61 to 92 percent of patients with dementia; the prevalence increases with disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. Sophisticated neuroimaging techniques are increasingly able to define neuroanatomical substrates for some of these behaviors; in particular, the right hemisphere and right frontal lobe appear important in the mediation of social and emotional behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of neuropsychiatric symptoms leads to greater functional impairment in patients with dementia and cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Agitation, hallucinations, depression, and aggression in patients with dementia often lead to nursing home placement [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. The most successful interventions are often symptom specific.",
"   </p>",
"   <p>",
"    Screening for behavioral symptoms in patients with dementia should be done at regular follow-up visits [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/2\">",
"     2",
"    </a>",
"    ]. Assessing the associated caregiver distress is also important in determining the urgency of intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Agitation and aggression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agitation and aggression may be provoked by several mechanisms in Alzheimer disease (AD):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Confusion or misunderstanding due to cognitive, language, or memory deficits",
"     </li>",
"     <li>",
"      Frightening, paranoid delusions",
"     </li>",
"     <li>",
"      Pain or discomfort",
"     </li>",
"     <li>",
"      Depression in a patient too impaired to express distress in any other manner (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Depression'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Sleep disorders (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Sleep disorders'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, aggression may manifest as abusive behavior toward the care giver.",
"   </p>",
"   <p>",
"    If aggression appears to emerge in moments of confusion, management is probably behavioral after analysis of the antecedent episodes. If delusions appear to trigger aggression, treatment with antipsychotic medication may be helpful (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Psychosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Psychosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delusions are more common than hallucinations in demented patients, with a reported prevalence of 30 percent of patients with severe AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/3\">",
"     3",
"    </a>",
"    ]. A long-term follow-up study suggests that it may be more pervasive; among 456 patients with mild to moderate AD followed for a mean of 4.5 years, 34 percent had delusions at baseline, but 70 percent had them during at least one evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/12\">",
"     12",
"    </a>",
"    ]. Hallucinations were present in 7 percent at baseline and in 33 percent at some point over the course of follow-up.",
"   </p>",
"   <p>",
"    Paranoid delusions in particular can be very distressing to the patient or caregivers. Common paranoid delusions include beliefs that the house has been invaded, that personal objects have been misplaced or stolen, that family members have been replaced by impostors (Capgras syndrome), or that spouses have been unfaithful.",
"   </p>",
"   <p>",
"    The presence of visual hallucinations early in the course of a dementing illness suggests Dementia with Lewy bodies (DLB) disease, a disorder with very specific management issues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=see_link\">",
"     \"Clinical features and diagnosis of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=see_link\">",
"     \"Prognosis and treatment of dementia with Lewy bodies\"",
"    </a>",
"    .) Nonetheless up to 20 percent of patients with AD can present with hallucinations, mostly commonly visual, less commonly auditory and rarely olfactory hallucinations.",
"   </p>",
"   <p>",
"    Delusions or hallucinations may be fleeting or unobtrusive. Pharmacotherapy is not necessary if neither the patient nor the family are disturbed by them; therapy is warranted if these symptoms become problematic. The presence of either delusions or hallucinations is associated with increased risk for cognitive and functional decline; hallucinations predict institutionalization and death [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of depression in patients with impaired cognition, or at least symptoms of impaired cognition, is complicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depression alone can produce symptoms and signs of cognitive impairment, particularly in elderly patients, a phenomenon called \"depressive pseudodementia.\" (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Elderly patients who become depressed are at increased risk of being demented or developing dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/13\">",
"       13",
"      </a>",
"      ]. The risk of developing AD associated with premorbid depression may be higher in men than women, and it may be independent of vascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with dementia may develop apathy, sleep impairment, and social withdrawal that suggest the presence of depression, but that are entirely due to cognitive deficits.",
"     </li>",
"     <li>",
"      Patients with dementia may become depressed in reaction to slipping mental capacity or as a direct biological consequence of the underlying neurologic disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further complicating the conundrum, patients with depression or dementia, let alone those with both, often cannot offer much illumination on their own mood or mental ability.",
"   </p>",
"   <p>",
"    We have experienced the greatest difficulty in patients with vascular dementia (multiple lacunar infarctions). These patients have relatively mild dementia, often not meeting DSM-IV criteria, with considerable apathy, while also reporting depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of vascular dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical studies to resolve this diagnostic problem have had mixed results perhaps because of the lack of reliable tools to measure the relative contributions of depression and dementia in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/13\">",
"     13",
"    </a>",
"    ]. A therapeutic trial with antidepressant medication may be the only reasonable diagnostic strategy in difficult cases. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Antidepressants'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sleep disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep disturbances are common in patients with AD, affecting an estimated 25 to 35 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/15\">",
"     15",
"    </a>",
"    ]. Causes are multifactorial, but can include contributions from depression and anxiety, a decrease in daytime physical activity, nocturia, as well as side effects of medications (eg, vivid dreaming with cholinesterase inhibitors) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonpharmacologic treatment strategies are generally preferred. Many aspects of good sleep hygiene that are emphasized in the management of insomnia in the general population can be adapted for patients with dementia. An",
"    <span class=\"nowrap\">",
"     activity/exercise",
"    </span>",
"    program, avoidance of daytime naps, limiting evening beverages, and elimination of evening alcohol and coffee are all useful in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/2\">",
"     2",
"    </a>",
"    ]. Delaying bed time is another useful strategy; many patients with \"poor sleep\" go to bed out of boredom and apathy at 8 or 9 PM, sleep perfectly well until 3 or 4 AM and then wake up. They get adequate amount of sleep but early morning awakening is problematic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of insomnia\", section on 'Sleep hygiene'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of insomnia\", section on 'Stimulus control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one randomized study of 36 patients with AD, a treatment approach that combined a sleep hygiene program, behavior management skills, and recommendations for daily exercise and use of a light box resulted in significant reductions in the frequency and duration of night-time awakenings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacotherapy as a primary treatment strategy is discouraged for the management of disrupted sleep although small doses of a sedative (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    ) can sometimes be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/15\">",
"     15",
"    </a>",
"    ]. Benzodiazepines tend not to have sustained benefits on disrupted sleep patterns and are associated with a high incidence of adverse effects in this population. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Benzodiazepines'",
"    </a>",
"    below.) Antihistamines are widely used but are also discouraged because of high rates of side effects. Melatonin and light therapy are safer treatment options but have not shown convincing evidence of efficacy in patients with dementia. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Other agents and approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other dementia syndromes may be associated with other, distinct sleep disturbances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have PD or progressive supranuclear palsy (PSP) appear to have very shallow sleep - mostly stage 1 and 2 - and are probably awakened easily. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=see_link\">",
"       \"Stages and architecture of normal sleep\"",
"      </a>",
"      .) They also have trouble turning in bed, and that may make them more restless in bed.",
"     </li>",
"     <li>",
"      Patients with PSP may be awakened by choking episodes at night that are triggered by sleeping on their backs.",
"     </li>",
"     <li>",
"      Patients with PD also probably have more periodic leg movements of sleep (PLMS or restless legs). These are highly treatable by shifting or adding a small dopamine agonist dose at bedtime.",
"     </li>",
"     <li>",
"      Patients with dementia with Lewy bodies (DLB) disease have a high incidence of rapid eye movement (REM) sleep behaviors. Nocturnal confusion may arise from awakening out of REM sleep into a dark room. This is also treated fairly easily with low doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"       clonazepam",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=see_link&amp;anchor=H7685205#H7685205\">",
"       \"Prognosis and treatment of dementia with Lewy bodies\", section on 'Other psychotropic medications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Wandering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distractibility and restlessness may lead to wandering. The issue of wandering and becoming lost, with the attendant potential for physical harm or death, is one of the concerns that often leads families and caregivers to place demented patients in nursing homes. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4552?source=see_link&amp;anchor=H4#H4\">",
"     \"Safety and societal issues related to dementia\", section on 'Wandering and becoming lost'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sexually inappropriate behavior",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveys and observational studies report that a significant minority (15 to 25 percent) of patients with dementia exhibit sexually inappropriate behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. This may be an under-estimate, as caregivers may be embarrassed to report this behavior to the physician. Examples of sexually inappropriate behavior include inappropriate explicit sex talk and sex acts (grabbing, fondling, public masturbation, exposing). Other behavioral symptoms (agitation, aggression,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depression) are usually present. This problem occurs in vascular dementia as well as AD and other neurodegenerative dementias.",
"   </p>",
"   <p>",
"    A limited number of studies have investigated this problem, almost always in men, and usually in the form of small case series or case reports. Efficacy has been reported with a variety of psychotropic medications including antidepressants, antipsychotic agents, and cholinesterase inhibitors, as well as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/22-26\">",
"     22-26",
"    </a>",
"    ]. Hormonal agents have also been used with anecdotal reports of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/22,25-27\">",
"     22,25-27",
"    </a>",
"    ]. However, given their side effect profile, these are not considered first line agents. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Other agents and approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Given the absence of controlled clinical data, treatment for this problem is necessarily empiric. Behavioral interventions (redirection, distraction, avoiding stimulants) should be tried first. If this is insufficient, medication trials seem reasonable [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]. One systematic review concluded that the preponderance of anecdotal data provided the most support for antidepressant agents, making these the first drug of choice (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Antidepressants'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/26\">",
"     26",
"    </a>",
"    ]. Another valid approach may be to examine the context of other behavioral symptoms that the patient may be experiencing and to try an agent that seems most appropriate for the overall symptom complex [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A concomitant medical illness (particularly urinary tract infection or pneumonia) or medication toxicity (particularly anticholinergic side effects of drugs used to treat other illnesses) and other causes of delirium must be considered whenever new behavioral disturbances arise, particularly in the setting of an acute worsening in cognition (",
"    <a class=\"graphic graphic_table graphicRef59893 \" href=\"UTD.htm?3/43/3773\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Most behavioral symptoms have precipitants.",
"   </p>",
"   <p>",
"    These possibilities should be ruled out prior to initiation of any treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPECIFIC TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of treatment options exist for the management of neuropsychiatric symptoms in dementia. However, efficacy is incomplete and often comes at a cost of side effects, including increased mortality. A proactive approach, with collaboration between health care providers, patients, caregivers, and community agencies may provide additional benefits in managing these troublesome symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonpharmacologic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing evidence suggests that nonpharmacologic measures, including behavioral methods, may be effective in reducing agitation and anxiety in patients with dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/2,32-34\">",
"     2,32-34",
"    </a>",
"    ]. Behavioral interventions employ different strategies and techniques. These include identifying any preceding events that generate agitation, determining whether unmet needs can be anticipated and alleviated, and avoiding environmental triggers such as a sudden change in surroundings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/32,34\">",
"     32,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As one example, a randomized, controlled trial studied 73 residents of skilled nursing homes who had aggression or agitation with assisted bathing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/35\">",
"     35",
"    </a>",
"    ]. Treatment groups were a usual care control group (showering), \"person-centered bathing,\" an intervention focused on resident comfort and preferences, and \"towel-bath,\" an in-bed bag bath method that kept the resident covered at all times and cleansed by using gentle massage. Both treatment groups showed significant declines in all measures of agitation, aggression, and discomfort compared with controls. The postulated mechanism underlying the effectiveness of the improved personal care involved a reduction in the insistent, task focused, impersonal, and intrusive \"usual care\" methods that can provoke agitation and aggression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other nonpharmacologic therapies have demonstrated some benefit for neuropsychiatric symptoms of dementia in small studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At least three placebo-controlled trials have reported a significant benefit of aromatherapy compared with placebo in patients with dementia and agitation, with almost complete compliance and no adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. Lemon balm or lavender oil are most frequently used and can be delivered by either inhalation or skin application. The mechanism by which these agents may be effective is unclear.",
"     </li>",
"     <li>",
"      Exercise training in combination with caregiver-education may improve outcomes in patients with Alzheimer disease (AD). A randomized trial in 153 community-dwelling patients with AD found that compared with routine medical care, patients who were assigned to exercise (goal minimum of 30 minutes per day) and whose caregivers received training in managing behavioral problems had improved physical functioning and less depression [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/39\">",
"       39",
"      </a>",
"      ]. We have found that regular physical activity can be very useful in managing behaviors in some patients with dementia.",
"     </li>",
"     <li>",
"      Music therapy and pet therapy also have some evidence of efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/40-42\">",
"       40-42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In preliminary studies, massage and touch therapy appear to be potentially beneficial in the immediate management of agitated behavior and in encouragement to eat [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these formal activities, caregivers can be counseled in strategies involving distraction and redirection, structured routines, and providing calm, reassuring responses when patients seem anxious [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/2\">",
"     2",
"    </a>",
"    ]. Certain behavioral problems may respond better to behavioral therapies than to medical therapy. These include wandering, hoarding or hiding objects, repetitive questioning, withdrawal, and social inappropriateness [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Behavioral approaches can be combined with medications. As an example, a sleep disorder may require both behavioral and pharmacological management. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Sleep disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Antipsychotic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical neuroleptics have been the agents of choice for treating hallucinations in patients with dementia. However, these drugs may increase mortality (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Serious adverse events'",
"    </a>",
"    below), and are not approved for the treatment of behavioral disorders in patients with dementia by the US Food and Drug Administration (FDA). Nonetheless, their benefits often still outweigh their risks in patients with dementia when treatment of hallucinations and delusions is critical. In the absence of other effective agents, we continue to use them cautiously, after informing the patients and families of the potential risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that these medications are widely used and believed to be efficacious, they have not been extensively studied in randomized controlled clinical trials. The trials that exist are often short, 6 to 12 weeks, despite the fact that patients are often maintained on these agents for much longer. Trials also often suffer from methodological limitations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typical antipsychotics &mdash; A systemic review of typical antipsychotics included two meta-analyses of 12 trials plus two additional studies of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"       thioridazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=see_link\">",
"       thiothixene",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/2/19495?source=see_link\">",
"       trifluoperazine",
"      </a>",
"      and acetophenazine, and concluded that, in the aggregate, there was no clear evidence of benefit for these agents in patients with dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44\">",
"       44",
"      </a>",
"      ]. A Cochrane review concluded that haloperidol may help control aggression, but not other neuropsychiatric manifestations of dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/45\">",
"       45",
"      </a>",
"      ]. No trials compared agents with one another.",
"     </li>",
"     <li>",
"      Atypical antipsychotics &mdash; These agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      and have been somewhat more extensively studied. Two independently conducted systematic reviews have concluded that these agents have, at most modest efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44,46\">",
"       44,46",
"      </a>",
"      ]. Of seven trials studied, four found a statistically significant benefit for the primary endpoint with olanzapine or risperidone; there were no studies of clozapine and quetiapine for this indication at the time of this analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent, small randomized clinical trial that compared the cholinesterase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    and the atypical antipsychotic agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    for agitation in nursing home patients with AD found no benefit for either treatment compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter, double-blind trial randomly assigned 421 patients with AD and either psychosis, aggression, or agitation to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/48\">",
"     48",
"    </a>",
"    ]. Median time to discontinuation of drug for any reason was similar in all four groups (5.3 to 8.1 weeks). However, more patients taking placebo discontinued medication for lack of efficacy compared with those on olanzapine or quetiapine (70 versus 39 and 44 percent). For patients still taking the assigned treatment at 12 weeks, there were no differences among groups in the percentages of patients who improved on the Clinical Global Impression of Change (CGIC) scale (range 21 to 32 percent). One limitation of the study was the inclusion of patients with a broad array of behavioral symptoms. It seems likely that a subset of patients, perhaps those with hallucinations, would have shown more clear improvement. However, the general use of antipsychotic drugs for the treatment of agitation in patients with AD should be avoided, as the benefit is likely to be small and offset by adverse effects. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of specific antipsychotic drug used to treat hallucinations is driven by drug side effects such as sedation or extrapyramidal disturbances. The older low potency typical (conventional) neuroleptics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    ) are highly sedating, and their anticholinergic activity can worsen memory and cognition. High potency neuroleptics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    ) are associated with an often unacceptable incidence of extrapyramidal side effects. In a trial of haloperidol, for example, there was a high rate of extrapyramidal side effects and decline in cognitive function even at relatively low doses of 1 to 5 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44,49\">",
"     44,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    has been associated with clinically significant QT prolongation requiring additional precautions regarding its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the atypical neuroleptics are perceived to have a lower incidence of adverse effects, this may be true only with low doses. Systematic reviews and clinical trials find that adverse events with these agents in patients with dementia are common and dose related [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44,46-48\">",
"     44,46-48",
"    </a>",
"    ]. These include extrapyramidal symptoms, confusion, somnolence, and falls. The additional risk of agranulocytosis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and the necessity for frequent blood tests make this agent less attractive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have dementia with Lewy bodies (DLB) disease may be especially sensitive to antipsychotic medication and may experience idiosyncratic, life-threatening adverse reactions. Very low doses of the atypical neuroleptics (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    ) should be used to initiate treatment for patients who have behavioral symptoms related to DLB.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     Risperidone",
"    </a>",
"    and the typical antipsychotic agents should not be used in patients who have DLB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=see_link\">",
"     \"Prognosis and treatment of dementia with Lewy bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Serious adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic medications have been associated with an increased risk of stroke, myocardial infarction, and death.",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) reported in a public health advisory that the use of second generation antipsychotic medications,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , for the treatment of behavioral symptoms in elderly patients with dementia is associated with increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Their findings were confirmed in an independently conducted meta-analysis, as well as a subsequent randomized, placebo-controlled study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The reported odds ratio for increased mortality in these analyses ranged from 1.54 to 1.7, with an absolute increased risk of death that ranged from 1 to 2 percent (3.5 to 4.5 versus 2.2 to 2.6 percent). Similar concerns have been raised for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and other conventional antipsychotics as well; all antipsychotic drugs should be considered a risk, although one analysis found that the risks were highest with haloperidol and lowest with quetiapine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Both short-term and long-term treatment appear to be problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence regarding increased stroke risk associated with the use of atypical antipsychotic drugs is conflicting. While several studies have reported such a link [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44,58-60\">",
"     44,58-60",
"    </a>",
"    ], others have not [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. A large population based cohort study of adults aged &ge;65 years found a similar risk of ischemic stroke among users of atypical versus typical antipsychotics, even among a subgroup at high risk (those with atrial fibrillation or prior stroke) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the risk of increased mortality associated with the use of atypical neuroleptics in elderly patients with dementia (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Serious adverse events'",
"    </a>",
"    above), we reserve their use for patients who have neuropsychiatric symptoms, particularly psychosis, that are severe and debilitating and inform patients and families of the risks. There is often no good alternative. Somnolence is also concern with all of these agents, and may be dose limiting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      can be started at a dose of 2.5 mg daily and titrated up to a maximum of 5 mg twice a day. This drug appears to be at least modestly effective for treating the neuropsychiatric symptoms of dementia in patients with AD or vascular dementia. The incidence of extrapyramidal symptoms is low at doses of 5 mg per day or less.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      is an alternative, starting at a dose of 25 mg at bedtime and titrating up to a maximum of 75 mg twice a day. There is little data regarding the effectiveness of quetiapine in this setting.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      at no more than 1 mg daily also appears to be at least modestly effective, but higher doses are associated with increased side effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment should be maintained only if benefits are apparent, and discontinuation should be attempted at regular intervals, weighing the risk of relapse versus the risk of adverse effects from continued treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/64\">",
"     64",
"    </a>",
"    ]. For some patients, discontinuation of antipsychotic agents may not be possible. One randomized study examined relapse risk in 180 patients with AD and psychosis or agitation who had initially responded to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/65\">",
"     65",
"    </a>",
"    ]. Discontinuation of risperidone was associated with an increased risk of relapse over 16 weeks of followup; 60 versus 33 percent in those assigned to early discontinuation and 48 versus 15 percent in those assigned to delayed discontinuation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cholinesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholinesterase inhibitors improve cognition in patients with dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=see_link\">",
"     \"Cholinesterase inhibitors in the treatment of dementia\"",
"    </a>",
"    .) In comparison, these drugs do not appear to improve neuropsychiatric symptoms related to dementia to a clinically significant extent.",
"   </p>",
"   <p>",
"    A 2005 systematic review reported that two meta-analyses and six randomized controlled trials of cholinesterase inhibitors for neuropsychiatric symptoms of dementia generally found small but statistically significant efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44\">",
"     44",
"    </a>",
"    ]. The small benefits seen were of questionable clinical significance, and most studies included patients with relatively mild neuropsychiatric symptoms. Furthermore, two subsequent trials found no benefit from such therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial compared the cholinesterase inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"       rivastigmine",
"      </a>",
"      and the atypical antipsychotic agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      for agitation in 93 nursing home patients with AD; there was no benefit for either treatment compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/47\">",
"       47",
"      </a>",
"      ]. Most of the patients in this study had severe dementia. Because agitation can arise from numerous conditions (eg, discomfort, sleep disturbance, superimposed delirium, disorientation, or frightening delusions), it seems unlikely that any single treatment strategy will be generally efficacious.",
"     </li>",
"     <li>",
"      No benefit with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"       donepezil",
"      </a>",
"      in terms of reduced agitation or improved neuropsychiatric symptoms was found in a 12-week, randomized, placebo-controlled trial of 272 patients with Alzheimer disease who had clinically significant agitation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/66\">",
"       66",
"      </a>",
"      ]. Patients in this study had severe disease (median MMSE score 8) and had failed a nonpharmacologic psychosocial intervention prior to enrollment, perhaps representing a population likely to be most resistant to treatment. As with the preceding study, potentially heterogeneous causes of agitation may have contributed to the lack of overall treatment effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cholinergic deficit in DLB is greater than in AD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients with DLB may have a more beneficial response to cholinesterase inhibitors than patients with AD. A double-blind, placebo-controlled study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    in patients with DLB showed reductions in hallucinations as well as improved cognition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=see_link\">",
"     \"Prognosis and treatment of dementia with Lewy bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the evidence for efficacy in the treatment of neurobehavioral symptoms is not as convincing as it is for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , cholinesterase inhibitors are well tolerated and may have additional benefit for cognition and function. Therefore, we recommend starting a cholinesterase inhibitor for patients with neuropsychiatric symptoms and mild to moderate dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=see_link\">",
"     \"Cholinesterase inhibitors in the treatment of dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidepressants have been studied in patients with dementia with regard to their effect on neuropsychiatric symptoms as well as depression.",
"   </p>",
"   <p>",
"    As with antipsychotic therapy discussed above, when antidepressant agents are administered to patients with dementia, there should be an ongoing assessment of benefits versus harms, and consideration for withdrawing the medications should be made periodically. However, in one randomized study of 128 patients with dementia who were treated with SSRIs for an indication other than depression, withdrawal of medication was associated with significantly worse depressive symptoms and a nonsignificant worsening of neuropsychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Neuropsychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical data suggest that serotonin deficits in AD may contribute to aggressive behavior and psychosis. The selective serotonin reuptake inhibitors (SSRIs) have been studied for treatment of these symptoms with varying results. Most studies were small, did not control for concurrent depressive symptoms, and included patients with relatively mild symptoms.",
"   </p>",
"   <p>",
"    A 2011 systematic review analyzed nine randomized controlled trials studying the effects of antidepressant medications in the treatment of neuropsychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Five studies compared SSRIs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"       fluvoxamine",
"      </a>",
"      ) to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/71-75\">",
"       71-75",
"      </a>",
"      ]. Only one trial found a significant benefit for citalopram in the reduction of neuropsychiatric symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/71\">",
"       71",
"      </a>",
"      ]. There was no difference in the rates of trial withdrawals due to adverse events for SSRIs compared to placebo.",
"     </li>",
"     <li>",
"      SSRIs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       citalopram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       sertraline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      ) were compared to antipsychotic agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"       perphenazine",
"      </a>",
"      ) in four trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/71,74,76,77\">",
"       71,74,76,77",
"      </a>",
"      ]. Overall, there was no difference between treatment groups in regard to benefit on neuropsychiatric symptoms nor on adverse events, although other studies have suggested risks with antipsychotic agents in this population (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Serious adverse events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       Trazodone",
"      </a>",
"      was compared to placebo in one trial that found no benefit on neuropsychiatric symptoms compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/78\">",
"       78",
"      </a>",
"      ]. Two trials that compared trazodone to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      found no significant relative benefit or harm between these two treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/78,79\">",
"       78,79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with a previous systematic review, the authors concluded that antidepressant agents are well tolerated but have limited evidence for efficacy in the treatment of neuropsychiatric symptoms of dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44,74\">",
"     44,74",
"    </a>",
"    ]. Despite these mixed results, we have found SSRIs (in particular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    ) useful in the management of agitation and paranoia in patients with AD, as the symptoms are often driven by a mood disorder that is poorly verbalized. We sometimes overlap with an antipsychotic (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ) in the first few weeks, as the efficacy of the SSRI may require that time frame to emerge. We have also found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    often reduces anxiety and aggressive behavior, particularly at night-time [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence suggests that deficits in the serotoninergic system have a major role in the production of behavioral symptoms in frontotemporal dementia (FTD). There is limited evidence of benefit, largely from uncontrolled observational studies, for serotonergic antidepressant agents in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/408?source=see_link&amp;anchor=H9729311#H9729311\">",
"     \"Frontotemporal dementia: Treatment\", section on 'Serotonergic medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few studies to guide selection of an antidepressant to treat depression in patients with dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trials of SSRIs for this indication have had somewhat mixed results. Two multicenter trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    (Celexa), an SSRI, demonstrated efficacy with reasonably mild side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/73,83\">",
"     73,83",
"    </a>",
"    ] However, a study in 131 patients with AD and depression found no efficacy for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    after 12 and 24 weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/84,85\">",
"     84,85",
"    </a>",
"    ], Finally, a randomized study comparing sertraline to placebo in 218 patients found no differences in depression scores at 13 or 39 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/86\">",
"     86",
"    </a>",
"    ]. A meta-analysis of five studies concluded there was insufficient evidence to support the use of SSRIs for the treatment of depression in patients with AD, but acknowledged that study design precluded a conclusion of absence of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tricyclic antidepressants can cause worsening confusion, likely due to their anticholinergic properties, and are not as well tolerated as SSRIs. In one study, for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    were equally effective for treating depressive symptoms in patients with AD, but 58 percent of amitriptyline-treated patients dropped out compared with 22 percent of those treated with fluoxetine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/88\">",
"     88",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/21/30040?source=see_link\">",
"     Nortriptyline",
"    </a>",
"    may be better tolerated than amitriptyline because of fewer anticholinergic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We strongly prefer SSRIs because of the anticholinergic activity of tricyclic antidepressants. Selection of a specific SSRI is generally based upon the side effect profile, drug interactions, and cost.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    has a long half-life and more drug interactions than other SSRIs, making it less desirable in the elderly.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     Paroxetine",
"    </a>",
"    is the most anticholinergic of the SSRIs and therefore can also theoretically affect cognition.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"     Citalopram",
"    </a>",
"    may also improve psychotic and other behavioral symptoms and may be particularly helpful if depression is either a likely or cannot be eliminated as a contributor to symptoms when no other cause is apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     Trazodone",
"    </a>",
"    can be combined with a SSRI, if major depression is suspected. The atypical antidepressants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"     venlafaxine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    may also be effective, but have not been well studied in AD. In a randomized trial of 219 patients with depression and AD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/41/32408?source=see_link\">",
"     mirtazapine",
"    </a>",
"    was no more effective than placebo after 13 or 39 weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antiepileptic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of antiepileptic drugs have been investigated for the treatment of neuropsychiatric symptoms in dementia because of their mood stabilizing properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      was effective in a placebo-controlled study of agitation in nursing home patients with advanced dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/89\">",
"       89",
"      </a>",
"      ]. Relatively low doses were used, with a modal dose of 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      achieving a mean serum level of 5.3",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      However, a subsequent trial found no benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/90\">",
"       90",
"      </a>",
"      ], and a systematic review concluded that there is currently not enough evidence of benefit for carbamazepine to recommend its use for neuropsychiatric symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      improved aggressive behavior in several earlier reports [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/91,92\">",
"       91,92",
"      </a>",
"      ]. However, a systematic review that analyzed three randomized controlled trials and two studies of valproate concluded that neither the short or long-acting preparations were effective for treatment of neuropsychiatric symptoms of dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      is often used because of its relatively mild side effect profile, but its efficacy is questionable, with one open-label prospective study showing little benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      has been advocated based on case reports, but no randomized, placebo-controlled studies have been published to date.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines have limited value in patients with AD. They are not recommended for the management of neuropsychiatric symptoms of dementia. One randomized controlled trial of a benzodiazepine for neuropsychiatric symptoms of dementia found benefit for both intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    compared with placebo at two hours after treatment; the benefit of lorazepam was not sustained at 24 hours on one outcome scale [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benzodiazepine side effects include worsening gait, potential paradoxical agitation, and possible physical dependence. Benzodiazepine use should be limited to brief stressful episodes, such as a change in residence or an anxiety-provoking medical event [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other agents and approaches",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/16/24837?source=see_link\">",
"       Memantine",
"      </a>",
"      &mdash; The potential efficacy of memantine to ameliorate the behavioral effects in AD requires further study. Post-hoc analyses of clinical trial results suggest that patients assigned to memantine treatment may have diminished",
"      <span class=\"nowrap\">",
"       agitation/aggression,",
"      </span>",
"      irritability, and other behavioral disturbances [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/96,97\">",
"       96,97",
"      </a>",
"      ]. However, systematic reviews have concluded that studies have not demonstrated a clinically significant effect of memantine for neuropsychiatric symptoms of dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/44,98\">",
"       44,98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Melatonin &mdash; The observation that circadian rhythm disturbances appear to be associated with depressed mood, impaired cognition, and behavioral and sleep disturbances have suggested a potential benefit for melatonin",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      light therapy in patients with dementia. Studies have had somewhat mixed results, but in the aggregate do not suggest convincing benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/99-103\">",
"       99-103",
"      </a>",
"      ]. As an example, a randomized clinical trial studying the effect of bright light and melatonin in 189 older patients residing in group care facilities; 87 percent had dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/99\">",
"       99",
"      </a>",
"      ]. Limitations of this study included multiple analyses and outcome measures and substantial loss to follow-up. Light therapy appeared to have a modest benefit on some cognitive and noncognitive symptoms. Melatonin improved sleep measures but had an adverse effect on mood when given without light. In contrast, a randomized study in 50 patients with AD found that combined light treatment and melatonin improved some sleep quality measures but that light treatment alone showed no benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/102\">",
"       102",
"      </a>",
"      ]. A smaller randomized trial in 41 patients with AD found that 10 days of melatonin had no effect on sleep or agitation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/101\">",
"       101",
"      </a>",
"      ]. A previously reported meta-analysis of three trials of melatonin treatment in patients with dementia demonstrated no evidence of benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hormonal agents &mdash; While hormonal agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      , diethylstilbestrol, estrogen,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"       leuprolide",
"      </a>",
"      ) have also been used with anecdotal reports of efficacy in treating sexually inappropriate behavior in individuals with dementia, these are not considered first line agents given their side effect profile [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/22,25-27\">",
"       22,25-27",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sexually inappropriate behavior'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Others &mdash; Other agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      have been tried in single cases or small groups. In our experience these drugs are of limited value both due to side effects and little efficacy.",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/60/39881?source=see_link\">",
"       Methylphenidate",
"      </a>",
"      was evaluated in the treatment of apathy in a 12-week open-label study in 23 patients with AD [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/104\">",
"       104",
"      </a>",
"      ]. Improvements in mini-mental state examination score and functional status were noted, along with reduced apathy and depression.",
"     </li>",
"     <li>",
"      One randomized study evaluated a systematic approach to pain evaluation and management in 352 patients with behavioral disturbances and dementia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/105\">",
"       105",
"      </a>",
"      ]. The intervention was a stepwise protocol that followed recommendations of the American Geriatrics Society. After eight weeks, those in the intervention group had reduced neuropsychiatric symptoms and lower agitation scores, although cognition and daily function were not affected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUPPORT FOR CAREGIVERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caregivers of patients with dementia can suffer significant stress, particularly as cognitive function declines or behavioral symptoms worsen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/106\">",
"     106",
"    </a>",
"    ]. Respite care and support groups are available in most areas, often through the local agency on aging.",
"   </p>",
"   <p>",
"    Attempts to measure the efficacy of caregiver support have had somewhat mixed results. One randomized, controlled trial of a counseling and support intervention for caregivers of patients with AD found that the intervention was associated with a 28 percent reduction in the rate of nursing home placement, or a 557-day delay to placement, compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/107\">",
"     107",
"    </a>",
"    ]. Outcomes were measured over almost 10 years. In another trial, a similar intervention improved caregiver quality of life but did not affect institutionalization rates at six months compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/108\">",
"     108",
"    </a>",
"    ]. In another randomized, controlled trial, access to a \"befriender\" (a volunteer trained to give psychosocial support to caregivers of patients with dementia) was not taken up by the majority of caregivers assigned to this group and did not improve their wellbeing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of 13 studies of support programs for caregivers found that interventions designed to provide support for caregivers decreased the odds of institutionalization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/48/27402/abstract/110\">",
"     110",
"    </a>",
"    ]. Among the heterogeneous and usually multi-component interventions used, no specific type stood out as most effective. However, those that allowed individualization and choice by the caregiver seemed more effective than those that were more rigorously standardized.",
"   </p>",
"   <p>",
"    Nationally, information can be obtained from the Alzheimer's Association at 1-800-272-3900, or on the internet at",
"    <a class=\"external\" href=\"file://www.alz.org/\">",
"     www.alz.org",
"    </a>",
"    . Information regarding frontotemporal dementia can be found at",
"    <a class=\"external\" href=\"file://www.theaftd.org/\">",
"     www.theaftd.org",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=see_link\">",
"       \"Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychiatric symptoms are common in dementia and contribute to nursing home admission and caregiver stress.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient develops neuropsychiatric symptoms, the first step is to rule out and treat a medical cause or superimposed delirium (",
"      <a class=\"graphic graphic_table graphicRef59893 \" href=\"UTD.htm?3/43/3773\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Environmental, behavioral, and other nonpharmacologic therapies can be effective in this population and, when appropriate, are preferred over medications, which have a high rate of adverse effects. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonpharmacologic management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cholinesterase inhibitors do not produce clinically significant improvement in neuropsychiatric symptoms in patients with dementia. However, many such patients are still treated with these drugs because of modest improvement in cognition. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cholinesterase inhibitors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=see_link\">",
"       \"Cholinesterase inhibitors in the treatment of dementia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antipsychotic agents have limited efficacy and are associated with increased mortality in patients with dementia. We suggest the use of low doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      in patients with severe, disabling symptoms after informing families of the mortality risk (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Short term use when possible, with regular reassessments of risks and benefits, is advised. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Antipsychotic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with dementia with Lewy bodies are at especially high risk of severe side effects with neuroleptic medications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/41/34455?source=see_link\">",
"       \"Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A trial of selective serotonin reuptake inhibitors (SSRIs) is suggested for the treatment of depression in Alzheimer disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/56/13193?source=see_link\">",
"       Citalopram",
"      </a>",
"      is often used because of its possible additional benefits for neuropsychiatric symptoms.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"       Sertraline",
"      </a>",
"      is a well studied alternative to citalopram. A trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      may also be considered to treat psychotic symptoms, especially when they interfere with sleep. Tricyclics should be avoided because of side effects and drug interactions. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Agitation may be due to unrecognized depression and respond to an SSRI.",
"     </li>",
"     <li>",
"      Because of the risk of side effects with long-term use, we suggest reserving benzodiazepines for acute stressful episodes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/1\">",
"      Savva GM, Zaccai J, Matthews FE, et al. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry 2009; 194:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/2\">",
"      Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA 2012; 308:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/3\">",
"      Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996; 46:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/4\">",
"      Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/5\">",
"      Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002; 288:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/6\">",
"      Sink KM, Covinsky KE, Newcomer R, Yaffe K. Ethnic differences in the prevalence and pattern of dementia-related behaviors. J Am Geriatr Soc 2004; 52:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/7\">",
"      Peters KR, Rockwood K, Black SE, et al. Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. Neurology 2006; 66:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/8\">",
"      Rosen HJ, Allison SC, Schauer GF, et al. Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005; 128:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/9\">",
"      Scarmeas N, Brandt J, Blacker D, et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol 2007; 64:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/10\">",
"      O'Donnell BF, Drachman DA, Barnes HJ, et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992; 5:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/11\">",
"      Morriss RK, Rovner BW, Folstein MF, German PS. Delusions in newly admitted residents of nursing homes. Am J Psychiatry 1990; 147:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/12\">",
"      Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005; 62:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/13\">",
"      Jones BN, Reifler BV. Depression coexisting with dementia. Evaluation and treatment. Med Clin North Am 1994; 78:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/14\">",
"      Dal Forno G, Palermo MT, Donohue JE, et al. Depressive symptoms, sex, and risk for Alzheimer's disease. Ann Neurol 2005; 57:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/15\">",
"      Deschenes CL, McCurry SM. Current treatments for sleep disturbances in individuals with dementia. Curr Psychiatry Rep 2009; 11:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/16\">",
"      McCurry SM, Logsdon RG, Teri L, et al. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. J Geriatr Psychiatry Neurol 1999; 12:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/17\">",
"      McCurry SM, Gibbons LE, Logsdon RG, et al. Nighttime insomnia treatment and education for Alzheimer's disease: a randomized, controlled trial. J Am Geriatr Soc 2005; 53:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/18\">",
"      Phillips VL, Diwan S, Egner A. Development of a tool for assessment and care planning for dementia-related problem behaviors in home and community-based services programs: the Problem Behavior Inventory. Home Health Care Serv Q 2002; 21:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/19\">",
"      Alagiakrishnan K, Lim D, Brahim A, et al. Sexually inappropriate behaviour in demented elderly people. Postgrad Med J 2005; 81:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/20\">",
"      Tsai SJ, Hwang JP, Yang CH, et al. Inappropriate sexual behaviors in dementia: a preliminary report. Alzheimer Dis Assoc Disord 1999; 13:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/21\">",
"      Zeiss AM, Davies HD, Tinklenberg JR. An observational study of sexual behavior in demented male patients. J Gerontol A Biol Sci Med Sci 1996; 51:M325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/22\">",
"      Ozkan B, Wilkins K, Muralee S, Tampi RR. Pharmacotherapy for inappropriate sexual behaviors in dementia: a systematic review of literature. Am J Alzheimers Dis Other Demen 2008; 23:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/23\">",
"      Prakash R, Pathak A, Munda S, Bagati D. Quetiapine effective in treatment of inappropriate sexual behavior of lewy body disease with predominant frontal lobe signs. Am J Alzheimers Dis Other Demen 2009; 24:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/24\">",
"      Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 2007; 8:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/25\">",
"      Black B, Muralee S, Tampi RR. Inappropriate sexual behaviors in dementia. J Geriatr Psychiatry Neurol 2005; 18:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/26\">",
"      Guay DR. Inappropriate sexual behaviors in cognitively impaired older individuals. Am J Geriatr Pharmacother 2008; 6:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/27\">",
"      Light SA, Holroyd S. The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia. J Psychiatry Neurosci 2006; 31:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/28\">",
"      Sky AJ, Grossberg GT. The use of psychotropic medication in the management of problem behaviors in the patient with Alzheimer's disease. Med Clin North Am 1994; 78:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/29\">",
"      Gitlin LN, Winter L, Dennis MP, et al. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc 2010; 58:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/30\">",
"      Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA 2006; 295:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/31\">",
"      Vickrey BG, Mittman BS, Connor KI, et al. The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial. Ann Intern Med 2006; 145:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/32\">",
"      Ayalon L, Gum AM, Feliciano L, Are&aacute;n PA. Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia: a systematic review. Arch Intern Med 2006; 166:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/33\">",
"      Gitlin LN, Winter L, Dennis MP, et al. A biobehavioral home-based intervention and the well-being of patients with dementia and their caregivers: the COPE randomized trial. JAMA 2010; 304:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/34\">",
"      Moniz Cook ED, Swift K, James I, et al. Functional analysis-based interventions for challenging behaviour in dementia. Cochrane Database Syst Rev 2012; 2:CD006929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/35\">",
"      Sloane PD, Hoeffer B, Mitchell CM, et al. Effect of person-centered showering and the towel bath on bathing-associated aggression, agitation, and discomfort in nursing home residents with dementia: a randomized, controlled trial. J Am Geriatr Soc 2004; 52:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/36\">",
"      Holmes C, Hopkins V, Hensford C, et al. Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. Int J Geriatr Psychiatry 2002; 17:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/37\">",
"      Smallwood J, Brown R, Coulter F, et al. Aromatherapy and behaviour disturbances in dementia: a randomized controlled trial. Int J Geriatr Psychiatry 2001; 16:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/38\">",
"      Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 2002; 63:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/39\">",
"      Teri L, Gibbons LE, McCurry SM, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003; 290:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/40\">",
"      Clark ME, Lipe AW, Bilbrey M. Use of music to decrease aggressive behaviors in people with dementia. J Gerontol Nurs 1998; 24:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/41\">",
"      Gerdner LA. Effects of individualized versus classical \"relaxation\" music on the frequency of agitation in elderly persons with Alzheimer's disease and related disorders. Int Psychogeriatr 2000; 12:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/42\">",
"      Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001; 9:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/43\">",
"      Viggo Hansen N, J&oslash;rgensen T, &Oslash;rtenblad L. Massage and touch for dementia. Cochrane Database Syst Rev 2006; :CD004989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/44\">",
"      Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/45\">",
"      Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002; :CD002852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/46\">",
"      Lee PE, Gill SS, Freedman M, et al. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/47\">",
"      Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 2005; 330:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/48\">",
"      Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/49\">",
"      Devanand DP, Sackeim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. Arch Neurol 1989; 46:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/50\">",
"      Dev VJ, Rosenberg T, Krupp P. Agranulocytosis and clozapine. BMJ 1994; 309:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/51\">",
"      Atypical antipsychotics in the elderly. Med Lett Drugs Ther 2005; 47:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/52\">",
"      Kuehn BM. FDA warns antipsychotic drugs may be risky for elderly. JAMA 2005; 293:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/53\">",
"      Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/54\">",
"      Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/55\">",
"      Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/56\">",
"      Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344:e977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/57\">",
"      Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/58\">",
"      Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/59\">",
"      Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002; 167:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/60\">",
"      Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/61\">",
"      Herrmann N, Mamdani M, Lanct&ocirc;t KL. Atypical antipsychotics and risk of cerebrovascular accidents. Am J Psychiatry 2004; 161:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/62\">",
"      Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/63\">",
"      Barnett MJ, Wehring H, Perry PJ. Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users. J Clin Psychopharmacol 2007; 27:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/64\">",
"      Antipsychotic drugs for dementia: a balancing act. Lancet Neurol 2009; 8:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/65\">",
"      Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N Engl J Med 2012; 367:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/66\">",
"      Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/67\">",
"      Perry EK, Haroutunian V, Davis KL, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994; 5:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/68\">",
"      Qizilbash N, Whitehead A, Higgins J, et al. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. JAMA 1998; 280:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/69\">",
"      Bergh S, Selb&aelig;k G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ 2012; 344:e1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/70\">",
"      Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; :CD008191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/71\">",
"      Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/72\">",
"      Finkel SI, Mintzer JE, Dysken M, et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004; 19:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/73\">",
"      Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990; 157:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/74\">",
"      Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1997; 9:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/75\">",
"      Olafsson K, J&oslash;rgensen S, Jensen HV, et al. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand 1992; 85:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/76\">",
"      Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007; 15:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/77\">",
"      Gaber S, Ronzoli S, Bruno A, Biagi A. Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia. Arch Gerontol Geriatr Suppl 2001; 7:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/78\">",
"      Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/79\">",
"      Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/80\">",
"      Greenwald BS, Marin DB, Silverman SM. Serotoninergic treatment of screaming and banging in dementia. Lancet 1986; 2:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/81\">",
"      Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002; :CD003944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/82\">",
"      Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord 2004; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/83\">",
"      Gottfries CG, Karlsson I, Nyth AL. Treatment of depression in elderly patients with and without dementia disorders. Int Clin Psychopharmacol 1992; 6 Suppl 5:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/84\">",
"      Rosenberg PB, Drye LT, Martin BK, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry 2010; 18:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/85\">",
"      Weintraub D, Rosenberg PB, Drye LT, et al. Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry 2010; 18:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/86\">",
"      Banerjee S, Hellier J, Dewey M, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet 2011; 378:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/87\">",
"      Sepehry AA, Lee PE, Hsiung GY, et al. Effect of selective serotonin reuptake inhibitors in Alzheimer's disease with comorbid depression: a meta-analysis of depression and cognitive outcomes. Drugs Aging 2012; 29:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/88\">",
"      Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997; 38:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/89\">",
"      Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/90\">",
"      Olin JT, Fox LS, Pawluczyk S, et al. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/91\">",
"      Lindenmayer JP, Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review. J Clin Psychiatry 2000; 61:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/92\">",
"      Porsteinsson AP, Tariot PN, Erb R, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/93\">",
"      Herrmann N, Lanct&ocirc;t K, Myszak M. Effectiveness of gabapentin for the treatment of behavioral disorders in dementia. J Clin Psychopharmacol 2000; 20:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/94\">",
"      Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/95\">",
"      Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology 1997; 48:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/96\">",
"      Cummings JL, Schneider E, Tariot PN, et al. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/97\">",
"      Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry 2008; 69:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/98\">",
"      McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; :CD003154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/99\">",
"      Riemersma-van der Lek RF, Swaab DF, Twisk J, et al. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008; 299:2642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/100\">",
"      Jansen SL, Forbes DA, Duncan V, Morgan DG. Melatonin for cognitive impairment. Cochrane Database Syst Rev 2006; :CD003802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/101\">",
"      Gehrman PR, Connor DJ, Martin JL, et al. Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease. Am J Geriatr Psychiatry 2009; 17:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/102\">",
"      Dowling GA, Burr RL, Van Someren EJ, et al. Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc 2008; 56:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/103\">",
"      Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/104\">",
"      Padala PR, Burke WJ, Shostrom VK, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 2010; 18:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/105\">",
"      Husebo BS, Ballard C, Sandvik R, et al. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2011; 343:d4065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/106\">",
"      Aarsland D, Br&oslash;nnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007; 78:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/107\">",
"      Mittelman MS, Haley WE, Clay OJ, Roth DL. Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 2006; 67:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/108\">",
"      Belle SH, Burgio L, Burns R, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med 2006; 145:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/109\">",
"      Charlesworth G, Shepstone L, Wilson E, et al. Befriending carers of people with dementia: randomised controlled trial. BMJ 2008; 336:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/48/27402/abstract/110\">",
"      Spijker A, Vernooij-Dassen M, Vasse E, et al. Effectiveness of nonpharmacological interventions in delaying the institutionalization of patients with dementia: a meta-analysis. J Am Geriatr Soc 2008; 56:1116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5082 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-59FAC149C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27402=[""].join("\n");
var outline_f26_48_27402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Agitation and aggression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Psychosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Wandering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sexually inappropriate behavior",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPECIFIC TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonpharmacologic management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Serious adverse events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cholinesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Neuropsychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other agents and approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUPPORT FOR CAREGIVERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5082\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5082|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/43/3773\" title=\"table 1\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1913?source=related_link\">",
"      Cholinesterase inhibitors in the treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1914?source=related_link\">",
"      Clinical features and diagnosis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/33/27162?source=related_link\">",
"      Clinical manifestations and diagnosis of Alzheimer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/41/34455?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37786?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of vascular dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12618?source=related_link\">",
"      Frontotemporal dementia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/408?source=related_link\">",
"      Frontotemporal dementia: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/22/32098?source=related_link\">",
"      Patient information: Tips for caregivers of people with Alzheimer disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=related_link\">",
"      Prognosis and treatment of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4552?source=related_link\">",
"      Safety and societal issues related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=related_link\">",
"      Stages and architecture of normal sleep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33865?source=related_link\">",
"      Treatment of dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_48_27403="Immune defects and trauma";
var content_f26_48_27403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immune defects associated with trauma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lymphocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous anergy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased CD4+ T cell count",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inverted CD4/CD8 ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased mitogen-induced proliferation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased cytokine production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased natural killer cell activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Monocytes/macrophages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased expression of MHC class II and complement receptors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased production of prostaglandin E2 (suppressive for lymphocytes and neutrophils)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neutrophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased chemotaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased phagocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased respiratory burst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased expression of integrins",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Faist, E, Schinkel, C, Zimmer, S. World J Surg 1996; 20:454.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27403=[""].join("\n");
var outline_f26_48_27403=null;
var title_f26_48_27404="Antimicrobial prophylaxis for thoracic non-cardiac surgery";
var content_f26_48_27404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F87205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F87205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial prophylaxis for thoracic (noncardiac) surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Common pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended antimicrobials",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual adult dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        S. aureus, S. epidermidis, streptococci, enteric gram-negative bacilli",
"       </td>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        ampicillin-sulbactam",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        3 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        vancomycin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 g IV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug (ampicillin-sulbactam every 2 hours, cefazolin every 4 hours, cefuroxime every 4 hours, cefoxitin every 2 hours, clindamycin every 6 hours, vancomycin every 12 hours) for the duration of the procedure in patients with normal renal function. If vancomycin or a fluoroquinolone is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Due to increasing resistance of E. coli to fluoroquinolones and ampicillin-sulbactam, local sensitivity profiles should be reviewed prior to use.",
"     <br/>",
"     &Delta; Vancomycin can be used in hospitals in which methicillin-resistant S. aureus and S. epidermidis are a frequent cause of postoperative wound infection, in patients previously colonized with MRSA, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. Some experts would give 15 mg/kg of vancomycin to patients weighing more than 75 kg, up to a maximum of 1.5 g, with a slower infusion rate (90 minutes for 1.5 g). For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (gentamicin, tobramycin, or amikacin), aztreonam, or a fluoroquinolone.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, October 2012; Vol. 10 (122):73.",
"     <a href=\"file://www.medicalletter.org\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27404=[""].join("\n");
var outline_f26_48_27404=null;
var title_f26_48_27405="Summary ACIP recs II";
var content_f26_48_27405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of ACIP recommendations on immunization of immunocompromised adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Routine",
"        <br/>",
"        (not immuno- compromised)",
"       </td>",
"       <td class=\"subtitle1\">",
"        HIV infection/ AIDS",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severely immuno- compromised",
"        <br/>",
"        (non-HIV related)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Post-solid organ transplantation, chronic immuno- suppressive therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Td",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MMR(MR/M/R)",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Recommended/ considered",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hib",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"       <td>",
"        Considered",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumococcal&loz;",
"       </td>",
"       <td>",
"        Recommended if &gt;65 years of age",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningococcal",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza",
"       </td>",
"       <td>",
"        Recommended if &gt;65 years of age",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Asplenia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Renal failure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alcoholism and diabetes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Alcoholic cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Td",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MMR(MR/M/R)",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Recommended",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hib",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumococcal&loz;",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meningococcal",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"       <td>",
"        Use if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Severe immunosuppression can be the result of congenital immunodeficiency, HIV infection, leukemia, lymphoma, generalized malignancy or therapy with alkylating agents, antimetabolites, radiation, or large amounts of coticosteroids.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Patients with renal failure on dialysis should have their anti-HBs response tested after vaccination, and those found not to respond should be revaccinated.",
"      <br>",
"       &Delta; Inactivated.",
"       <br>",
"        &loz; In 2012, the ACIP recommended the use of the 13-valent pneumococcal conjugate vaccine in children and adults with immunocompromising conditions or functional or anatomic asplenia, in addition to the pneumococcal polysaccharide vaccine (PPSV23). Patients who have not been previously immunized with the unconjugated vaccine should receive 13-valent conjugate vaccine first, followed 8 weeks later by PPSV23. Patients who have previously received PPSV23 should receive the 13-valent conjugate vaccine after an interval of at least one year.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: CDC. Recommendations of the advisory committee on immunization practices (ACIP): use of vaccines and immune globulins for persons with altered immune competence. MMWR 2006; 55RR-15:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27405=[""].join("\n");
var outline_f26_48_27405=null;
var title_f26_48_27406="Doppler indices of venous flow";
var content_f26_48_27406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Venous flow profile and Doppler indices",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 357px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows a diagrammatic representation of a venous flow profile on the left illustrating the components of the waveform. The calculations for the various Doppler indices reported in the literature are displayed on the right.",
"    <div class=\"footnotes\">",
"     S: systolic peak blood flow velocity; D: diastolic peak blood flow velocity; a: atrial systolic peak blood flow velocity; TAMX: time averaged maximum velocity calculated from the area under the curve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27406=[""].join("\n");
var outline_f26_48_27406=null;
var title_f26_48_27407="Endoscopic view of appendiceal mucocele";
var content_f26_48_27407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic view of appendiceal mucocele",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 267px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Louis-Michel Wong Kee Song, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_48_27407=[""].join("\n");
var outline_f26_48_27407=null;
